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ABSTRACT
The effect of various compounds on the gastric emptying 
rate of a non-absorbable marker (^^C-polyethylene glycol) in the rat 
has been studied. A correlation between gastric emptying rate and 
anticholinergic activity has been observed. It is postulated that compounds 
with anticholinergic activity delay gastric emptying as a result of this 
activity.
Imipramine, a compound found to be a potent inhibitor 
of gastric emptying, has been used to delay gastric emptying in studies 
of the intestinal absorption of drugs in the rat. Absorption has been 
assessed by examination of the plasma level profile of radioactivity and 
by fitting plasma radioactivity levels, resulting from ^^C labelled 
drug, to a single compartment open model.
Delayed gastric emptying has been found to reduce the 
rate of absorption of trimethoprim in both fed and starved rats. The 
results indicate that, when reduced, gastric emptying rate becomes the rate 
limiting step in absorption. The rate of absorption of trimethoprim has 
also been found to be more rapid in fed than in starved rats. A slower 
rate of intestinal motility is suggested as the reason for this finding.
The rate of absorption in starved rats of salicylic acid 
was also found to be reduced by delayed gastric emptying. The results 
indicated that when emptying is delayed gastric absorption of salicylate 
contributes significantly to its overall rate of intestinal absorption. 
Imipramine has also been shown to increase the amount of both salicylic 
acid and trimethoprim absorbed via intestinal lymph.
A novel mathematical model has been proposed to describe 
intestinal transit in the rat. Using this model the rate of intestinal 
transit has been shoivn to be rapid near the stomach and to decrease 
exponentially as the distance along the intestine increases. Transit 
rate was found to be slower in fed animals. Imipramine pretreatment 
caused a decrease in the rate of transit in both fed and starved animals.
An experiment is described which was designed to investigate 
the effects of some anticholinergic compounds on the absorption of salicylic 
acid in human volunteers.
Suggestions are made as to the relevance of the results 
presented in relation to investigations of toxicology and metabolism of 
drugs. The possible consequences of alterations in gastric emptying 
caused by the administration of therapeutic agents to humans are 
discussed. In particular potential adverse drug interactions and toxic 
side-effects are indicated.
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Thought^ he is inclined to hold is still secreted 
by the brain^ but then Poetry and Religion are 'a 
product of the smaller intestines'i
Thomas Carlyle 
1795-1881
It seems to me that the disease called sacred is 
no more divine than any other. It has a natural 
cause, just as other diseases have. Men think 
it divine because they do not understand it .... 
In Nature all things are alike in this, that they 
can all be traced to preceding causes.
Hippocrates writing of the 
'sacred' disease epilepsy
The use of chemicals often brings great benefits, 
but could under some circumstances be harmful to 
human health. We must be selective in the 
chemicals approved for use, and exert control 
over how they are used, to minimize the possible 
risk.
Marc La lende 
1973
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CHAPTER 1
INTRODUCTION
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Absorption in its simplest form may be regarded as the 
passage of a substance from one discrete compartment to another through 
a separating barrier. Intestinal absorption is the passage of a substance 
from the lumen of the intestine into the body. Theoretically a substance 
has been absorbed into the body once it has entered or passed the mucosal 
membrane. In practice however intestinal absorption is regarded as the 
passage of a substance from the mucosal to the serosal side of the 
intestine.
The intestinal absorption of drugs has been, until recently, 
a relatively neglected area of study. The major site of drug absorption 
from the gastrointestinal tract appears to be the small intestine. The 
rate at which drugs reach the small intestine is dependent on the rate at 
which they leave the stomach. It follows that factors which alter gastric 
emptying rate may also influence the rate of drug absorption. The work 
described in this thesis was designed to investigate the effects of 
certain drugs on the rate of gastric emptying, and to examine the effect 
of a reduction of gastric emptying rate on drug absorption.
THE GASTROINTESTINAL TRACT
The major site of entry of fluids, nutrients and foreign 
compounds in mammals is the gastrointestinal tract. This tract extends 
from the mouth to the anus and the entire lumen of this organ forms part 
of the external environment of the body. The intestinal tract has 
evolved to perform the specialized functions of digestion and absorption. 
The various parts of the tract serve differing functions and have 
significantly different structures and absorptive capacities. A 
diagrammatic representation of the gastrointestinal tract is shown in 
Fig. 1.
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DIAGRAMATIC REPRESENTATION OF THE GASTROINTESTINAL TRACT
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There is very little published data on the environment and 
conditions in the gastrointestinal tract of the rat. For this reason most 
of the following discussion refers to the human gastrointestinal tract. 
Where data on the rat is available it has been included.
Mouth and Oesophagus
The upper part of the intestinal tract from the mouth to 
the gastro-oesophageal junction does not generally serve any major 
absorptive function as substances do not usually remain in the mouth very 
long; in normal circumstances they are rapidly transported down the 
oesophagus. However the buccal cavity has been used as a model system in 
the study of absorption, firstly by Beckett and Triggs (1967) and 
subsequently by many other workers. The salivary glands empty into the 
mouth, creating a slightly acid to neutral pH. The salivary secretions 
contain mucin, a glycoprotein found in most intestinal secretions, and 
salivary amylase. Bicarbonate and phosphate provide a degree of 
buffering, and other ions are also present.
Stomach '
The stomach has secretory functions, but is principally a 
storage organ and a pump. It is the antral region of the stomach which 
performs the function of the pump propelling the stomach contents into 
the small intestine. The musculature of the stomach consists of an 
external longitudinal layer with a layer of circular muscle beneath it.
It is this layer of circular muscle which increases in thickness to form 
the pyloric sphincter. Beneath the circular layer in the antral region 
there is also a well developed oblique layer of muscle.
The mucosa of the stomach may be divided into two types.
The pyloric mucosa extends from the pylorus up to the region of the 
angular notch; the glands in the mucosa in this region consist almost
15
exclusively of neck chief cells. The remainder of the stomach is covered 
with oxyntic mucosa which contains oxyntic acid secreting cells and neck 
chief cells. In the rat the pyloric mucosa performs all the glandular 
functions; the upper part of the stomach, the fundus (corresponding to the 
oxyntic region in the human stomach), is an alimentary reservoir lined with 
oesophageal type mucosa and is not functionally a true stomach.
In humans, secretion of gastric juices is a continuous 
process whereas the rat gastric juices are only secreted in response to 
stimulus. Gastric secretions are rich in hydrochloric acid and prot^lytic 
enzymes. Hydrochloric acid is actually secreted at a strength of about 
O.17 N but is neutralized to some extent by mucin and other alkaline 
constituents in the gastric juice. The pH in the fasted human stomach is
1.0 to 1.5 and in the rat 1.8 to 3.2. The mucus serves to protect the 
mucosa from acidic and mechanical damage and acts as a lubricant.
The Small Intestine
The basic structure of the small intestine is similar to 
that of the stomach. The major differences are the highly invaginated and 
folded mucosa and the modified function of the mucosal cells. The 
surface mucosal cells are brush border epithelial cells and there are 
secretory cells at the base of the villi. A more extensive discussion of 
the morphology and physiology of the small intestine may be found elsewhere 
(Deren 1968 and Trier 1968). The alkaline environment pH 6.5 - 8.2 of the 
small intestine is largely the result of the entrance of pancreatic juice 
and bile into the intestine. These two secretions in humans have a pH of
7.1 - 8.2 and 7.0 - 7.6 respectively. Combined with bicarbonate-containing 
mucosal secretions they maintain a slightly alkaline environment.
Pancreatic secretions have a high content of organic matter and the 
bicarbonate is present in sufficient quantities such that one volume of 
pancreatic juice will neutralize one volume of gastric juice.
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Bile also contains a high proportion of solids and is the 
most important secretion in terms of a direct effect on absorption. A 
comprehensive description of bile function and composition has been given 
by Smith (1973). The other source of intestinal secretions are the 
mucosal cells of the small intestine. These mucosal secretions contain 
mucin, which has a degree of buffering capacity, and a variety of enzymes. 
The inorganic constituents of the mucosal secretions include bicarbonate 
which also contributes to the overall alkaline environment. The pH of the 
mucosal secretions increases from 6.5 at the duodenal end of the intestine 
to 7.6 at the distal ileum.
The Large Intestine
The colon secretes significant amounts of bicarbonate ions, 
which neutralize the acidic fermentation products of the bacterial flora 
in this organ. This is also the case in the caecum. It is unlikely that 
foreign compounds, which pass unabsorbed through the small intestine, will 
be significantly absorbed in the colon. The colon does not appear to be 
important in the absorption of orally administered foreign compounds 
although it does have a.role in the resorption of water and sodium.
It should be noted that in certain countries rectal 
administration of drugs is common. The blood supply to the rectal 
region of the tract is part of the systemic circulation as are the blood 
vessels of the mouth. It is claimed that rectal drug administration 
bypasses, at least in part, the portal circulation. It was noted by 
Binns (1971) that in certain circumstances with certain drugs, rectal 
administration may be advantageous, although the claim that the liver is 
bypassed may not be substantiated.
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Comparison of Stomach and Small Intestine
The stomach and small intestine appear to be the major 
potential sites for absorption. It is worthwhile considering in detail 
the morphological features of these organs which are of importance in 
absorption, namely the surface area, the blood supply and the lymphatics.
There is no data published on the mucosal surface area of 
the rat stomach. A crude approximation of the surface area may be made.
If the stomach of a 200 g rat is filled with 6 ml of water it has a length 
of about 4 cm and a maximum diameter of 2.0 cm. If the stomach is 
approximated to a cylinder with hemispherical ends the surface area may 
be calculated as approximately 40 cm^. However the fundal region which 
constitutes a large part of the stomach surface area in a rat, is very 
poorly supplied with blood vessels and it is unlikely that it plays a 
significant part in the absorptive processes. Thus it may be assumed that 
approximately 20 to 40 cm^ of stomach surface area in a 200 g rat is 
available as a functional absorptive surface.
Several measurements of the surface area of the small
intestine in rats have been reported. The most rigorous analysis is that
of Fisher and Parsons (1950). They showed that the mucosal surface area 
decreased in a linear fashion from the proximal to the distal end of the 
intestine, and that the length and surface area of the intestine was 
independent of.body weight in rats over 150 g. The estimated total mucosal 
surface in rats over 150 g was approximately 700 cm^. However Fisher and 
Parsons did not include in their calculations any contribution made by the 
microvilli. Spencer (1968) suggests that the microvilli are likely to 
increase the surface area by a factor of 15 to 25. This would indicate that 
the total mucosal surface area of the rat small intestine could be in the
region of 1.05 to 1.75 ni^ . A gradient in intestinal surface similar to
that in the rat, has been reported in man (Wilson 1967).
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There is a difference between the structure of the small 
intestine in man and the rat. In man submucosal folds are also observed; 
these are called the folds of Kerkring. The anatomical mechanisms for 
increasing surface area have been calculated by Wilson (1962) to increase 
the surface area of the human small intestine by a factor of 600, as 
compared with a simple cylinder of the same dimensions. It is apparent 
that the small intestine has a considerably larger surface area than the 
stomach and this must be a significant factor in the consideration of 
passive diffusion as mentioned subsequently.
The small intestine is a more highly perfused organ in terms 
of blood supply than the stomach. The villi of the small intestine are 
individually supplied with an arterial vessel and capillary network which 
drains to the venous systen. it has been shown that the volume of blood 
flow and the villous capillary surface area in the small intestin^ do not 
constitute rate limiting factors in the absorption of lipid soluble 
substances in the small intestine (Svanvik 1973). There is evidence that 
blood flow in the small intestine does affect actively transported 
substances, (Robirtson et al. 1965; Varro et al. 1965). In contrast the 
mucosal blood flow in the stomach appeared to be a rate limiting factor 
in absorption (Shore et al. 1957). These data were supported by the 
observations that an increase in gastric blood flow caused by ethanol, 
increased passive drug absorption from the stomach (Magnussen 1968).
The small intestine is also more richly perfused with 
lymphatic vessels than the stomach. Each villus in the intestine has a 
lacteal draining into the mesenteric lymph duct. There is evidence that 
the lymphatics do not normally play a significant part in drug absorption 
and no information is available as to the relative capacities of 
intestinal and gastric lymphatics.
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INTESTINAL ABSORPTION
Mechanisms of Absorption
There are five general headings for transport mechanisms: 
pinocytosis; pore filtration; active transport; facilitated diffusion and 
passive diffusion. The latter mechanism appears to be the most important 
mechanism for the absorption of the great majority of drugs; the others 
will be considered briefly.
Pinocytosis and Pore Filtration
Pinocytosis is a process by which cells engulf particulate
material or globules of solution by vésiculation. This process has not
been shown to be important in drug absorption although there is evidence
that insoluble dyes enter the rat duodenal epithelium by this mechanism,
(Barrnett, 1959). It has also been shown that mice can absorb latex
spheres by a pinocytotic process (Ashworth et al. 1960).
The membranes of the intestinal mucosal cells are complex
dynamic lipoprotein structures (Stein 1967; Rouser et al. 1968; Lucy 1968).
Pores exist in the membrane; these are highly polar regions solvated with
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water. The effective radius of the pores has been estimated as 4A in the 
rat intestine (Lindemann and Solomon 1962). Only water-soluble 
molecules with a molecular diameter of less than 8A may be expected to gain 
entry to the cells by pore passage. It has been shown (Fordtran et al. 
1965) that water and urea but not mannitol will cross the epithelial 
membrane by pore passage. As most drugs are larger molecules than 
mannitol it is unlikely that pore filtration plays a significant part in 
drug absorption.
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Active Transport
There is no completely acceptable definition of active 
transport. However Wilson (1962) gives a useful general definition; 
"carrier mediated transport through a membrane against a concentration 
gradient requiring the expenditure of energy". It is reasonable to 
assume that for an active transport system to evolve in an organism, the 
organism would have to be exposed to the substance to be transported for 
a length of time measurable on an evolutionary time scale. Further, the 
organism is likely to have an absolute requirement for the substance which 
needed to be transported. It is therefore not surprising that very few 
foreign compounds are transported by an active mechanism. Those compounds 
which are, are analogues of naturally occurring compounds which have 
active transport systems. Examples are 5-fluorouracil (Schanker and 
Jeffrey 1961) and serine or threonine derivatives of certain nitrogen 
mustards (Evered and Randall 1962). Active transport may not be regarded 
as a major mechanism of drug absorption.
Facilitated Diffusion
Facilitated diffusion is defined as carrier mediated 
transport through a membrane and down a concentration gradient. This type 
of transport^ requiring the involvement of some form of carrier molecule or 
moiety, does not involve the direct expenditure of energy, but is a 
saturable mechanism. Levine and Pelikan (1964) used the term "augmented 
absorption" and have demonstrated that it may occur in addition to normal 
diffusion. The absorption of benzomethamine could not be accounted for 
by passive diffusion, and it has been suggested that this compound may 
be transported by facilitated diffusion with the possible involvement of 
a phosphatido-peptide fraction from the small intestine (Levine and 
Pelikan 1964). Levine (1970) has further summarized the data on 
facilitated diffusion. It may be concluded that this method of transport
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may play a role in drug absorption but only in a limited number of 
cases.
Passive Diffusion
The most important of the absorptive processes is 
undoubtedly passive diffusion. This process may be defined as the 
diffusion of a substance through a membrane down a concentration gradient. 
This system has no specificity except that dictated by the physiochemical 
properties of the membrane and the compound; i.e. it must be physically 
possible for the compound to cross the membrane.
An extensive mathematical and thermodynamic treatment of 
passive diffusion is given by Curren and Schultz (1968) as it applies to 
transport across membranes in the general case. The process can be simply 
described by Picks Law.
ds
—  = K A (C^ - C2 ) where K is the diffusion constant
dt
^ A is the area available for diffusion
C% is the internal concentration
C2 is the external concentration 
D is the thickness of the membrane
ds is the rate of movement of the solute
dt
with respect to time.
In practice however it is difficult to measure D; for this 
reason a new constant P (permeability constant) is defined where:
P = K 
D
therefore ds^  = P A (C^ - C2 ) .
dt
As foreign compounds are in many instances rapidly removed 
from the serosal side of the intestinal tract by the blood supply the 
blood concentration will be low compared with the lumen. This results in
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a large concentration gradient and gives rise to first order kinetics with 
respect to the lumen concentration. Thus the absorption rate constant will
be proportional to the permeability constant and the area available for
absorption. It is apparent that the area available for absorption is a
significant factor in passive diffusion. The previous discussion of the
relative surface area of the stomach and small intestine assumes
considerable significance in this context. The ratio of the surface area
of the stomach to that of the small intestine in the rat, is in the region
of 1:300 . If the whole surface of the small intestine is available as
an absorptive surface, absorption would, all other factors being constant,
be much faster in the small intestine. Even if only 10% of the small
intestine surface area were available, the ratio would still be 1:30
and absorption would proceed much more rapidly from the intestine.
FACTORS AFFECTING DRUG ABSORPTION
The pH Partition Hypothesis and Lipophilicity
The relationship between the rate of absorption of 
compounds, their pKa and lipid solubility have been extensively 
investigated. Schanker and his co-workers (Hogben et al., 1957; Hogben et al., 
1959; Schanker et al., 1957; Schanker et al., 1958 and Shore et al., 1957) 
formulated the pH partition hypothesis. This hypothesis requires that the 
unionized form of a drug is the one which is absorbed and predicts that the 
rate of drug absorption is a function of the degree of ionization of the 
compound and the liposolubility of the unionized form.
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The Henderson-Hasselbach equation describes the 
relationship between pH, pKa and degree of ionization:
for an acid pKa - pH = log
C±
for a base pKa - pH = log
Cu
where Cj^  and are the concentrations of the ionized and unionized drug 
molecules respectively.
It follows from these equations that a weak acid will be
largely undissociated at low pH and largely ionized at high pH and vice
versa for a weak base. The pH partition hypothesis predicts that weak
acids largely undissociated in the acidic environment of the stomach
should be well absorbed and weak bases largely dissociated should be poorly 
absorbed. The reverse should hold true in the more alkaline environment 
of the small intestine.
Schanker et al. (1957) and'Hogben et al. (1957) demonstrated 
that the pH partition hypothesis was valid for the absorption of drugs in 
the human and the rat stomach. Schanker et al. (1958) showed the 
hypothesis to be effective when considering absorption from the rat small 
intestine. Certain discrepancies were noted between prediction and 
observation, especially in respect of absorption from the small intestine.
It was noted (Hogben et al. 1959) that relatively strong acids like 
salicylic and benzoic acid were readily absorbed from the almost neutral 
environment of the small intestine, where they would be largely dissociated. 
Jacobs (1940) had derived an equation to describe the distribution of a 
drug between solutions of different pH, separated by a barrier permeable 
only to the unionized moiety:
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fora base this equation was
C gut 1 + ,
C plasma = ' P» Plasma)
and for acid
C gut 1 + loJPf, P f  - PKa',. ,
C plasma = m ï ï ' P ” Plasma - pKa)
where C gut and C plasma are the concentration of drug in the gut and 
plasma respectively; similarly for pH gut and pH plasma.
Using these equations and the experimental data they
obtained, Hogben et al. (1959) calculated that a minimum ratio of ionized 
to unionized drug of 1:200 would be required for rapid absorption. At the
pH of the contents of the small intestine in their experiments the ratio
of unionized to ionized acidic drug was estimated as 1:4000. The 
estimated ratio was much larger than that required for rapid absorption 
and was not compatible with the observed absorption rate. To account for 
the observed absorption rate they calculated the "virtual pH" at the 
mucosal wall as 5.4 using the above equations.
This virtual pH has never been demonstrated. Physiologically 
it seems improbable that such a condition exists. The mucosal cells in 
the crypts between the villi are known to secrete mucus and bicarbonate 
ions; these secretions have a higher pH than the intestinal contents, 
especially in the duodenum. Furthermore the mucus is a viscous substance 
which probably clings to the mucosal walls. This is supported by Smolen 
(1973) who showed that when the lumen contents were pH 7.0 the mucosal 
surface had a pH of 7.4
In recent years several examples of compounds which do not 
fit the pH partition hypothesis have arisen. It has been shown that many 
drugs including barbituric acids (Kakemi et al. 1967 and Crouthamel et al.
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1971), sulphonamides (Nogami et al. 1962 and Crouthamel et al. 1971), 
quaternary ammonium compounds (Levine 1961; Levine et al. 1955; Levine 
and Clark 1957), tetracyclines (Pindell et al. 1959), aminopyrine (Nogami 
and Matsuzama 1962), carbenoxolone (Houston, 1973), and a variety 
of organic anions (Lanman et al. 1971) are absorbed in a manner 
inconsistent with the pH partition hypothesis. Crouthamel et al. (1971) 
showed that the absorption of weakly acid drugs from the gastrointestinal 
tract followed first order kinetics, but they found no evidence for the 
existence of a "virtual pH". They also showed that although absorption 
rates could be pH dependent, the absorption of ionized moieties could make 
a significant contribution to the total amount of drug absorbed; e.g. 
at pH 6.1 absorption of sulphaethidole ions account for 42% of the total 
drug absorbed in an in situ preparation* DiSanto and Wagner (1972) 
demonstrated that 53 to 97% of an oral dose of the highly ionized drug, 
methylene blue (10 mg), was recovered in the urine of man but only 2.4 to
3.8% of a 15 mg/kg dose was recovered in the dog. The authors suggest
these results indicate possible species differences in.absorption of 
ionizable drugs.
The fundamental misconception in the pH partition
hypothesis appears to be the assumption that ionized molecules will not
pass the lipoprotein membrane. Crouthamel et al. (1971) devised an 
equation which allowed an estimation of the amount of ionized drug which 
was absorbed. Turner et al. (1970), using an in vitro system concluded; 
'drug ions do cross the intestine, passage of ions from mucosal to serosal 
side of the intestine is more rapid than the reverse passage, the 
difference in directional permeability may be related to sodium ion 
coupled transport, and that the virtual pH hypothesis is not operative 
in vitro'.
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Recently the pH partition hypothesis has been reassessed 
by Smolen (1973) . After a thermodynamic consideration of the hypothesis 
he concluded, "although the pH partition hypothesis often provides a good 
approximation of the solute transport and distribution behaviour of 
biological barriers and is an excellent rule of thumb, it cannot be 
considered so seriously as to postulate that biological barriers are 
generally impermeable to ions and to attribute deviations from its 
predictions to thermodynamically untenable mechanisms which invoke a 
virtual pH".
Liposolubility is a major factor in determining the rate 
at which drugs will be absorbed. A good correlation may be obtained 
between liposolubility and rates of drug absorption. In the study of the 
absorption of barbiturates from a homologous series (Schanker (1959)), 
a diverse range of compounds (Lanman et al. 1971), a homologous series of 
carbamates (Houston et al. 1974) and a series of steroids (Schedl and 
Clifton 1951) , a parallel was observed between lipid-water partition 
coefficients and absorption rates, at least over a limited range.
Whbn considering the relationship between lipophilicity 
and absorption caution must be exercised. Partition coefficients vary 
according to the system used to measure them. In some of the earlier 
work (Schanker et al. 1958; Hogben et al. 1959) partition coefficients 
were measured using chloroform or heptane-water. These two systems did not 
give the same order of partition coefficients for a range of compounds and 
did not give a good correlation between obtained coefficients and 
absorption. In more recent work the octanol water system has been 
favoured,it is argued that the hydroxyl group in the octanol helps to 
provide a more realistic lipophilic environment.
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Further evidence for the importance of lipophilicity is 
provided by the observations that slight modification of a molecule which 
increases its lipophilicity correspondingly increases absorption rate 
(Hoeksema et al. 1961 and Handschumacher et al. 1962).
It may be concluded that the pH partition hypothesis in its 
original form does not account for observed experimental findings. If the 
passage of ionized drug molecules is accounted for in considerations of drug 
absorption, then an interrelationship between lipophilicity , pH and degree 
of ionization may exist, but it is a complex and as yet incompletely 
defined one.
A correlation between pKa and secretion of drugs into the 
stomach has been observed (Shore et al. 195 7). These workers found that 
the concentration ratio (concentration of drug in the gastric juice 
divided by the concentration in the plasma) was related to the pKa of 
the drug. A limiting concentration ratio of 1:40 was found to exist; 
this ratio was apparently a limiting value imposed by gastric mucosal 
blood flow rate. The quantitative importance of gastric secretion of 
drugs has not been determined.
The Effect of Diet and Dietary Constituents on Drug Absorption
The effect of diet or dietary constituents may arise from 
several possible sources. The bulk effect of food may decrease the 
effective drug concentration by complex formation between dietary 
components and a drug, or by an effect of diet on gastrointestinal motility.
A decrease in plasma phenobarbitone levels and sleeping 
times were observed following oral dosage of phenobarbitone to fed rats 
as compared with starved rats (Kojima et al. 1971), although the total 
amount of phenobarbitone absorbed was the same in both groups. Very
little work has been reported on the effect of food on absorptive
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ability of the intestine in the rat, although Singh et al. (1972) reported
adaptive changes in the rat small intestine in response to alterations 
in diet. However possibility of alterations in absorptive ability in 
response to changes of diet should not be overlooked.
In man dicloxacillin absorption rate was significantly 
decreased by food and the total amount absorbed was slightly decreased 
(Doluisio et al. 1969). Su]phonamide absorption is delayed but the total 
amount absorbed is unaffected by food (MacDonald et al. 1967) and 
absorption of paracetamol is delayed but not reduced by food (McGilveray 
and Mattok, 1972). It is likely in these cases that the effect of food 
is to restrict access of the drug to the intestinal mucosa and to slow 
gastric emptying.
Various carbohydrates have been shown to decrease drug 
absorption in everted gut sacs (Mayersohn and Gibaldi 1971). This effect 
was correlated with increased fluid uptake in the tissue. A 50% sucrose 
syrup was shown to slow the absorption of aminopyrine and methampyrone in 
rabbit probably by reducing gastric emptying rate (Kato et al. 1969).
A test diet high in carbohydrate reduced absorption of paracetamol 
in man whilst a high lipid or protein diet had no effect (Jaffe et al. 
1971). It was suggested that the reduced absorption resulted from the 
drug binding to pectin in the high carbohydrate diet.
The Effect of Bile on Drug Absorption
One of the major physiological functions of bile is that 
of "solubilization" and micelle formation to assist absorption of certain 
compounds, notably cholesterol and lipids. The effect of bile on drug 
absorption has not been extensively studied and yet it is a potentially 
important factor in drug absorption.
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The concentration of bile salts decreases from the proximal 
to distal end of the small intestine, and the overall concentration but not 
distribution is affected by diet (Eastwood and Boyd 1967). The effect of 
bile on intestinal absorption depends on many factors; in one 
circumstance absorption may be inhibited, in another enhanced.
Taurocholate decreases alanine and 3-0-methylglucose transport whilst 
increasing mannitol transport in the presence of Na+. In the absence of 
Na"^  the situation is reversed. Thus, active transport is inhibited whilst 
passive diffusion is enhanced (Frizzell and Schultz. 1970). The uptake 
of oleic acid was increased in bile fistula rats (Rampone 1972), i.e. 
in the absence of bile. The partition of isopropamide iodine between 
octanol-water was shown to be increased in the presence of bile salts, 
whilst absorption of this compound in situ was decreased (Gaginella 
et al. 1973). Kakemi et al. (1970) demonstrated that sodium glycocholate 
and taurocholate inhibited absorption of the amide 2-allyloxy-4-chloro-N- 
(2-diethylaminoethyl)-benzamide, when the salts were present above the 
critical micelle concentration. They also showed that sulphaguanidine 
absorption was enhanced by sodium taurocholate through a measurable 
direct action of the bile salt on the absorptive surface and 
demonstrated that the enhancement of absorption was more predominant 
in the ileum than the jejunum. Further work by Kimura et al. (1972) 
indicates that sodium taurocholate itself is absorbed almost exclusively 
in the ileum. However the absorption of imipramine and quinine was 
inhibited by bile salts. When studying the effects of bile on drug 
absorption it must be remembered that many drugs and natural compounds 
are excreted in the bile. The excreted compounds could have an effect on 
drug absorption or confuse the absorption picture, a possibility which 
does not appear to have been taken into consideration in the studies 
reported in the literature.
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The Effect of Solvent Drag in Drug Absorption
Solvent flow was shown to have an influence on the 
absorption of urea, creatinine and sorbitol (Fisher 1955). Mayersohn and 
Gibaldi (1970) demonstrated that drug absorption was influenced by cations; 
they attributed this to fluid uptake by the gut. The absorption of 
sulphaethidole was increased from a hypotonic solution and decreased 
from a hypertonic solution (Kojima et al. 1972). Ochsenfahrt and 
Winne (1972) demonstrated that positive water flux enhanced the absorption 
of amidopyrine and antipyrine. From a kinetic analysis of the data they 
concluded that this effect resulted from an interaction between water and 
drug within the epithelial membrane.
Whilst investigations of solvent drag effects are of 
fundamental importance they must be viewed in perspective. All the
experiments discussed above were performed in in vitro or in situ
preparations and it is difficult to assess their relevance to the whole
animal. It is unlikely that drugs will be administered to man or
experimental animals in large volumes of hypo- or hypertonic solutions 
and in the intact animal intestinal hydration is held at a relatively 
constant level. It is nevertheless important to consider the possible 
contribution by solvent drag phenomena to in vitro and in situ 
investigations of drug absorption.
Complex Formation
The formation of complexes between drugs and endogenous 
or foreign material may enhance or decrease drug absorption. The 
biopharmaceutical aspects of complex formation have been reviewed 
elsewhere (Hamlin and Shah 1972). The potential value of utilizing 
complex formation to enhance drug absorption is high. However the 
practical uses of this approach so far are limited. Unfortunately it is 
frequently the case that once formed a complex may be absorbed but will
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then not break down, as in the case of iron and ethylenediaminetetracetic 
acid (Weiner 1967). Absorption of drugs (reserpine, prednisone and 
prednisolone) has been shown to be advantageously enhanced by complex 
formation (Stupak and Bates 1972; Hayton and Levy 1972). The methodology 
of complex formation may prove to be a useful way of increasing the 
absorption of poorly absorbed compounds.
Complex formation may also reduce drug absorption. There 
is evidence that complex formation between intestinal mucopolysaccharides 
and quartefnary ammonium compounds reduces their absorption, (Levine 
and Pelikan 1964; Levine et al. 1955). Ineffective absorption of 
tetracyline has also been attributed to chelation with calcium and 
magnesium ions and formation of complexes with protein (Dearborn et al. 
1957; Kohn 1961).
PHYSIOLOGICAL FACTORS AFFECTING DRUG ABSORPTION
The physiological condition of the small intestine may be 
expected to affect the rates of absorption of drugs. Because of 
experimental difficulties most of the studies on the effect of altered 
physiological conditions have been carried out using in vitro or in situ 
preparations. Whilst not ideal these systems do give some insight into the 
likely consequences of alteration in the physiology of the intestine.
Blood Flow
The gastrointestinal tract receives a substantial 
proportion, 28%, of the total cardiac output, (Texter et al. 1968). 
Estimates of the proportion of this blood which is diverted to the mucosa 
range from 17% (Winne 1966) to 60% (Lundgren 1967). In an extensive and 
thorough study of absorption and intestinal blood flow in the cat, Svanvik 
(1973) showed that in the normal resting condition the villi received
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10-20% of the total intestinal blood flow. The villous vessels were shown 
to exhibit a high degree of resting tone. Villous plasma flow could be 
increased 15 times by isopropylnoradrenaline whereas a maximum increase 
of 8-fold over the resting state was recorded for total mucosal blood.
The ability of the intestinal blood flow to alter so dramatically would 
suggest that blood flow could be a major controlling factor in intestinal 
absorption.
Opinions and results are conflicting as to the significance 
of blood flow in controlling absorption. Ochsenfahrt and Winne (1968) 
have shown that a decrease in the blood supplied to the intestinal villi 
retarded the absorption of actively transported drugs but did not affect 
passively absorbed compounds. In a subsequent paper Winne(1971) 
produced evidence that passive absorption was dependent on blood flow and 
that the dependence increased as the ease of absorption increased. The 
absorption of cardiac glycosides has been shown to be blood flow 
dependent (Haass et al. 1972). Ethanol increased drug absorption from the 
stomach; this effect was attributed to the increase in blood flow caused 
by the alcohol; conversely, absorption from the small intestine has been 
reported not to be affected by ethanol (Magnussen 1968). Svanvik (1973) 
investigated the effect of blood flow alterations on the absorption of 
®^Kr, an easily diffusible lipid soluble substance. He concluded it was 
difficult to ascribe the regulation of intestinal absorption, for an 
easily diffusable lipid soluble substance to change in either total 
intestinal blood flow, mucosal blood flow or villous blood flow or any 
combination of these three factors. He presented evidence that neither the 
perfused capillary surface area nor the rate of diffusion from lumen to 
the capillary are controlling factors. However a close correlation was 
observed between linear blood flow rate and absorption.
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Linear flow rate was defined as the rate of flow in the 
main villous vein or artery from the villous tip to base. The linear flow 
rate is largely independent of the volume or rate of flow in the deeper 
mucosal vessels and is dependent on local control mechanisms rather than 
gross intestinal blood flow. Svanvik (1973) deduced that this relationship 
suggests that the counter current diffusion exchange between ascending and 
descending vessels in the mucosa is an important factor in the control of 
absorption. From the preceding it may be concluded that the importance 
of blood flow is incompletely understood. The presently available 
evidence indicates that under normal physiological conditions gross blood 
flow is not a controlling factor in the absorption of easily diffusible 
lipid soluble materials.
Lymphatic Absorption
The small intestine is well endowed with lymphatic vessels. 
Several workers have investigated the possibility that drugs might be 
absorbed via this route. Triglycerides (Bloom et al. 1948), vitamin A 
(Greenberg 1969) and cholesterol (Sylven 1968 & Borgstrom 1968; Heilman et al. 
1960) are extensively absorbed by the lymphatics. There is an obvious 
therapeutic advantage if a drug is absorbed via the lymphatic system, 
in that it will enter directly the systemic circulation thereby avoiding 
any first pass effects in the liver.
The lymphatic absorption of p-aminosalicylic acid, 
tetracyline, three quaternary ammonium compounds and four sulphonamides 
was studied by Levine et al. (1969). They demonstrated that there was no 
relationship between liposolubility and absorption and that the percentage 
of the compounds absorbed into the lymph was very small; also their 
results indicated that lymphatic absorption was flow dependent. The work 
of Sieber (1970), who investigated the lymphatic absorption of 21 different 
drugs, supported the contention that only a small proportion of a drug dose
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was absorbed via the lymphatics. However Sieber's results indicated there 
was a correlation between lipid solubility and lymphatic absorption. This 
is not easily explained as both workers used chloroform buffer systems 
to measure partition coefficients. It may be explained by the greater 
number and more diverse range of compounds studied by Sieber. Also many 
of the compounds in the latter study were uncharged molecules, whereas 
those in the former study were charged molecules.
The low degree of lymphatic absorption, in the absence of a
specific absorptive mechanism, may be explained largely in terms of the 
relative flow rates of lymph and blood. The ratio of lymph to blood flow 
is in the region of ^/500 to ^/700 (Hendrix and Sweet 1917). It should be 
remembered, however, that the number of drugs studied with respect to 
lymphatic absorption is small and whilst the current indications are that 
this route of absorption is not an important one, at the present time it 
should not be excluded from consideration when studying the absorption of 
new drugs.
The Intestinal Mucosa
It was an accepted view until recently that the intestinal 
epithelium was the rate limiting barrier in intestinal absorption (Wilson 
1962; Schanker 1963; Levine 1970). The work of Gibaldi and Grundhofer 
(1972) indicates that the intestinal mucosa may be a rate limiting barrier 
for poorly lipid soluble slowly absorbed compounds, but not for readily 
absorbed lipid soluble compounds. They also pointed out that the 
hypothesis of Wilson et al. (1971), which postulated that unstirred water
layers adjacent to the mucosal surface are a rate limiting barrier is 
unproven. Using everted gut sacs prepared from intestine stripped of 
the serosa and muscularis externa Wolfe et al. (1973) showed these two 
components to be rate limiting in vitro. They suggested that their 
in vitro preparations gave a truer reflection of the in vivo absorption rate,
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The relationship between the morphology of the intestine and 
its absorptive capacity in malabsorption syndromes in humans is well 
documented (Laster and Ingelfinger 1961). The effect of drug on the 
gastrointestinal mucosa is not so well documented although a diverse 
range of drugs, particularly anti-inflammatory agents, have been shown to 
cause ulceration (Chvasta and Cooke 1973). The effect of ulcerogenic 
drugs in drug absorption does not appear to have been investigated. It 
remains to be seen whether these compounds affect drug absorption.
There is increasing evidence that the intestinal tract is 
able tocarry out a diverse range of biotransformations; many of these have 
been reviewed by Aitio (1974) and include N and 0-demethylation, 
diethylation, aromatic hydroxylation, side-change cleavage, oxidation, 
desulphuration, sulphoxidation and azoreduction. Several workers 
(Hartiala 1968; Barr and Riegelman 1970; Fischer and Millburn 1970;
Herz et al. 1961 and Smith et al. 1963) have shown that the mucosa is
capable of glucuronide formation, and the last three groups of workers
suggest that this mechanism is important in the absorption of stilboestrol,
thyroxine, and oestradiol. It is postulated that the mucosa is less
permeable to the glucuronides and so back diffusion is inhibited. However,
the drug metabolizing activity of the mucosa appears to be low compared with the
liver and it has not been demonstrated to be generally important in drug
absorption.
It should be remembered that the gastrointestinal tract 
has a large content of metabolically active microflora. In the rat the 
microflora are present from the stomach to the rectum; in man there are 
few micro-organisms in the stomach and proximal small intestine, but the 
rest of the intestine is highly populated (Draser et al. 1970). These 
microflora have been shown capable of performing a large number of 
metabolic reactions (Draser et al. 1970; Williams 1970; Scheline 1968a
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and Scheline 1968b). The metabolic activity of the microflora would only 
be expected to affect absorption if the metabolites produced were more or 
less easily absorbed than the parent compound or provoked damage to the
intestinal wall. It has been shown that rats bred germ-free have 30% lower
surface area in the small intestine as compared with conventional rats 
(Gordon and Buckner-Kardoss 1961). Whether this is important in absorption 
has not been examined and whether a decrease in intestinal flora or 
prolonged treatment with antibiotics affect the surface area and 
subsequently absorption has not been studied either.
Two other physiological factors, gastrointestinal motility 
and gastric emptying rate, have also been shown to influence drug
absorption. However before the influence of these factors on drug
absorption are discussed, some discussion of these factors is useful.
GASTRIC EMPTYING
The regulation of gastric emptying has been extensively 
reviewed elsewhere (Hunt and Knox 1968) and only a brief description will 
be given here. It is apparent that receptors in the duodenum react to 
stimuli from the gastric content and control gastric emptying via neural 
and/or hormonal pathways. It is also apparent that the control of 
gastric emptying is incompletely understood.
Effect of Acid on Gastric Emptying
The pH of the gastric contents entering the duodenum 
affects gastric emptying rate. VanLiere and Sleeth (1940) demonstrated 
that an acid reaction in the duodenum slowed gastric emptying,whilst it 
has also been demonstrated that an acid reaction in the duodenum 
stimulates the release of pancreatic and liver secretions (Grossman et al. 
1949). Largerlof et al. (1960) found a time lag between the appearance of
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acid in the duodenum and inhibition of gastric emptying; he took this 
to indicate that the action of acid may be mediated through a hormonal 
mechanism. The effect of acid in inhibiting gastric emptying was 
demonstrated in humans (Lotber and Shay 1956) although considerable daily 
and individual variation was found (Vagne and Andre 1971). In contrast 
Quigley et al. (1942) demonstrated that the acid reaction in the duodenum 
slows gastric emptying by directly affecting antral peristalsis and the 
onset of this effect is so rapid it can only be accounted for by a neural 
mechanism.
A threshold limit for the inhibition of gastric emptying 
by acid was demonstrated (Hunt and Knox 1968). Below the threshold, 
gastric emptying rate increases with increasing acid concentration (Vagne 
and Andre 1971). Hunt and Knox (1972) demonstrated that the inhibitory 
effect of weak acids increased with increasing molecular weight; this 
effect was not as obvious with strong acids which were, in any case, more 
potent inhibitors. Fatty acids also affect gastric emptying and a 
physiochemical relationship between the fatty acid anions and duodenal 
receptors is postulated to explain their differing potencies (Hunt and 
Knox 1968). The effect of solutions with alkaline pH on gastric emptying 
does not appear to have been studied, with the exception of one study 
reported by Davenport (1971) where isotonic NaHCO] had no effect on 
gastric emptying rate.
Osmotic Control of Gastric Emptying
. The existence of receptors sensitive to osmotic pressure 
in the duodenum has been recognized for many years. That these receptors 
are distinct from those sensitive to acid, and that the effects of acid 
are not the result of osmotic pressure effects was shown by Shay and 
Gershon-Cohen (1934). Hypotonic solutions leave the stomach a little
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more slowly than isotonic solutions, while hypertonic solutions empty 
more slowly still. A degree of correlation between osmolarity and 
emptying rate has also been reported (Davenport 1971; Hunt and Knox 1968). 
Although there has been criticism of the osmoreceptor theory (Thomas and 
Baldwin 1968), in a recent paper Barker et al. (1974) indicate that 
osmoreceptors do play a role in the control of gastric emptying.
Hormonal Control of Gastric Emptying
Several hormones have been shown to affect gastric 
emptying, but their role in the control of gastric emptying has not been 
fully elucidated.
Both natural and synthetic secretins delay gastric
emptying (Chey et al. 1968; Chey et al. 1970; Chvasta and Cooke 1973).
However Chey et al. (1968) used a single large dose of secretin and the 
effect they observed could have been a pharmacological rather than 
physiological one. Vagne et al. (196 8) using a continuous infusion 
found that 1.25 yg of secretin per kg per hour was a submaximal dose;
Vagne and Andre (1971) used this dose level to show that secretin slowed 
gastric emptying. Ramsbottom and Hunt (1973) found that large doses of 
secretin slowed rapid gastric emptying but had no effect on osmotically 
or acid-induced slowed gastric emptying. They took this to indicate that 
secretin was not directly involved in osmotically or acid-induced 
retardation of gastric emptying. A decrease in the frequency of antral 
contractions has been associated with administration of natural or 
synthetic secretin (Chvasta and Cooke 1973) which may be the prime 
mechanismhy which secretin modifies gastric emptying.
The hormone gastrin, which is secreted by the gastric mucosa
has been shown to stimulate gastric contractions (Gregory and Tracy 1964)
and might therefore be expected to affect gastric emptying. The
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recorded physiological effects of gastrin and related substances conflict. 
Vizi et al. (1973) found that gastrin and cholcystokinin released acetyl 
choline from Auerbach plexus, an action which would be expected to 
cause increased muscle contraction and speed gastric emptying. However 
Dozois and Kelly (1971) found gastrin markedly reduced or abolished the 
mean frequency and increased the propagation time of the gastric pace 
setter potential, an action which would be expected to and in fact does slow 
gastric emptying. The slowing of gastric emptying by gastrin was also 
observed by Hunt and Ramsbottom (1967).
The secretion of hydrochloric acid secondary to gastrin 
administration and the subsequent discharge of this acid into the duodenum 
causing the release of secretin (Vagne et al. 1968), or activation of neural 
reflexes (Schapiro and Woodward 1959) were postulated as a possible 
sequence of events by which gastrin may inhibit gastric emptying.
However, gastrin also inhibits emptying of NaHCOg solution with a pH of 
8.0, which makes the involvement of acid unlikely (Dozois and Kelly 1971). 
Dozois and Kelly demonstrated that gastrin affected the electrical index 
(a measure of the amplitude and duration of nervous transmissions in the 
intestine related to the pace setter potential in the stomach) and that 
the observed effect was directly related to the volume of the gastric 
content^ in such a way that gastrin would speed emptying in a full 
stomach and slow emptying of a partially empty stomach. If these results 
are considered in conjunction with the finding that rapid gastric 
emptying (in dogs) is associated with strong antral contractions and 
weak infrequent duodenal contractions, the reverse being true for slowed 
gastric emptying (Weisbrodt et al. 1969), it may be postulated that 
gastrin affects gastric emptying by mediating these two functions, the 
electrical index and the antral/duodenal contraction strength and 
frequency.
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The effect of prostaglandins, natural or synthetic, is 
dependent on the nature of the prostaglandin. As a generalization it 
appears that they increase intestinal motility (Horton et al. 1968;
Waller 1973). The latter author, in a review article, concludes they 
are probably involved in local regulations of gastrointestinal motility. 
There has apparently not been a study of the effect of prostaglandins 
on gastric emptying.
Vasopressin causes rapid gastric emptying and vomiting 
in man by an unknown mechanism (Schapiro and Britt 1972). The 
parathyroid hormones may speed gastric emptying in the rat (Segerstrom 1973) 
From the above discussion it would appear that secretin and gastrin 
are the major known hormones involved in control of gastric emptying, 
but the actual mechanisms by which they operate are far from understood.
Other Factors in the Control of Gastric Emptying
The composition of the diet, including pH and osmotic 
pressure, affect gastric emptying rate. The rate of gastric emptying 
varies with volume, composition which may be related to osmotic pressure, 
lipid composition and possibly temperature; these factors are reviewed 
by Hunt and Knox (1968).
Nervous Control of Gastric Emptying
The nervous control of gastric emtpying is highly complex.
The description presented here is necessarily a very simplified one and
a more detailed description may be found elsewhere (Code and Carlson
1968; Daniel and Irwin 1968; Davenport 1971; Edwards and Rowland 1968;
Kelly and Code 1971). Control of gastric emptying is achieved by a
dynamic balance between inhibitory and stimulating nervous impulses. Both
sympathetic and parasympathetic nerves of the autonomic nervous system
0
are involved. The sympathetic inervation is via the celiac plexus,
\r
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and the parasympathetic via the vagus. The myenteric and submucosal 
plexuses which are the intrinsic nervous system in the stomach, in some 
way as yet unknown, regulate the response of the stomach to excitation.
In man the effect of sympathetic stimulation is to depress 
all movement of the stomach, whilst parasympathetic stimulation enhances 
it. Both sets of nerves act through the intrinsic plexuses to reduce or 
enhance contractions of the gastric muscle.
Reflexes controlling gastric motility are initiated in 
visceral and somatic receptors. The somatic receptors respond to 
changes in blood pressure and activity in the somatic musculature; 
the central pathways and their significance is not clearly understood.
The visceral receptors located in the upper intestine respond to such 
stimuli as osmotic pressure, pH, stretching of the intestinal muscle 
and pressure on the mucosa. Similar receptors are believed to be located 
in the stomach. Visceral afferent fibres are found in the vagus; 
afferent impulses travel to the vagal nucleus which in turn affect 
gastric motility.
Efferent impulses in the vagus increase gastric muscle 
tone and motility. Vagal impulses maintain the normal motility of the 
stomach; this motility can be inhibited by a reduction of vagal 
stimulation or by inhibition of contractions at the site of muscle 
contraction in the presence of ongoing vagal stimulation. The vagus 
also supplies the stomach with efferent inhibitory fibres. Distention of 
the stomach initiates afferent impulses which activate vagally mediated 
relaxation of the stomach. Afferent impulses from nerve endings in many 
other abdominal structures will initiate a similar reflex. Vagal inhibition 
of gastric motility is not mediated by acetylcholine or catecholamines.
It is likely that preganglionic fibres in the vagus may act by releasing 
5-hydroxytryptamine. Afferent excitory fibres in the vagus are 
cholinergic.
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Afferent fibres in the sympathetic system respond to 
noxious stimuli such as pain. The efferent pathways in the sympathetic
nervous system cause a reduction in gastric motility. Sympathetic
stimulation causes a reduction in the rate and frequency of conduction 
of the basic electrical rhythm and reduces the strength of muscle 
contraction in the stomach. The sympathetic nervous control of the 
stomach is probably not very important compared with vagally mediated 
control. Patients who have undergone sympathectomies have normal 
gastric function, whereas bilateral vagotomy in man and animals reduces 
gastric motility often to a degree where it is completely absent.
Stimulation of the nervous system at all levels has been 
shown to affect motility of the stomach. Direct stimulation of the brain 
results in an alteration in gastric motility. In general, a decrease in 
motility is more frequently observed than augmented motility. Central 
nervous activity with emotional accompaniments often has an expression 
in altered gastric motility but the particular effect is often not 
predictable. So far no coherent picture of central nervous control of
gastric motility has emerged.
Foreign Compounds Affecting Gastric Emptying
In recent years it has been observed that several drugs, 
including antacids, affect gastric emptying rate. In some instances 
an alteration in gastric emptying rate must be regarded as a side- 
effect, and in other instances is the desired pharmacological activity 
of the drug. Slowed gastric emptying may result from surgical procedures; 
in these circumstances a drug which will speed gastric emptying is 
therapeutically useful. Recently metoclopramide has been used to accelerate 
gastric emptying (Stadaas and Aune, 1971), although there is some
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dispute as to whether metoclopramide is clinically effective in 
increasing normal gastric emptying rate. (A discussion of the uses and 
effects of metoclopramide may be found in The Postgraduate Medical Journal, 
July Supplement, 1973). Evidence that metoclopramide speeds gastric 
emptying in pregnant women during labour has been produced (Howard and 
Sharp 1973). This drug has also been shown to abolish apomorphine 
inhibition of gastric emptying in man but did not affect the emptying rate 
of glucose or sodium citrate test meals, (Ramsbottom and Hunt, 1970). 
Barbital has also been shown to increase gastric emptying in the rabbit 
(Goto et al. 1972).
Isoniazid absorption in the rat was delayed by aluminium 
hydroxide, (Hurwitz and Schlozman 1974). This effect was attributed to 
delayed gastric emptying caused by the presence of aluminium ions in the 
stomach. Both aluminium and magnesium hydroxide gels have been shown by 
radiographic techniques to slow gastric emptying in children, the former 
to a greater extent than the latter (Vats et al. 1973).
There is a small amount of direct evidence that certain 
drugs inhibit gastric emptying, although there is a larger amount of 
indirect evidence to this effect. This indirect evidence arises mostly 
from absorption data in instances of multiple drug therapy and from 
observed drug side-effects. For example, epigastric distress, constipation, 
and paralytic ileus are commonly recorded side-effects of dibenzazepine 
compounds, opium alkaloids, sympathomimetic amines, catecholamines 
and belladonna alkaloids (Goodman and Gilman 1965).
The number of direct measurements of the effect of drugs 
on gastric emptying is much smaller. Sacchetti et al. (1964) showed that 
levomepate inhibited gastric emptying of a barium sulphate meal in humans. 
Dioctyl sodium sulphosuccinate, an anionic surfactant was found to slow 
gastric emptying of charcoal in the rat (Lish 1961). This effect could
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not be accounted for in terms of the anticholinergic activity of the 
compound, and it was suggested that the inhibition of gastric emptying 
resulted from stimulation of the fat sensitive receptors in the small 
intestine. Oral pretreatment of rats with iproniazid was found to delay 
gastric emptying of a series of sugars and to increase fluid retention in 
the stomach (Leijnse and Van Praag 1964)  ^ >ihile the gastric emptying rate of 
polyethylene glycol was slowed by pretreatment of rats with SKF 525-A 
(Hayton and Levy 1971).
Other drugs have been shown by inference, from their 
effects on the plasma levels of simultaneously administered drugs, to 
affect gastric emptying. Propantheline bromide (Ashley and Levy 1973) , 
desmethylimipramine (Console, 1968; Console and Garattini 1969), 
chlorpromazine, protriptyline, amitryptyline, and atropine (Console and 
Ladinsky 1971) have all been implicated in decreasing gastric emptying.
Altered Gastric Emptying and Drug Absorption
It would seem logical that a modification of the pattern 
of gastric emptying might result in an alteration of the pharmacokinetics 
of intestinally absorbed drugs. If a drug which is rapidly absorbed 
principally in the small intestine is retained in the stomach, its 
absorption will be delayed by comparison with a situation where passage 
into the intestine is rapid. Delayed emptying may also result in slower 
presentation to the absorption site and this may increase the total amount 
of drug absorbed in the case of a poorly absorbed compound. Conversely, 
if a rapidly absorbed drug were to be emptied from the stomach more 
rapidly than normal, its absorption would be more rapid, whereas the 
absorption of a poorly absorbed compound could, under these circumstances, 
be decreased.
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Levy et al. (1972) found that propanthaline bromide 
increased absorption of riboflavin, a poorly absorbed compound; 
propanthaline bromide or a viscous dosage vehicle, increased the 
absorption of another poorly absorbed compound, phenolsulphonphthalein 
(Ashley and Levy 1973). These effects were attributed to a slower 
presentation of the agent to the absorbing surfaces in the upper intestine.
The effect of aluminium and magnesium hydroxide on the 
absorption of pentobarbitone sulphadiazine and quinine in rats 
has been studied (Hurwitz and Sheehan 1971; Hurwitz 1971). Both antacids 
delayed pentobarbitone absorption lowered blood levels and delayed the 
onset of sleep. It is suggested that magnesium hydroxide raises the pH 
so that pentobarbitone is mostly ionized and unabsorbable whilst 
aluminium hydroxide reduces gastric emptying as measured by increased 
fluid volume in the stomach. Both magnesium and aluminium hydroxide 
depressed gastrointestinal absorption of quinine, the former by raising 
the pH sufficiently to precipitate the quinine, the latter by retarding 
gastric emptying. The effects on sulphadiazine absorption were more 
variable. Sodium sulphadiazine absorption was transiently and slightly 
depressed by magnesium hydroxide or atropine and considerably reduced by 
aluminium hydroxide. Sulphadiazine acid absorption was increased by 
magnesium hydroxide which raised the pH sufficiently to increase the 
water solubility of the drug. It is unfortunate that in this work no 
accurate independent measure of gastric emptying rate was made.
Measurements of the volume of stomach contents must be a reflection of 
the secretory activity of the stomach, water intake and gastric emptying. It is 
interesting to note that the inhibition of gastric emptying caused by 
aluminium hydroxide was indicated to be due to aluminium ions; since other 
aluminium salts caused fluid retention in the stomach. In another study 
(Leon and Spiegel 1972) the plasma levels in man of L-dopa, resulting
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from oral dosage, were unaffected by prior administration of an antacid.
The antacid was a mixture of aluminium and magnesium hydroxide and 
polysiloxane.
A 50% sucrose syrup was shown to delay gastric emptying 
of phenol red in rats (Kato et al. 1969) . When these workers administered 
aminopyrine and sulphapyrine to rabbits orally in a syrup, the maximum 
plasma levels obtained were lower and the time taken for the maximum 
to occur was extended. The syrup used in this experiment was: Sucrose 
400 g, D-sorbitol 50 g. Sodium cyclamate 4 g. Saccharin 0.5 g all in 1 L of 
water. Although gastric emptying was not measured in this instance, it 
was assumed gastric emptying was inhibited by the syrup in the same 
fashion as a 50% sucrose solution inhibited emptying in the rat.
It has been shown that SKF 525-A slows gastric emptying 
and also slows drug absorption in rats (Hayton and Levy 1971). Gastric 
emptying rate was measured using labelled polyethylene glycol.
The absorption of sulphacetamide was studied; absorption was assessed 
by examination of the serum levels at 20 and 30 minutes after 
dosing and by measuring the amount of dose remaining in the stomach and 
small intestine 20 min after dosing. It was concluded that sulphacetamide 
absorption was delayed by SKF 525-A pretreatment due to this latter 
compound inhibiting the gastric emptying of the former. It was also shown 
that sulphacetamide absorption from the small intestine was unaffected by 
pretreatment with SKF 525-A. These authors suggest that inhibited gastric 
emptying may result from the parasympatholytic and/or sympathomimetic 
activity due to monoamine oxidase inhibition, which would decrease the tone 
and motility of the gastrointestinal tract.
In a series of papers (Console 1968; Console and Garattini 
1969; Console and Ladinsky 1971) Console and his co-workers attempted 
to demonstrate that certain tricyclic compounds decreased the absorption
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of phenylbutazone and oxyphenylbutazone. In the first of these papers, 
a preliminary communication, it is suggested that pretreatment of 
rats with imipramine or desmethylimipramine, 15 mg/kg i.p., decreases 
the plasma levels of phenylbutazone which result from subsequent oral 
administration of this compound. In the second paper, (Console and 
Garattini 1969) this phenomenon was further investigated. Pretreatment 
of rats with imipramine or desmethylimipramine, 15 mg/kg i.p., decreased 
the maximum oxyphenylbutazone levels, increased the time of occurrence of 
the maximum, decreased the amount of phenylbutazone and oxyphenylbutazone 
excreted in 24 hr urine, and increased the amount of phenylbutazone 
remaining in the stomach of the rats at 4 hr after dosing.
It is claimed that pretreatment of rats with desmethyl­
imipramine did not affect plasma levels of orally administered 
amphetamine and pentobarbital, whilst it did affect those of salicylate 
and hydrocortisone. In fact the results shown in the paper indicate 
a possible enhancement of amphetamine plasma levels in pretreated 
animals. Unfortunately, meaned data is given but number of animals is 
not stated. If the effects reported in this paper are real, it is 
unfortunate that the authors have not attempted to explain all of them.
In the third paper (Console and Ladinsky 1971) an attempt 
is made to correlate the anticholinergic activity of several tricyclic 
compounds with their effect on the rate of gastric emptying and 
plasma levels of oxyphenylbutazone. Rats were pretreated intraperitoneally 
with the various anticholinergic agents and then given oral doses of 
oxyphenylbutazone; plasma levels of oxyphenylbutazone were measured by 
killing groups of animals at various time intervals. The amount of 
oxyphenylbutazone remaining in the stomach of some animals (whether they 
were the same as those used for plasma levels is not stated) was measured 
at three time intervals after dosing. The authors conclude that the
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anticholinergics decrease gastric emptying rate and lower the plasma levels 
resulting from the oral administration of oxyphenylbutazone. There are , 
however, several unexplained and unacceptable features of this paper.
The statistical method used for the comparison of means 
is not stated; when the results given are tested using the independent 
t test the significances given cannot be duplicated. Comparisons of 
plasma levels were made at individual time points. No attempt was made 
to fit plasma level curves to the points. The number of animals used in 
each group varies considerably for no apparent reason. In one instance, 
there were more animals in a test group than in the corresponding 
control group. In another instance, there were 91 animals in the control 
group and the largest test group had only 20 animals; the next largest 
control group was only 31 animals. Finally, when comparing the amount of 
oxyphenylbutazone remaining in the stomach, the mean amount remaining, 
in several instances, exceeded the maximum dose given to individual 
animals.
With these criticisms in mind it is difficult to assess 
the significance 'of the conclusion of these authors. They conclude that 
the anticholinergic activity of the compounds tested correlates with 
gastric emptying. As the doses of compounds used were neither 
equimolar, equal on a weight basis,or of equal pharmacological potency, 
and in view of the other inadequacies in the papeç their results must 
be viewed with caution. The hypothesis that anticholinergic activity may 
be responsible for the inhibition of gastric emptying may be a valid one 
but cannot be said to be supported by Console and his colleagues' work.
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METHODS FOR STUDYING DRUG ABSORPTION
The methodology for the study of absorption has been 
reviewed by Parsons (1968). It falls into three main categories; in vivo, 
in situ and in vitro. Each of these categories is open to criticism.
The first is the most difficult to use and invariably relies on
measurements such as urinary excretion or plasma levels to give an index
of absorption. Results have to be interpreted with caution, especially 
in cases where tissue uptake or biliary excretion are suspected. The 
in vivo methods are however the only methods available, in most cases, for 
the study of absorption in humans. The in situ methods can only be used 
in animals and provide reasonably physiological conditions. The major 
criticisms of in situ systems are that the animals are usually 
continuously under anaesthesia, there is frequently a loss of normal 
intestinal motility patterns, the volumes of solutions used are often 
very large and factors such as bile are not present in physiologically 
normal quantities. The in vitro systems are by far the most commonly 
used to study absorption and factors affecting it. They suffer from the 
disadvantage that they are usually grossly unphysiological/ no blood 
supply exists, peristalsis is absent, and the volumes of solution and 
concentration of drugs are unlikely to be encountered in the in vivo 
situation, there is also some evidence that the functional integrity of
the tissue may be rapidly lost (Levine et al. 1970) .
In spite of the foregoing criticisms a great deal of 
knowledge can and has been gained about absorptive processes using these 
systems. Since Parsons' (1968) review article appeared, there have been 
very few major contributions to the methodology of the study of intestinal 
absorption. A preparation of rat colon perfused through the vascular 
bed has been described (Parsons and Powis 1971). This system may be 
useful for studying drug absorption but has not yet been applied to the
50
problem. In principle this system could be applied to the small 
intestine and as such would be a great step forward. However, the 
vascular system of the small intestine is vastly more complex than that 
of the colon and the technical problems involved with the development of 
such a system are great.
In a recent paper (Strieker 1973) the use of a model 
system, the 'Sartorius Absorption Model', is described. This apparatus 
utilizes an artificial lipoid barrier with artificial gastric and 
intestinal juice and an artificial plasma solution. Initial reports- of 
the apparatus and methods associated with it indicate that it may be a 
very useful method for determination of rate constants and examination of 
the thermodynamics associated with passive drug absorption. The method's 
usefulness in predicting and assessing in vivo drug absorption i^ at the 
present time, questionable.
MEASUREMENT OF GASTRIC EMPTYING RATE
There are several methods of assessing gastric emptying 
rate in humans and they have been reviewed by Sacchetti (1971). In 
essence they fall into two categories, either aspiration of part (George 1968) 
or all (Hunt and Spurrell 1951) of the gastric contents and assessment 
of the amount of a known volume which has left the stomach, or alternatively 
assessment by X-ray planimetry (Sacchetti et al. 1964) or scintography 
(Calderon et al. 1971; Cowley et al. 1972) of stomach
volume,following administration of a radio-opaque marker or y-emitting 
marker. It is possible that these latter methods could be successfully 
applied to small animals.
The easiest way of measuring gastric emptying and 
intestinal motility in small animals is by the measurement of the 
distribution of a non-absorbable marker. A non-absorbable marker 
being a substance which is not absorbed from the gastrointestinal tract.
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does not bind to tissue and has no pharmacological action on the 
intestine. Several substances have been used as markers; Lish and 
Dungan (1958) used a charcoal mix, Reynell and Spray (1956) used phenol 
red whilst Lish (1961) used another dye, xylene cyanol. These markers 
were estimated by washing them out of the gastrointestinal tract 
at the end of the experiments and measuring them spectrophotometrically.
The use of radiolabelled marker substances simplifies the estimation of 
marker concentrations. A method using radiolabelled sodium chromate has 
been described (Derblom et al. 1966) and this compound has been used by 
several workers. More recently, Hayton and Levy (1971) described the use 
of l^C-labelled polyethylene glycol (PEG) with a molecular weight of 
4000 as a marker for gastric emptying measurements. This compound had 
also been used by several workers, notably in investigations in farm 
animals. Sperber et al. (1953) demonstrated that absorption of PEG was 
negligible and that it was not degraded microbiologically in sheep. These 
results were confirmed by other workers (Hyden 1959; Corbett et al.
1959). Jacobson et al. (L963) demonstrated that PEG was not absorbed in 
rats. These studies were performed using-unlabelled PEG which was 
assayed turbidometrically using a method described by Hyden (1955).
OBJECTIVES OF THE CURRENT STUDY
It is apparent from the preceeding discussion that although it 
is accepted that_ the rate of gastric emptying is a factor influencing drug 
absorption, there has been no investigation specifically designed to establish 
the nature of this relationship. The objectives of the study described here were
1. To investigate the normal patterns of gastric emptying 
in the rat.
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2. To investigate the effects of various compounds 
on gastric emptying.
3. To investigate the importance of gastric emptying 
rate as related to drug absorption in vivo in the 
rat and man.
As a result of some of the studies on gastric emptying it 
became apparent that there was no adequate way of describing, quantitatively, 
intestinal motility. Consequently an attempt has been made to derive a 
mathematical model to describe intestinal motility.
CHAPTER 2
MATERIALS AND METHODS
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CHEMICALS AND DRUGS
Drugs
The drugs used in these studies were obtained from the 
following sources: amitriptyline HCl, Merck Sharp and Dohme; nortriptyline 
HCl, Dista Products; imipramine HCl, desmethylimipramine HCl and 
oxyphenylbutazone, Ciba Geigy; phenobarbitone, Chas Zimmermann; 
dexamphetamine sulphate, methyl amphetamine, piperazine, trimethoprim lactate,
salicylic acid, quinidine sulphate. Compound I (3 am ino-1:1-diphenylprop- 
1-ene), its secondary amine derivative Compound II, tertiary amine 
derivative Compound III, and Compound IV (1,1-Di-(4-diphenylyl)-3- 
dimethylaminoprop-l-ene), Burroughs Wellcome. The structures of all these 
compounds are given in Table 1.
Radiochemicals
Polyethylene (1,2-^^C) glycol mol. wt. approximately 4,000, 
0.46 mCi/g (NEN Chemicals GMbH) was supplied by Microbio Labs. Carbon-14 
imipramine (N-(3-Dimethylaminopropyl)amino-dibenzyl (methylene-^ ^ ) 
hydrochloride) 4.6 mCi/mmole, ^^C acetylsalicylic acid (Acetyl-(Carboxyl 
1^0 salicylic acid) 22 mCi/mmol, n-(l-^^C) hexadecane standard for 
scintillation counting, D-(l-^^C) glucose 3.4 mCi/mmole, were all obtained 
from the Radiochemical Centre, Amersham. Carbon-14 labelled trimethoprim 
(2,4-Diamino-5-(3,4,5-trimethoxy-benzyl) pyrimidine-2-^^C) was prepared 
according to an unpublished method of P.B. Thorogood by the Radiochemical 
Centre, Amersham. The sample had a specific activity of 6.5 mCi/mmole.
The radiochemical purity of ^^C-imipramine, ^^C-trimethoprim, ^^C-poly- 
ethylene glycol and ^^C-acetylysalicylic, was checked by standard TLC 
techniques and found to be at least 98% in all cases.
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BASIC STRUCTURE
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DESMETHYLIMIPRAMINE
IMIPRAMINE
NORTRIPTYLINE
AMITRIPTYLINE
DEXAMPHETAMINE 
METHYLAMPHETAMINE
COMPOUND I 
COMPOUND II 
COMPOUND III
ABBREVIATION
DMI
COMPOUND IV
TRIMETHOPRIM
PIPERAZINE
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OXYPHENYLBUTAZONE
SALICYLIC ACID
IMI
NT
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I
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OPB
SA
,Ofl
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* Indicates position of label where appropriate.
TABLE 1
Structures of the Compounds Studied
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Preparation of  ^ Salicylic Acid
Carbon-14 salicylic acid was prepared from acetyl­
salicylic acid by alkaline hydrolysis; 0.2 mg of ^**C-acetyl-salicylic 
acid were mixed with 0.2 ml of 0.5 M NaOH. The mixture was heated at 
50° for 1 hr. Then 30 mg of pure salicylic acid were added to the 
mixture and the total volume made up to 2 ml with water. The mixture was 
then made slightly acid by addition of HCl and extracted 3 times with 
6 ml of diethyl ether. Portions of the pooled extract were run on silica 
gel TLC plates in acetic acid :benzene : ether :methanol (18:120:60:1). The 
yield of ^^C-.salicylic acid was 94.3%.
Chemicals
Aerosil (fumed silica) was obtained from Beach Bush and 
Segner Bayley, Butyl PBD from Ciba laboratories, Dioxan from Intertechnique 
and Halothane (veterinary) from May and Baker. Triton XlOO was purchased 
in bulk from Lennig Chemicals and Triton X405 for scintillation counting 
(75% aqueous solution) was obtained from Koch Light. The toluene used 
for scintillation counting was technical grade supplied by Carless 
Chemicals. 3-Glucuronidase/arylsulphatase from helix pomatia (GRD 
activity 5.2 U/ml, ARS activity 2.6 U/ml) was obtained from Boehringer 
Mannheim. All other chemicals and solvents were BDH Analar or laboratory 
reagent grades.
MEASUREMENT OF RADIOACTIVITY
An Intertechnique SL40 ABAC and a Nuclear Chicago Mk. II 
scintillation counter were used throughout this work. Counting efficiencies 
were determined using the external standard channels ratio (ESCR)
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technique (Johnson, et al., 1972) from quench curves which were 
constructed using biological samples. In every batch of samples 
counted, the validity of the ESCR results were checked by internal 
standardization of a representative range of samples. Agreement between 
the two methods was better than 1 .5%.
Solubilization of Tissues
It was apparent at an early stage in this work that a large 
number of biological samples would need to be analysed for ^^C. The cost 
of commercially available solubilizers prohibited their use for this 
purpose and combustion techniques were obviously unsuitable because of 
the number of samples involved. It was therefore thought necessary and 
desirable to develop an inexpensive solubilizer which would be compatible 
with an inexpensive scintillator. Such a solubilizer (SHT) was 
developed which was sufficiently inexpensive to allow whole stomachs 
and intestines to be solubilized. The composition of SHT is shown in 
Table 2.
TABLE 2
Composition of SHT
Sodium hydroxide 80 g
Water 600 ml
Methanol 300 ml
Triton X405 100 ml
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SHT tissue digests were counted after neutralization with 
nitric acid in a toluene/triton scintillator (Patterson and Green, 1965), 
the composition of which is shown in Table 3.
TABLE 3
Compositon of tT21 scintillator
Toluene 1,000 ml
Triton XlOO 500 ml
Butyl PBD 10.25 g
The tT21/SHT combination was extensively investigated and 
shown to be an accurate and reliable method of determining in rat
tissues. This work has been fully reported elsewhere (Dent and Johnson, 
1974a and 1974b), and only a brief summary of the results obtained in 
validation of the method will be given here.
Method '
Up to 250 mg wet weight of tissue per ml of SHT were 
solubilized by treatment in an ultrasonic cleaning bath (Kerry 
Pulsatronic Model K901) at 50-70° and maximum power in 1 hr. One ml of 
the digest was then acidified with 0.5 ml of 4.4 M HNOg. This volume of 
HNO3 provides a 10% excess of acid to ensure the samples were never 
alkaline. 10 ml of tT21 scintillator were then added. Chemiluminescence 
was not found to be a problem with this system so long as samples were 
neutral or acidic when the scintillator was added.
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Solubilizing Capacity of SHT
To determine the solubilizing capacity of SHT various 
weights of rat liver were solubilized in 1 ml SHT, acidified and 
scintillator added. The samples were then assessed visually and the ESCR 
of the samples measured over 7 days. Samples of up to 250 mg were stable 
for at least 7 days at room temperature and a counting chamber temperature 
of 14°.
Effect of Excess Acid on Counting Efficiency
Samples of liver, lOO mg wet weight, were solubilized with 
SHT and then acidified with 8 M nitric acid. Water was added to each 
sample to make the volume up to 1.5 ml. 10 ml of tT21 were added and 
counting efficiency was measured by internal standardization. As can be 
seen in Table 4 a 10% excess of acid has no effect on counting efficiency. 
A 100% excess, such as would occur if a sample received two additions of 
acid in error, gives a lowered but acceptable counting efficiency.
TABLE 4
Effect of excess HNO3 on counting efficiency 
of 100 mg of rat liver digested in 1 ml SHT.
% Excess Acid O 20 60 lOO
% Counting Eff. 85.0 85.0 82.6 78.0
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Counting Efficiency of Aqueous and Organically Soluble 
Material in SHT/tT21
Water, toluene and triton form a heterogeneous mixture and 
it has been reported that at certain ratios of water, toluene and Triton, 
counting efficiency is dependent on the solubility properties of the 
material containing the radioactive label (Fox, 1972). An experiment was 
performed to determine whether the lipophilicity of the labelled material 
affected counting efficiency in the SHT/tT21 system in a range of samples 
which could be encountered in normal use.
Triplicate samples of 200 mg of liver homogenates, 1:1 with 
water, were solubilized in various volumes of SHT and acidified with 
various volumes of HNO3 . Scintillator solution was then added and the 
samples spiked with either standardized ^^C-hexadecane or a standardized 
aqueous solution of D-(l-^^C) glucose. The samples were then counted 
and the counting efficiency was computed; the results are shown in Table 5.
TABLE 5
Counting efficiency of aqueous and 
organically soluble material in SHT/tT21
Sample vol.* Mean % 
Aqueous
Counting Efficiency 
Organic
1.15 76.6 74.3
1.35 74.2 73.3
1.70 74.3 74.6
2. 1 0 73.1 73.4
*Samples comprised of liver homogenate, (assumed to be 0.2
and HNO3 4.4 M in the ratio 2 ;1 make up the remaining volume.
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It is apparent that in the range of sample size 
■investigated, the nature of the labelled material does not affect the 
counting efficiency.
Recovery of from Spiked Homogenates
Aqueous 1:1 rat tissue homogenates were prepared and these 
were spiked with D-(l-^^C) glucose at two activity levels (66300 dpm/g 
high activity, 5900 dpm/g low activity). Triplicate 200 mg samples of the 
homogenates were solubilized with SHT by two different operators, neither 
of whom knew the levels of activity originally added. The solubilized 
tissues were counted and the activity levels calculated and compared 
with the original activity added.
TABLE 6
Recovery of from rat tissue homogenates
as measured by two independent operators.
TISSUE OPERATOR
PERCENTAGE RECOVERY ± S.D.
HIGH ACTIVITY LOW ACTIVITY
66300 dpm/g 5900 dpm/g
Water JD 100 + 2 100 + 1
EB 100 + 2 101 ± 2
Plasma JD 99 + 1 102 + 1
EB 100 + 2 104 + 1
Brain JD 98 + 2 104 + 1
EB 92 + 1 99 + 1
Liver JD 99 + 1 99 + 1
EB 99 + 2 104 + 2
Heart JD 102 + 2 101 + 2
EB 102 + 1 101 + 1
Lung JD 103 + 1 101 + 2
EB 105 ± 1 102 + 1
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Table 6 shows that the recovery of from spiked 
homogenates closely approximates to 1 0 0% and is independent of operator. 
These results provide good evidence as to the quantitative accuracy of the 
method.
A comparative study of SHT with other commercially available 
solubilizers has been reported elsewhere (Dent and Johnson, 1974a). It 
may be concluded that SHT provides a cheap, efficient and accurate method 
of assaying in rat tissues. The ESCR method of computing efficiency
can be applied to the SHT/tT21 system and in the case of ^^C the lipo­
philicity of the labelled material being assayed is not important in the 
range of sample volumes normally encountered.
ANIMALS AND DOSING PROCEDURES
Animals
An inbred strain of Wistar derived rats were used 
throughout this study. Practically all the animals used showed signs of 
pulmonary infection, exhibiting pneumonic lesions. Some sample lesions 
examined by the Pathology Department were thought to have arisen from a 
strain pneumonococcus. This condition is common in rats and very difficult 
to completely eliminate. It was thought that these conditions were 
unlikely to affect the validity of the experiments, especially as all 
experiments involved comparisons with controls. Rats were maintained on 
a normal cube diet (Thompson's diet, Heygates formula).
Dosing Procedures
Oral dosing was performed with a 1 ml disposable plastic 
syringe (Gillette Scimitar), fitted with a SWG16 needle, the end of
which had been rounded off. The syringe in many cases was fitted with a 
constant delivery device (Johnson and Trist, 1974). Intraperitoneal and
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intravenous injections were performed using a 1 ml disposable syringe 
fitted with a 25G x ^/q " needle (Gillette Scimitar).
Selection and Housing of Animals
Batches of animals were selected for experiments by weight. 
The animals were then assigned numbers and distributed to cages, two to a 
cage, according to a random number distribution table. For convenience 
the animals were then renumbered from 1 upwards. In all instances 
animals were handled several times on the two days preceding the 
experiments.
MEASUREMENT OF GASTRIC EMPTYING RATE
Gastric emptying rate and intestinal transit time was 
measured as the passage of a non-absorbable radiolabelled marker through 
the stomach and intestine. The marker used was polyethylene (1,2-^^C) 
glycol (l^c-PEG).
Experimental Procedure
Gastric emptying rate was measured in fed and starved 
animals; in the former case free access to food and water was allowed at 
all times; in the latter case free access was allowed to water at all 
times, but food was withheld for 16-20 hr prior to and for the duration 
of the experiment.
All the experiments were started between 08.00 and 09.00 hr. 
Two dosing procedures were used to investigate the effects of drugs on 
gastric emptying rate. In the first method the drugs and the ^^C-PEG 
(5 mg ca. 1 x 10^ DPM) were dosed orally in 1 ml of water; two hours 
later the animals were killed by CO2 euthanasia followed by cervical 
dislocation. In the second method animals received 1 ml of an aqueous
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solution of the drug or 1 ml of water (controls) orally, followed 45 min 
later by 1 ml of an aqueous solution of PEG (5 mg ca. 1 x 10^ dpm); 
the animals were killed, in the manner described above, 1 hr 15 min after 
the PEG dose. Several methods of killing the rats were tried; 00%
euthanasia was chosen as animals killed by this method exhibited least 
observable intestinal contractions after death.
Immediately on death the gastrointestinal tract was 
exposed by a mid-line incision in the abdomen. The stomach was clamped at 
the oesophageal and pyloric junctions with Spenser-Wells forceps, and 
removed. The small intestine was also clamped at the pyloric and 
ilio-caecal junction and was removed from the animal by pulling gently 
from the pyloric end. When handled in this way, the small intestine 
"runs" out of the peritoneal cavity leaving the mesentary behind. The 
intestine was then layed on a pre-marked table and divided into the 
required number of segments. The colon and caecum were removed together. 
With practice the whole operation could be performed in 60 seconds.
Once removed from the animal the tissues were solubilized 
in SHT. The stomach and intestinal segments, along with their contents, 
were solubilized in 10 ml of SHT, then diluted to 20 ml with water; 
duplicate 1 ml portions of this mixture were acidified and counted in tT21. 
The colon, caecum and contents were solubilized in 20 ml SHT, the volume 
of the final digest was measured, and duplicate 1 ml portions were 
acidified and counted in tT21. The contents of the colon and caecum 
would not solubilize completely, the fibrous material from the diet 
remained as a solid suspension. The content of this fibrous material
was assayed by combustion in a tube furnace (Griffiths and Mallinson, 1968). 
The content of the solid material was approximately the same as an
equivalent weight of the supernatant. It was therefore decided that the 
non-solubilized material would not significantly affect the accuracy of
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the assay. Samples of the colon and caecum digests were taken with a 
wide bore pipette after shaking the sample vigorously.
Measurement of Intestinal Transit
Intestinal motility was measured as the transit of PEG
along the gastrointestinal tract. Animals were dosed with 1 ml of
aqueous drug solution or 1 ml of water then 1 hour later with 1 ml of
PEG (5 mg 1 X 10^ dpm). Two animals were killed at each time interval 
by the method previously described. The stomach, small intestine, and 
colon together with the caecum were removed as described for gastric 
emptying. In one series of experiments, the intestines were treated 
exactly as described in the previous section. In the second series of 
experiments the small intestine was divided into ten segments. Each
segment was solubilized in 1 ml of SHT, neutralized and counted in 10 ml
tT21. The stomach, colon and caecum were treated as described 
previously.
MEASUREMENT OF PLASMA LEVELS AND ABSORPTION
The plasma levels of radioactivity following an oral dose 
of imipramine, trimethoprim and salicylic acid, were measured. Initially
a method involving dosing large groups of animals, killing pairs of animals 
at various time intervals, and taking blood by heart puncture was used. 
However this method proved unsatisfactory for reasons discussed later and 
so a method for measuring plasma levels in individual animals was 
developed.
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Measurement of Gastric Emptying, Absorption and Plasma Levels 
of Radioactivity from  ^^ C-Imipramine and  ^ C-Trimethoprim
Rats 200 ± 5 g were starved for 16 hr prior to dosing.
They were dosed orally with 1 ml aqueous solution of -imipramine HCl 
(0.2 mmole/kg) 12.64 mg approx. 1 x 10^ dpm per animal. At various time 
intervals after dosing, pairs of animals were anaesthetized with ether, 
blood taken by heart puncture and transferred to a heparinized tube. The 
animals were then killed by cervical dislocation and the gastrointestinal 
tract removed. The stomach, the small intestine and colon and caecum 
were solubilized as described previously. The blood was centrifuged and 
duplicate 0.2 ml samples of plasma were diluted to 1 ml with water and 
counted directly in 10 ml of tT21.
A similar procedure was followed for determining the 
emptying rate and plasma levels of radioactivity following an oral dose 
of ^^C-trimethoprim. In this case two groups of animals were used: 
an imipramine pretreated group dosed with 0.2 mM/kg imipramine (dose 
volume 1 ml) one hour before the trimethoprim and a control group dosed 
with 1 ml of water 1 hr prior to the trimethoprim. The trimethoprim was 
given as the lactate (5 mg/kg free base), 1 mg, approx. 2 x 10^ dpm, per 
animal in 1 ml of water.
Plasma Levels of Radioactivity in Individual Animals Following 
Oral Administration of ^^C-Trimethoprim and ^^C-Salicylic Acid
Starved or fed rats 200 ± 10 g were dosed with 1 ml of 
imipramine HCl 0.2 mmole/kg followed 1 hr later by 1 ml aqueous ^^C- 
trimethoprim lactate 5 mg free base/kg, Approx. 5 x 10^ dpm) per rat; 
or 1 ml aqueous ^^C-salicylic acid Na salt 15 mg/kg free acid (approx.
5 X lO^ dp# per animal. At regular time intervals after dosing 0.2 ml 
of blood were taken from the rat's tail. The tail was warmed in water at 
approximately 40° for 30-60 seconds then carefully wiped dry. For the 
first sample 2-3 mm of the tail was chopped off with a scalpel and the
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blood was taken by a very gentle stroking action onto a white dimpled 
tile. For subsequent samples it was not usually necessary to re-cut 
the tail. The blood, 0.2 ml, was transferred to 0,8 ml of heparinized 
saline (ca. 5,000 units of heparin/100 ml normal saline). This was 
centrifuged and 2 x 0 . 3 5  ml of supernatant were diluted to 1 ml with 
water and counted in 10 ml of tT21.
The validity of this method for assaying radioactivity 
from trimethoprim and salicylic acid in plasma was checked by a
variety of methods. At the end of an experiment, blood was taken from 
each animal by heart puncture and this was assayed for radioactivity as 
whole blood, plasma and saline-diluted-blood supernatant. For trimethoprim 
there were no significant differences between plasma and saline plasma.
The ratio of in the red blood cells (R.B.C.'s) to plasma was close to 
1, as shown in Table 7.
TABLE 7
The plasma/red blood cell ratio for the 
distribution of radioactivity in rats 
following oral administration of ^^C- 
trimethoprim.
Rat Treatment Ratio
SI Imipramine Starved 1.04
52 1.00
S3 0.96
S4 Control 0.95
S5 0.99
56 0.96
F7 Imipramine Fed 1.10
F 8 1.06
F9 1.11
Flo Control 1.12
Fll 0.99
F12
Mean Ratio 1.0 1 ± 0 . 1
0.94
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In the case of salicylic acid the R.B.C. plasma ratio for 
the distribution of ^^C was not found to equal 1. When whole plasma 
prepared directly from blood was assayed for radioactivity the ^^C 
level was lower than that obtained when blood was diluted with saline 
before centrifugation, as shown in Table 8 .
TABLE 8
Plasma ^^C to saline-blood-supernatant l^C ratio in 
rats.following an oral dose of ^^C-salicylate.
Animal Treatment Ratio
Plasma/Saline-Blood-Supernatant
30 Imipramine 0.80
31 " 0.84
32 " 0.77
33 Control 0.76
34 " 0.78.
35 " 0.73
Mean Ratio 0.78 ± 0.03 S.D.
The mean ratio shown in Table 8 was used as a correction
factor to calculate the plasma concentrations from the experimental
results. This ratio was also checked by adding differing amounts of ^^C-
salicylic acid to rat blood, incubating at 30° for 3 hr and determining
the ratio. The ratio was found to be constant over the range of plasma
concentrations encountered.
Assessment of the Accuracy of ^^C Measurements in Plasma
The value obtained for plasma ^^C in the last sample taken 
from the tail was compared with the value obtained for plasma ^^C level 
measured in plasma prepared from the heart puncture blood, taken 
minutes after the last tail bleed. When the correction factor was applied 
to the salicylate results obtained from saline supernatant they differed by not
more than 8% from those obtained with heart puncture plasma. The
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trimethoprim showed a greater difference of up to 12%. However, the levels 
of activity were low in the case of trimethoprim.
Metabolism of ^^C-Trimethoprim in the Rat
Rats (200 ± 10 g) were starved for 16 hr and then dosed 
with 1 ml of water or aqueous imipramine HCl solution 0.2 mmole/kg. One 
hr later they received 1 mg (4.4 x 10^ dpm) of trimethoprim as the lactate 
in 1 ml of water by the oral route or the same amount in 0.25 ml saline by 
the intraperitoneal route. Urine was collected at 24 and 48 hr; the 
animals were housed individually in all-glass metabolism cages. Portions 
of the urine 50 to 100 y 1, were diluted to 1 ml with water and counted in 
tT21.
Samples of urine were then spotted onto Silica gel TLC 
plates (Eastman Chromagram Sheets No. 13181 supplied by Kodak), and run
in CHCI3 :n-propanol:ammonia, 80:20:1, on silica gel plates. To obtain
reproducible results it Was necessary to allow the tanks to equilibrate 
for 4 hr prior to the run.
Samples of urine were also treated with glusulase. To 3 ml 
of urine 0.05 ml of 2 M sodium acetate buffer pH 5.2 (2 M sodium 
acetate adjusted to pH 5.2 with acetic acid) and 0.05 ml of glusulase 
were added. The mixture was incubated at 37° for 4 hr and the 10 y1 
portions were subjected to TLC as previously described. When the 
chromatograms had developed they were initially visualized using a Panax 
Scintagraph and then autoradiographed on Industrex D X-ray film for
5-10 days. The autoradiographs were developed using Kodak DX80
developer and FX40 fixer in the manner recommended by the manufacturers.
The areas corresponding to the darkened spots on the 
autoradiographs were marked on the chromatogram. These areas were cut 
out and then cut into pieces 6-8 mm square, placed in a scintillation 
vial with 1 ml of water and sonicated in the ultrasonic bath for 30 min
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to 1 hr, Aerosil dioxan scintillator 10 ml, (100 g napthalene, 50 g 
aerosil, 8 g butyl PBD made up to 1 1 with dioxan) (Blanchard and 
Takahashi, 1961), was then added and the samples counted. The activity 
recovered from the plate was expressed as a percentage of the total 
activity recovered for any given sample. Total recovery from each 
animal was within the range 89-107% of the activity of the dose given.
Excretion of Radioactivity Following Oral Dosage 
of •^^C-Trimethoprim
Rats 200 ± 10 g were placed in glass metabolism cages. 
Three were starved for 16 hr and three were allowed free access to food. 
They were then orally dosed with 1 mg of trimethoprim free base (2 x 
10^ dpm) as the lactate in 1 ml of water. Urine samples were 
collected at intervals over a period of 48 hr. Faeces were collected at 
24 and 48 hr. The volume of each urine sample was measured and portions 
were counted, after dilution to 1 ml with water, in tT21. Faeces were
solubilized in SHT, lOO mg in 1 ml of SET. The SET did not solubilize
completely the fibrous material; samples of fibre remaining after 
solubilization weire combusted in a tube furnace (Griffiths and Mallinson, 
1968). The amount of activity in the fibrous material was negligible.
Lymphatic Absorption of Trimethoprim and Salicylic Acid
The cannulation of the rat mesenteric lymph duct was
performed by a modification of the method of H. GalloTorres, (personal
communication). A 250-300 g rat was dosed orally with 0.5 ml of olive 
oil, two to three hours before the operation. The animal was then 
anaesthetized with halothane using a British Oxygen anaesthetic machine 
modified for rats. The animal was opened by a mid-line incision, from 
the xiphoid process of the sternum to the lower abdomen. The abdominal 
contents were reflected laterally towards the animal's left side, and 
covered with a saline moistened gauze. The superior mesenteric artery
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was then located; the connective tissue covering the artery was teased away 
with a blunt disector to expose the artery flanked on either side by the 
intestinal lymph duct. The smaller of the two ducts was separated from 
the artery and tied off. The larger duct was then separated from the 
artery and two ligatures passed under it; one as near the aorta as 
possible, one as far away from it as possible. The ligature nearest the 
aorta was tied to halt the lymph flow. A small incision was then made 
in the duct with microscissors or a sharp disector. A sharpened
siliconized PP2 5 cannula was immediately inserted into the duct and the
other ligature tied. Finally, a small amount of Eastman's 910 adhesive 
was used to secure further the cannula. The cannula was passed into 
a glass peritoneal bulb (Johnson and Pover, 1963). The animal was then 
sewn up and allowed 20 hr to recover. A post operative drink (50 g 
glucose 0.5 g KCl 0.9g NaCl in a litre of water) was provided for the 
duration of the recovery and experimental period. Food was withheld for
the duration of recovery and for eight hours after dosing.
The animals were dosed with 1 ml of aqueous imipramine HCl 
(0.2 mmole/kg) or 1 ml of water. One hour later they received ^^C- 
trimethoprim 5 mg free base/kg as the lactate (2-2.5 x 10^ dpm) or ^^C- 
salicylic acid Na Salt 15 rag/kg (approx. 5 x 10^ dpm). Lymph samples were 
taken at time intervals over 24 hr. When each lymph sample was taken the 
bulb was washed out with 1 ml of heparinized saline (ca. 5,000 units/10 ml). 
The volume of the lymph samples was measured and portions (0.2-0.6 ml) were 
made up to 1 ml with water and counted in tT21.
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VOLUNTEER STUDY 
The protocol for the volunteer study is shown below.
Subjects
Four healthy male volunteers over 21 were selected. Their 
health was checked by interview and letter to general practitioner. The gastric 
acid secreting status of the subject was checked using the Squibb Diagnex 
Blue test. They reported to the laboratory at 07.30 hr and received a 
standard light breakfast of cereal, rolls and fruit juice. No cigarettes, 
tea or coffee.
Pretreatment
At 08.00 hr the following preparations were given orally each to 
one subject: lactose dummy, atropine sulphate 0.6 mg, imipramine 25 mg 
(base) and Compound II 25 mg (base). On subsequent occasions at weekly intervals 
over four weeks each subject received each treatment according to a balanced 
Latin square design.
Blood Sampling
Venous catheters were inserted into the arm veins between 
08.00 hr and 09.00 hr in readiness to take blood samples of 5 ml at 10 
minute intervals for 3 hr after administration of trimethoprim and 
salicylic acid. Throughout the whole morning subjects rested quietly.
Additional blood samples were taken at 14.00, 15.30 and 17.00 hr.
Drugs
At 09.30 after initial blood samples the 4 subjects 
received trimethoprim (l60 mg in 10 ml of water) and salicylic acid 
(200 mg in 10 ml of water) orally; these solutions were taken rapidly, one after 
the other, and washed down with 50 ml of water. No other fluid or food 
intake was allowed until 12.30 hr.
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Urine Collection
A sample of urine was collected immediately before and 
3, 6 and 24 hr after administration of trimethoprim and salicylic acid. 
Urinary pH was measured and recorded.
Analysis of Salicylate in Human Plasma
Plasma salicylate levels were measured using a modification 
of a method described by Chirigos and Udenfriend (1959). This assay 
measures salicylate, both free and protein bound. Conjugated salicylic
acid is not extracted and salicyluric acid does not significantly interfere 
with the assay.
Procedure
Plasma (0.1 ml) was transferred to a stoppered test tube 
containing diethyl ether (10 ml) and 2 N HCl (1.5 ml). The tube was 
shaken manually for 30 sec and allowed to stand for 5 minutes. 5 ml of the 
ether layer were transferred to a similar tube containing 0.1 N NaOH
(10 ml). The tube was again shaken for 30 sec, and on settling the ether 
layer was removed by aspiration. The tubes were then placed in a water 
bath at 45° for 30 min to drive off any excess ether. On cooling, a sample 
of the lower phase was transferred to a fluorimeter cuvette. The relative 
fluorescence index was measured at 300 nm excitation, 400 nm emission in a 
Hitachi Perkin Elmer Fluorescence Spectrophotometer Model MPF2A. The 
instrument settings were: excitation and emission slit widths 10 my; no 
photomultiplier or excitation filters were used; the instrument was always 
used in the ratio mode.
The extraction procedure used was checked. ^^C-salicylic 
acid extraction efficiency was better than 94%; less than 1% of 
trimethoprim was extracted with the salicylate. A standard calibration 
curve was constructed using salicylate-free human plasma. The
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standards were prepared by adding known quantities of salicylate to 
20 ml portions of plasma. 1 ml portions of these were stored at -2 0° 
until required. The standards were not thawed more than three times.
Using the procedure described, the fluorimeter response was linear up to 
at least 20 yg/ml. A best fit line was fitted to the standards by linear 
regression and the unknown salicylate values were calculated from the 
equation for a straight line.
Background and Interference from Other Drugs
In all instances, 0.1 yg/ml of salicylate gave a 
fluorescence reading which was at least twice background. The 
background fluorescence came mostly from the reagent used with only a 
small contribution from the plasma. However, due to the adequately 
high sensitivity of the method no attempt was made to improve this.
None of the other drugs involved in the trial interfered with the assay 
procedure. None of the other drugs in the study caused a significantly 
increased background fluorescence when 5 and 10 yg were added to the 
cuvette. Trimethoprim had no effect even when 100 yg were added.
Analysis of Trimethoprim in Human Plasma
Trimethoprim in. human plasma was to have been measured by 
the Wellcome (1970) modification of Schwartz et al. (1969) spectro- 
photofluorometric method. The other drugs did not interfere with this 
analysis. This method is not a particularly good one, as it relies 
on alkaline permanganate oxidation of the trimethoprim to trimethoxy 
benzoic acid. This reaction has a nominal 70% yield. However, attempts 
to develop a suitable alternative failed. The most promising approach 
which would stand further investigation involved extraction of the 
trimethoprim and finally fluorescence measurement in freshly re-distilled 
n-butanol or iso-propanol. The relative fluorescence index of trimethoprim
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in these solvents is approximately equal to that of trimethoxybenzoic 
acid in chloroform. It was however not possible to obtain a plasma 
blank with a fluorescence background equivalent to a trimethoprim 
concentration of less than 1 yg/ml.
Computer Analysis of Data
The data obtained from experiments to investigate gastric 
emptying and drug absorption, was fitted to single and double exponential 
expressions by computer methods. The data was fitted by the non-linear 
least squares methods, on an I.C.L. 1900 series computer. The statistics 
for the parameters derived were obtained by examination of the shape of the 
least squares function around the minima, by a method similar to that described 
in the I.C.L. Mark 2 statistics manual.
CHAPTER 3
THE EFFECT OF VARIOUS COMPOUNDS 
ON GASTRIC EMPTYING IN  THE RAT
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INTRODUCTION
Several posssible mechanisms exist by which d m g s  could 
inhibit gastric emptying. The secretion of gastric hormones, or the 
secretion of hydrochloric acid from the stomach could be affected. The 
osmo-receptors in the duodenum could respond to the drug concentrations 
leaving the stomach or the drugs could affect the nervous control of 
stomach motility. Consolo and Ladinsky (1971) presented data which, with 
limitations, suggested that a range of compounds with anticholinergic 
activity inhibit gastric emptying. In order to test this hypothesis more 
rigorously, a wide range of compounds with differing anticholinergic 
activities were examined for a possible effect on gastric emptying. It 
transpired that most of the compounds selected for this study had cogeners 
which differed only in the degree of N-methylation (see Table 1). Where 
possible, cogeners were incorporated in the study to determine if the 
degree of N-methylation was of importance in inhibiting gastric emptying.
A number of non-anticholinergic compounds were also included in the study. 
Trimethoprim, salicylic acid and quinidine sulphate were candidates for 
subsequent work on the effect of gastric emptying on absorption. Compound 
IV is structurally similar to compound III but devoid of anticholinergic 
activity. Piperazine was included as an example of a heterocyclic amine 
with little pharmacological activity. Phenobarbitone was included as an 
example of a hypnotic which was known to reduce gastric muscle tone and the 
amplitude of gastric contractions whilst possessing no anticholinergic 
activity (Sharpless, 1965). Oxyphenylbutazone was examined for its 
effects in view of the apparently very slow rate at which it left the stomach 
in the work reported by Consolo and Ladinsky (1971).
In order to investigate a possible correlation between 
anticholinergic activity and potency in inhibiting gastric emptying, the 
compounds were administered on an equi-molar basis. The selected dose level
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of 0.2 mM/kg was at least 50% lower than the LDgg of all the compounds.
Due to its high molecular weight and relatively low solubility, quinidine 
sulphate was dosed at 0.1 mM/kg. Oxyphenylbutazone was dosed at 15 mg/kg 
dispersed in 4% Gum Arabica in saline.
THE EFFECT OF VARIOUS COMPOUNDS ON GASTRIC EMPTYING
The Use of ^^C-Polyethylene Glycol 4000 
as a Marker for Gastric Emptying Studies
An ideal marker for measuring gastric emptying rate should 
be chemically inert, pharmacologically inactive, non-absorbable, 
quantitatively recoverable from the gastrointestinal tract and easy to 
assay. There are several compounds which have been used as markers as 
mentioned earlier. Phenol red and ^^C-polyethylene glycol (^^C-PEG) have 
both been widely used.
Phenol red may, to a limited extent, be absorbable (Reynell 
and Spray, 1956). There is evidence that phenol red is absorbed from rat 
lung (Enna and Schanker, 1973). Furthermore, phenol red has to be estimated 
spectrophotometrically and the possible interference from the contents of the 
gastrointestinal tract must be considered, especially in fed animals. The 
assay of ^^C-PEG is a radiometric procedure and interference from other 
substances in the gut is not a problem.
A preliminary study in six starved rats, where ^^C-PEG was 
administered orally, the gastrointestinal tract subsequently washed out with 
water and the washings assayed for ^^C, indicated that ^^C-PEG could be 
quantitatively recovered from the rat gastrointestinal tract. An analysis 
of the recovery from all the animals (195) where the entire gastrointestinal 
tract was assayed for showed a recovery of 98.9 ± 6.7 (S.D.) %. Recent
reports (Domschke et al. 1973; Wingate et al. 1972) show that the recovery 
of l^C-PEG from the human gastrointestinal tract can be quantitative, and
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Offer et al. (1972) have shown that recoveiry of l^C-PEG in the sheep is 
quantitative. These reports, and also the findings of Hayton and Levy 
(1971) together with the results presented here substantiate the conclusion 
that l^C-PEG is non-absorbable and quantitatively recovered from the gastro­
intestinal tract.
It can be seen from the mean percentage recovery, quoted 
above, that recovery was not 100% in all cases. In order to eliminate slight 
differences in recovery, arising mainly from dosing error, the recovery from 
each individual animal was normalized to 1CXD%.
In the experiments described here, ^^C-PEG was administered 
as an aqueous solution. There is no reason to believe that ^^C-PEG would 
be precipitated by the conditions in the gastrointestinal tract. The emptying 
rate of ^^C-PEG solution may therefore be taken to represent the rate at which 
water or a drug solution will leave the stomach. The distribution of ^^C-PEG 
in the small intestine will reflect the rate of passage along the intestine 
of water or a drug solution.
Normal Gastric Emptying Patterns in the Rat
The normal gastric emptying pattern of ^^C-PEG in stairved rats 
is shown at the top of Fig. 11, and in fed rats in Fig. 12. Previously, 
gastric emptying of a test meal in man has been shown to be exponential; it 
is also claimed that a linear relationship between the square root of the 
stomach volume and time exists (Hunt and Knox, 1968)- The gastric emptying 
of a large volume (4 ml) of a glucose solution in rats was considered to be 
exponential (Reynell and Spray, 1956) , as was the emptying of a solution 
of: ^^C-PEG 5%, phenol red 1 mg, glucose 1 mg, and sodium chromate 
(insignificant mass) in 1 ml of phosphate buffer (Nylander and Wikstrom, 1968) . 
There are no descriptions of the gastric emptying pattern of water in starved 
or fed rats. The data in Figs. 11 and 12 suggested an exponential pattern and 
when the data was fitted to a single exponential expression of the form
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—otty = Ae a good fit was obtained. The values of for starved and fed 
control rats are shown in Table 11.
The normal pattern of gastric emptying in control animals is 
very variable and rapid, as shown by a comparison of Fig. 11 and 12. The
_3
rate of gastric emptying is slower in fed control animals (a^ = 48.1 x 10
_1 _3 _1
min ) than in control starved animals (a^ = 92,3 x 10 min ). The
difference between these values is significant (P <.OOl) (Table 14).
The th of emptying of ^^C-PEG in fed rats was calculated from 
«g as 22 min. From a visual inspection of the stomach and small intestine 
of fed animals killed at 10, 20 and 30 min after administration of PEG, it 
was obvious that 50% of the stomach contents did not leave the stomach in 
20 min. It is therefore unlikely that the emptying rate of ^^C-PEG in fed 
rats represents the emptying of the stomachs solid contents, and more 
probably it passes round or through the gastric contents.
The Effect of Various Compounds on Gastric Emptying
The retention of marker in the stomach of rats 2 hr after 
co-administration of compounds and ^^C-PEG is shown in Table 9. Group means 
were tested for significance from control means by the method of Welch (1938) 
It was necessary to use Welch's method as the population variances were 
observed to be unequal. It was found that significant amounts of marker 
were retained in the stomach of DMI, IM, NT and DA treated animals.
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TABLE 9
Retention of marker (^^C-PEG) in rats stomachs after simultaneous 
administration of ^^C-PEG and various compounds
Compounds are listed in order of decreasing anticholinergic activity. 
Compounds dosed 0.2 mmole/kg
Compound % marker retained 
± S.E. n = 4
Amitriptyline (AT)
Nortriptyline (NT)
Desmethylimipramine (DMI)
Imipramine (IM)
Compound II (II)
Compound III (III)
Dexamphetamine (DA)
Methylamphetamine (MA)
Control
14.1 ± 5.8 
***36.0 ± 4.0 
**39.0 ± 9.1 
**24.3 ± 3.9 
11.8 ± 4.4 
11.0 ± 6.3 
* 9.2 ± 2.4 
15.6 ± 6.1 
0.4 ± 0.1
* .05>P>.01 ** .01>P>.001 *** .001>P
It can be seen that in animals pretreated with test compound 
45 min prior to the administration of marker, the amount of marker retained 
in the stomachs was greater than in animals where marker and compounds were 
co-administered (Table 10). However, in this second situation the animals 
were killed 1 hr 15 min after administration of the marker. This timing 
was used in order to keep the time after administration of the test compound 
as a constant parameter. (As control animals were employed in both 
situations, this is not of great importance but in comparing results from 
the two methods this time difference with respect to PEG marker compound 
should not be overlooked) The amount of marker retained in the stomach of 
animals pretreated with DMI, IM, AT, NT, Q, Compound I, II and III was
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TABLE lO
Retention of marker (^^C-PEG) in rats stomachs 2 hours after administration 
of various compounds. ■‘■^C-PEG administered 45 minutes after drugs
Compounds are listed in order of decreasing anticholinergic activity. 
Compounds dosed at 0.2 mmole/kg except where otherwise stated.
Compound i marker retained 
± S.E. n = 4
Amitriptyline (AT) 57.4 + 10.3**
Nortriptyline (NT) 56.2 + 5.9***
Desmethylimipramine (DMI) 78.5 + 4.2***
Imipramine (IM) 62.4 + 8.3**
Compound I (I) 50.6 + 6.9**
Compound II (II) 46.8 ± 9.7*
Compound III (III) 41.4 + 10.7*
Dexamphetamine (DA) 33.9 + 15.1§
Methylamphetamine (MA) 41.4 + 18.1§
Desmethylimipramine (0.02 mmole/kg) 6. 8 + 1.3
Desemthylimipramine (0 . 0 0 2 mmole/kg) 2.4 + 0.7
Phenobarbitonet (PB) 7.0 ± 4.7
Piperazinet (PP) 3.4 + 2.4
Oxyphenylbutazonet (15 mg/kg) (OPB) 3.2 + 0.7
Compound IVt (IV) 2.2 + 1.1
Salicylatet (SA) 1.25 ;± 0.2
Trimethoprimt (TMP) 10.9 + 4.9
Quinidine SOi+t (0.1 mmole /kg) (Q) 57.01 :t 8.72*
Control (n = 6 ) 3.9 + 1.5
j" Indicates compounds with little or no anticholinergic activity. 
§ P-.l * .05>P>.01 ** .01>P>.001 *** -001>P
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significant compared with controls. The marker retained in DA and MA 
treated animals was only significant at the 10% level. It was observed 
during the experiments that DA and MA treated animals had considerably 
distended stomachs. The volume of the stomach contents in these animals was 
estimated to be 3 to 4 times that of the stomach contents of any of the 
other animals. This may be of significance in that the stomachs of these 
animals contained less marker than other test groups. It may be assumed that 
this large volume of stomach content, was the result of inhibited gastric 
emptying and stimulated drinking, or increasing secretory activity. The 
pressure created by the increase in volume of stomach contents may, to some 
extent, have overcome the inhibition of gastric emptying. The only natural 
physiological factor which is known to speed gastric emptying is increased 
gastric pressure (Hunt and MacDonald, 1954).
It can be seen in Table 10 that DMI dosed at a level 
equivalent to the human therapeutic dose range, did not inhibit gastric 
emptying under the test conditions used. However, the distribution of 
marker in the intestine of rats treated at these dose levels (Fig. 5) 
indicates that DMI either alters intestinal motility or affects the timing 
and pattern of gastric emptying.
Under the experimental conditions used in this work 
oxyphenylbutazone did not inhibit gastric emptying. The results published 
by Consolo and Ladinsky (1971) indicated that 70% of an oral dose of OPB 
is found in the stomach of rats at 2 hr and 25% at 4 hr after dosing.
The results presented here indicate that some factor other than gastric 
emptying delay must be considered to account for their results. Phenobarbitone, 
DA, TMP and PP did not affect gastric emptying whilst quinidine caused a 
significant retention of marker in the stomach. When the inhibition of 
gastric emptying caused by cogeners was examined, no significant differences 
were found; suggesting that the degree of N-methylation is not important in 
the inhibition of gastric emptying.
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The differences in marker distribution in the small intestine 
resulting from the two different experimental procedures is most marked in 
animals treated with DMI, IM, Compound II and Compound III. In animals where 
DMI and IM were co-administered (Fig. 2), the marker was found mostly in the 
last quarter of the intestine and in the colon and caecum. In contrast when 
DMI and IM were administered as pretreatments (Fig. 4) the marker was more 
evenly spread throughout the small intestine. Similarly marker co-administered 
with Compound II and III (Fig. 3) was mostly in the last quarter of the small 
intestine and the colon and caecum, whereas in animals pretreated with 
Compounds II and III an even distribution of marker was observed (Fig. 6 ).
It may be postulated that the marker in the distal part of the small intestine 
of animals when drug and marker were co-administered is largely a result of 
marker which left the stomach before gastric emptying was inhibited. This 
postulate is supported by the fact that the amount of ^^C-PEG which would 
be expected to be found in the stomach of imipramine pretreated animals 2 hr 
after administration of marker, can be calculated from emptying rate constants 
for ^^C-PEG in imipramine pretreated animals as 45%. The percentage of marker 
retained in the stomach of animals 2 hr after imipramine was co-administered 
with l^C-PEG was only 24% (Table 9). It is also supported by the results of 
the study of the emptying rate of imipramine as discussed subsequently. The 
apparently greater potency of compounds when used as a pretreatment (Table 10) 
could be reasoned to result from the amount of drug absorbed in the 45 min 
prior to the administration of marker.
It is difficult to conceive of a feasible experiment to test 
critically between the possible central and local effects. An i.p. 
administration of compounds would present a high local concentration of the 
drug but high blood levels would also be rapidly attained. If the drug were 
administered i.v., the high blood levels would rapidly occur; this would 
result in a similar concentration of drug arriving at any "central receptors" 
and also at the stomach where a local effect may be mediated. The situation
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is made more complex because there is evidence that basic drugs can be 
secreted into the intestinal tract (Shore et al. 1957) and many of the 
compounds under study or their metabolites would also be expected to be 
excreted in the bile. The evidence presented here points to a post- 
absorptive effect but gives little indication as to whether this is a 
central or local effect.
THE EFFECT OF IMIPRAMINE ON GASTRIC EMPTYING 
AND INTESTINAL MOTILITY
In order to study the effect of altered gastric emptying on 
drug absorption, it was necessary to select a compound which would cause 
a potent inhibition of gastric emptying. Imipramine was chosen for this 
purpose because in the studies described above it was found to be a potent 
inhibitor of gastric emptying (Tables 9 and 10) and was available ^^C 
labelled, which allowed easy measurement both of the emptying rate of 
imipramine itself and of imipramine plasma levels in the form of plasma 
radioactivity.
The Gastric Emptying and Plasma ^^C Levels Following 
Oral Administration of ^^C-Imipramine
The gastric emptying rate of radioactivity following oral
administration of ^^C-imipramine to starved rats was considered to be
exponential. The data was fitted to the single exponential expression
radioactivity from  ^^ C-^ _ _
(Fig. 9). The value of for^imipramine (3.7 x 10  ^ min ^) was very much
smaller than that obtained for ^^C-PEG in control animals (92.3 x 10 min ^).
A very considerable inter-animal variation in emptying rate was found. The
value of the intercept on the abscissa. A, as calculated from the best fit
computation and representing percentage dose in the stomach at time O was only
60%. This supports the postulate that passage into the intestine and absorption
are prerequisite for maximum activity in delaying gastric emptying and suggests
that as much as 40% of the initial dose of imipramine leaves the stomach before
gastric emptying is maximally inhibited.
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The plasma levels of in rats following oral administration
of ^^C-imipramine are shown in Fig. 10. These data were fitted to a one 
compartment model in the manner described in Chapter 4. The two rate constants 
obtained were 5.3 x 10“  ^min“  ^ and 4.7 x 10”  ^min“^. The larger of these was 
assigned as the absorption rate constant (Table 12). This assignment is 
consistent with reports that buccal absorption of imipramine is rapid 
(Bickel and Weder, 1969). In an earlier paper, Bickel and Weder (1968) 
investigated the excretion of imipramine and its metabolites in the rat 
following intraperitoneal administration and found that the major metabolite,
DMI, was excreted most slowly with an elimination half-life of 20 hr. The 
elimination half-life for calculated from the value of k.2 obtained in this
work is 24.4 hr, whereas if the large coefficient is designated as k2 the t^ 
is only O.22 hr.
The considerable inter-animal variation in gastric emptying 
rate as seen in Fig. 9 and Table 13 is reflected in a considerable variation 
in plasma levels of at different times seen in Fig. 10 and Table 13. There
is an apparent correlation between the percentage dose retained in the stomach 
and the plasma levels of at any given time. The experimental values shown
in Table 13 were tested for correlation using a t test for correlated data, 
and found to be highly correlated (P <.001). This implies that gastric emptying 
is CL rate modifying step in the absorption of imipramine, and predicts that 
the absorption rate constant must be the same order of magnitude as, or less 
than, the gastric emptying rate constant for imipramine. A statistical 
comparison of (3.7 ± 0.9 x 10“ )^ and k% (5.3 ± 2.0 x 10~^) shows that they 
are significantly different from each other (z = 2.48 P <.05). The absorption 
rate constant is substantially larger than the emptying rate constant. This 
finding is consistent with the suggestion that the gastric emptying of imipramine 
is initially rapid, and subsequently reduced as imipramine inhibits its own gastric 
emptying. An alternative explanation would be that imipramine is gastrically 
absorbed. However this possibility is unlikely; imipramine has a pKa of
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10.2 and strong bases do not appear to be absorbed gastrically (Schanker et al. 
1957).
The Effect of Imipramine on Gastric Emptying
The t max for the plasma of impramine was calculated as 
90 ± 25 min and the level of at this time was 6.85 ± 0.62 yg eq/ml 
(Table 12). The plasma level 60 min after administration of ^^C-imlpramine
was 6.71 yg eq/ml as seen in Fig. 10 and the plasma level profile is 
practically flat by this time. It was decided that in the investigation of 
the effect of imipramine pretreatment on gastric emptying and drug absorption, 
the imipramine would be administered 1 hr before marker was given, to ensure 
high and fairly constant plasma levels of imipramine and metabolites for 
several hours.
The gastric emptying pattern of ^^C-PEG in imipramine pre­
treated starved and fed animals is shown in Figs. 11 and 12 respectively.
The values of a are shown in Table 11. Treatment with imipramine causes a E
significant reduction in the gastric emptying rate; in both fed and starved 
animals the t^ for emptying is increased from 7.5 and 14.4 min to 81.5 and 177.8 
min for starved and fed animals respectively. These are highly significant 
decreases in emptying rate as indicated in Table 14. Gastric emptying in 
pretreated fed animals was considerably slower than in pretreated starved 
animals and it may be that unlike the situation in the control fed animals, 
the emptying of PEG in this case does reflect more nearly the rate of 
emptying of the total stomach contents.
The Effect of Imipramine on Intestinal Motility
The possibility that drugs which inhibit gastric emptying may 
also affect intestinal motility has already been mentioned. The difficulty 
in distinguishing whether distribution of marker in the intestine represents 
altered intestinal motility or an alteration in the timing of gastric 
emptying has also been discussed. It is possible that imipramine not only
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affects gastric emptying but also affects intestinal motility. It is 
particularly difficult to determine whether the distribution of marker in 
imipramine pretreated animals (Fig. 4) represents altered intestinal motility 
patterns as so little of the marker has passed into the intestine.
Experiments in vivo were designed to determine the distribution 
of marker in the intestine at different time intervals and assess intestinal 
transit rate. It was hoped that this would give a more detailed insight into 
the effects of imipramine on intestinal transit. It was considered invalid 
to use an in situ method involving direct instillation of the marker into the 
intestine to eliminate the effects of drugs on gastric emptying. The surgery 
necessary in such a method would probably have a pronounced effect on intestinal 
motility.
Normal gastric emptying and intestinal motility patterns were 
determined in control starved rats. On dividing the intestines into ten 
equal segments, the distribution patterns shown in Fig. 13 were obtained.
Transit through the upper intestine was very rapid. Segment 
1 never contained more than 1 0 % of the dose, and marker had reached segment 
5, which ends at the half-way point in less than 10 minutes. It took a 
further 50 minutes for the marker to reach the end of the intestine. Thus, 
the transit rate appears to be rapid in the proximal small-intestine 
decreasing towards the distal end. A similar pattern is observed in fed 
control rats (Fig. 15). The presence of food does not appear to have much 
obvious effect on the intestinal transit pattern of PEG.
The effects of imipramine are not easily distinguished. In 
imipramine pretreated starved animals (Fig. 14) at 10 minutes marker has 
reached segment 4, whereas in control animals at the same time, segment 5 
has been reached. At 40 and 50 min in the pretreated animals there was 
marker in segment 5; in the corresponding controls it had reached segment 9. 
However at 60 minutes the pretreated animals had marker in segment 9. It 
would appear that the peak of the intestinal distribution of marker is later
89
in pretreated animals, although it is difficult to assess this accurately 
because so little marker enters the intestine in these animals. Similar 
comments apply to the distribution of PEG in pretreated fed animals (Fig. 18). 
It may be concluded that the possibility exists that imipramine may exert 
an effect on intestinal transit as well as gastric emptying. An attempt 
was made to derive a mathematical model for intestinal transit in order to 
quantify the effects of imipramine on intestinal motility; this is described 
in detail in Chapter 7.
GENERAL DISCUSSION
All the anticholinergic compounds tested in this work caused 
an inhibition of gastric emptying. In most instances the extent of this 
inhibition was very marked. In control starved rats the th for gastric 
emptying is 7.5 min. The stomach is effectively completely empty of marker 
in less than 1 hr in control animals, whereas in all the pretreated animals 
there is a substantial amount of marker in the stomach at 2 hr.
There is apparently some correlation between the anti­
cholinergic activity of the compounds studied and their potency in inhibiting 
gastric emptying. The activity of the compounds in inhibiting gastric emptying 
falls in the same order as the anticholinergic activity. Furthermore, the 
results suggest that neither hormonal activity, pH changes, nor osmotic 
pressure can account for the observed effects. It must, however, be remembered 
that the potency of the compounds tested may be related to the timing of 
dosing, the pharmacokinetic profiles of the individual compound and the time 
at which the stomach content of marker was measured. •
Quinidine was the only compound studied which is not anti­
cholinergic and which inhibits gastric emptying. Its activity in inhibiting 
gastric emptying may be accounted for by other mechanisms. There are very 
few reports of non-anticholinergic compounds inhibiting gastric emptying.
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Phthalapromine, a compound "essentially devoid of anticholinergic activity", 
has been reported to inhibit gastric motility (Stadaas and Aune, 1971). It 
is postulated that the action of this compound is via the adrenergic 
stimulation of the intramural cholinergic ganglia of the gastric wall. The 
only other report of non-anticholinergic acompounds inhibiting gastric 
emptying comes from Takanaka et al. (1973) who claim that several phenyl- 
pyrazolone derivatives delay gastric emptying. Gastric emptying was measured 
using phenol red (10 mg/kg) as a marker. The drugs were administered at 
100 mg/kg and gastric emptying was assessed 30 min after marker administration. 
Several of the compounds tested caused a significant delay of gastric emptying. 
There are several aspects of their paper which need further investigation.
For example, marker compound was detected in the large intestine 30 min after 
administration; this was not observed in an earlier publication by the same 
group (Kato et al. 1972). Such rapid intestinal transit was not seen in the 
work reported on in this thesis; also the retention of marker in the stomach 
of control animals as described in their earlier paper (Kato et al. 1972) 
was significantly higher than in the later report by the same authors. 
Furthermore, the variation in gastric emptying rate is very small as judged 
by the mean and standard errors given. These authors do not postulate by what 
mechanism the phenylpyrazoles were acting.
In order to gain a statistical measure of the correlation 
between anticholinergic activity and inhibition of gastric emptying, it would 
be necessary to obtain some direct measure of potency in inhibiting gastric 
emptying such as an EDgg value. This could then be correlated with the pA 
values (Schild, 1947) for anticholinergic activity. Unfortunately, it is 
difficult to conceive of a reliable method for measuring an ED5Q for potency 
in inhibiting gastric emptying. There is no evidence that the time course 
of drug action is the same for all drugs. It is axiomatic that if potency 
is related to plasma levels, the pharmacokinetic profile of the different 
compounds will affect their potency. Possibly the best method for measuring
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potency would be to measure the gastric emptying rate constant for PEG in 
animals given differing doses of the compound. However this approach would 
require a considerable number of experimental animals and would still leave 
several problems, such as whether compounds should be administered as pre­
treatments, if so at what time interval and should the time intervals be the 
same for all compounds? There is no obvious simple solution to this problem.
It is possible to perform a crude statistical analysis on the 
results presented here. The Spearmans rank correlation coefficient may be 
calculated from the data as shown in Table lO. Using only the compounds which 
exhibit anticholinergic activity, the coefficient is 0.85 (P 0.01) indicating 
that the activities are highly correlated as ranks. However, this test is 
not strictly applicable since, in general, the anticholinergic activities 
of the cogeners are very close and the assignment of anticholinergic potency 
in the rank may be open to question.
The problem of measuring EDgg, and the investigation of gastric 
emptying would be much simplified if it were possible to devise a method for 
directly measuring gastric emptying in individual animals. The two 
approaches to this problem which seem to hold most prospects are the use of 
X-ray methods or the use of scintographic techniques. Neither of these 
possibilities seem to have been investigated in small animals.
In the absence of a direct correlation between anticholinergic 
effect and potency in inhibiting gastric emptying, support for the hypothesis 
that these compounds act by an anticholinergic mechanism must, of necessity, 
rest on indirect evidence. The anticholinergic agents are known to cause a 
general reduction of tone and motility in the gastrointestinal tract. Sharma 
et al. (1972) showed that several anticholinergic agents inhibit the peristaltic 
activity of isolated rat stomachs. Atropine and drugs related to it cause 
hypertrophic pyloric stenosis and pylorospasms in infants (Cullumbine, 1971). 
Paralytic ileus and constipation are frequently reported side-effects of 
amitriptyline and nortriptyline (Milner, 1969). In humans atropine, levomepate.
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(Sacchetti et al. 1964) and propanthaline (Nimmo et al. 1973) have been shown 
to slow gastric emptying. All three of these compounds have anticholinergic 
activity. These data, combined with the fact that all the compounds tested 
in this work which exhibited anticholinergic activity also inhibited gastric 
emptying, that a degree of correlation between anticholinergic activity and 
inhibition of gastric emptying exists, and that the results obtained could not 
be accounted for by other mechanisms, support the hypothesis that inhibition 
of gastric emptying is related to anticholinergic activity.
Whether compounds which inhibit gastric emptying do so as a 
result of a local surface action on the stomach from within the stomach, or 
as a consequence of the absorption of the drug and the levels which are then 
attained in the plasma, is not clearly established. The results presented 
here suggest that absorption is a prerequisite for maximum activity. This 
does not preclude a combined local and central effect and does not clarify 
whether or not such an effect arises from the plasma concentration of the 
drug.
The plasma levels of imipramine are directly correlated with 
the gastric emptying of the drug, indicating that gastric emptying is a 
modifying factor in the absorption of imipramine at the dose levels used. It 
is of interest that the LDgg imipramine is 650 mg/kg p.o. and 25 mg/kg 
i.v. It is likely that the higher value for the oral figure is the result 
of the imipramine inhibiting its own gastric emptying and thus allowing a 
slower presentation of the drug to the absorptive surfaces of the intestine, 
and a lower maximum plasma level than obtained from the very much smaller 
dose given intravenously.
Gastric emptying rate and factors affecting it, may have a 
profound effect on toxicological and metabolic experiments in animals and 
should not be overlooked as a factor for consideration, both in planning 
experiments and in the interpretation of results. Gastric emptying rate in
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experimental animals has been shown in the work reported here to differ by a 
factor of two between fed and starved animals. It is probable that factors 
such as the volume, viscosity, osmolarity and pH of dose solutions will affect 
gastric emptying rate. It is likely that other factors such as environment, 
stress, and diet will also affect gastric emptying rate in experimental 
animals. The pattern of gastric emptying in man differs from that in the 
rat and it may be assumed that other species differences exist.
The fact that gastric emptying of a solution of ^^C-PEG does 
not appear to represent the emptying pattern of the solid contents of the 
rat stomach indicates that a different pattern of gastric emptying may be 
expected with a drug dosed as a suspension as compared with a solution. It 
is possible that the solid contents of the stomach might act as a filter 
allowing the dose vehicle to pass into the intestine whilst retaining the 
suspended drug.
Variations in gastric emptying may be expected to have an 
effect on the pharmacokinetics of orally administered drugs. Decreases 
in gastric emptying rate could decrease the rate of absorption of well 
absorbed compounds and increase the absorption of poorly absorbed compounds. 
Compounds which are rapidly absorbed from the upper small intestine might be 
less well absorbed in animals with a rapid gastric emptying rate than in a 
situation where the compound was delivered more slowly to the intestinal 
mucosa. The factors, both environmental and experimental, which affect gastric 
emptying rate are frequently overlooked in the design and execution of metabolic 
and toxicological experiments in animals and also in drug treatment of humans. 
Yet it can be argued that the primary rate limiting step in the intestinal 
absorption of drugs is the rate at which the drug reaches the intestine. This 
function is principally the rate of gastric emptying.
The fact that imipramine causes a significant increase in 
gastric emptying time and has a long duration of action makes it a suitable 
compound with which to study the effects of alterations in gastric emptying
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on drug absorption. Treatment of animals with imipramine allows gastric 
enptying rate to be altered without the involvement of surgery and the 
concomitant problems of post-operative shock, anaesthetic effects, stress, 
and the changes in physiology which may be associated with operative 
procedures. If the plasma level profiles of orally administered drugs are 
compared in pretreated and non-pretreated animals it should be possible to 
deduce the effects of alteration in gastric emptying on drug absorption.
TABLE 11
Coefficients for gastric emptying rate derived from 
non-linear least squares fits
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n r.s.s.
A
± S.E.
a X 1 0 “ ^ 
min”  ^ ± S.E, Figure
Control starved 
l^c-PEG
lO 559 104 ± 6.74 *80.8 ± 9.65 11 (Gl)
Control starved 
 ^^ C-PEG
10 740 99.1 ± 8.20 *112.6 ± 17.1 11 (G2)
Combined control starved
14C-PEG
92.3 ± 8.72
IM pretreated starved 
l^c-PEG
14 349 97.2 ± 2.9 8.5 ± 0.9 11 (G3)
Control Fed 
l^c-PEG
16 687 95.5 ± 4.5 48.1 ± 2.67 12
IM Pretreated fed
14C-PEG
20 496 79.4 ± 6.2 3.9 ± 1.2 12
Imipramine gastric 
emptying
18 1530 59.6 ± 5.5 3.7 ± 0.9
Figure = Figure in test where data and fit are plotted. 
Residual sum of square for fit.r.s.s.
n = No. of data points. Data was fitted to the expression y = Ae-at
* The emptying rate constants for control starved rats as measured in two 
different experiments were not significantly different from each other 
(z = 1.62 P>.05). Combined a^ for control starved rats was obtained by 
combination of the two values for in control rats as described in 
Appendix 1.
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TABLE 12
Data obtained by a least squares fit to the plasma 
levels of following oral administration of ^^C-
imipramine to starved rats. (Data plotted in Fig. 10)
Parameter Value S.E.
r.s.s. 47.02
A 7.145 ± 0.9602
ki 5.29 X 10-2 min'l ± 1.98 x 10~2
k£ 4.74 X 10“  ^ min-1 ± 5.7 x 10“^
t max 89.9 min ± 25.3
y at t max 6.85 yg eq/ral ± 0.62
r.s.s. = Residual sum of squares. The other parameters 
are for a single compartment open model as 
described in Chapter 4.
TABLE 13
Correlation between plasma *^^ C and percentage dose 
remaining in the stomach of individual starved rats 
at different time intervals following oral adminis­
tration of l^C-imipramine 0.2 mmole/kg.
Time Plasma ^^C Stomach
min. yg Eq/ml % dose
15 2.61 6 6 . 0
4.40 49.5
30 7.17 45.1
4.10 70.4
60 11.53 31.4
4.43 53.8
90 6.72 41.5
5.80 39.7
1 20 5.43 29.8
7.35 36.0
180 5.68 34.8
7.64 21.5
240 5.51 46.8
7.80 14.3
360 8.13 23.5
6.63 10.8
480 5.01 11.7
5.47 11.3
tind - -6.49 P < 0 0 1
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TABLE 14
Statistical comparisons of gastric emptying 
rate constants for ^^C-PEG in rats
Comparison ^  2
Combined for starved control rats with 9.29 <.001
for imipramine pretreated starved rats.
Combined a for starved control rats with 6.47 <.001
for control, fed rats.
(Xg for control fed rats with for imipramine 9.21 <.001
pretreated fed rats.
for imipramine pretreated starved rats with 3.07 <.01
Ug for imipramine pretreated fed rats.
z = statistic for standard normal distribution (see Appendix 1) 
P = probability
Ug = gastric emptying rate constant as defined in the text. 
Values of are given in Table 11.
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FIGURE 2
THE EFFECTS OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE INTESTINAL TRACT OF STARVED RATS, 2 HOURS AFTER CO­
ADMINISTRATION OF  ^^ C-POLYETHYLENE GLYCOL AND COMPOUND.
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means from 4 animals. Vertical bars represent standard errors 
and are only shown where the error is greater than 2 %.
FIGURE 3
THE EFFECTS OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE INTESTINAL TRACT OF STARVED RATS, 2 HOURS AFTER CO­
ADMINISTRATION OF 1^C-POLYETHYLENE GLYCOL AND COMPOUND.
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FIGURE 4
THE EFFECT OF COMPOUNDS ON THE DISTRIBUTION OF RADIO­
ACTIVITY IN THE GASTROINTESTINAL TRACT OF STARVED RATS 
1.25 HOURS AFTER ADMINISTRATION OF 1 *+0 -POLYETHYLENE 
GLYCOL AND 2 HOURS AFTER THE ADMINISTRATION OF COMPOUNDS.
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FIGURE 5
THE EFFECT OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE GASTROINTESTINAL TRACT OF STARVED RATS 1.25 HOURS 
AFTER ADMINISTRATION OF ^^C-POLYETHYLENE GLYCOL AND 2 HOURS 
AFTER THE ADMINISTRATION OF COMPOUNDS.
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FIGURE 6
THE EFFECT OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE GASTROINTESTINAL TRACT OF STARVED RATS 1.2 5 HOURS 
AFTER ADMINISTRATION OF 1 "+C-POLYETHYLENE GLYCOL AND 2 HOURS 
AFTER THE ADMINISTRATION OF COMPOUNDS.
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FIGURE 7
THE EFFECT OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE GASTROINTESTINAL TRACT OF STARVED RATS 1.25 HOURS 
AFTER ADMINISTRATION OF  ^^ C POLYETHYLENE GLYCOL AND 2 HOURS 
AFTER THE ADMINISTRATION OF COMPOTTNn.s.
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FIGURE 8
THE EFFECT OF COMPOUNDS ON THE DISTRIBUTION OF RADIOACTIVITY 
IN THE GASTROINTESTINAL TRACT OF STARVED RATS 1.25 HOURS 
AFTER ADMINISTRATION OF  ^^ C-POLYETHYLENE GLYCOL AND 2 HOURS 
AFTER THE ADMINISTRATION OF COMPOUNDS.
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FIGURE 9
GASTRIC EMPTYING OF RADIOACTIVITY FOLLOWING 
ORAL ADMINISTRATION OF 
^^C-IMIPRAMINE TO STARVED RATS
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FIGURE 10
PLASMA LEVELS OF RADIOACTIVITY FOLLOWING ORAL ADMINISTRATION OF 
1‘♦C-IMIPRAMINE TO STARVED RATS
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FIGURE 11
GASTRIC EMPTYING OF ORALLY DOSED ^^^-poLYETHYLENE GLYCOL IN CONTROL 
AND IMIPRAMINE PRETREATED STARVED RATS
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FIGURE 12
GASTRIC EMPTYING OF ORALLY DOSED ^-POLYETHYLENE GLYCOL 
IN CONTROL AND IMIPRAMINE PRETREATED FED RATS
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FIGURE 13
D IS T R IB U T IO N  W ITH T IM E  OF  ^ '+C-POLYETHYLENE GLYCOL IN  THE 
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FIGURE 14
D IS T R IB U T IO N  W ITH T IM E  OF  ^ -POLYETHYLENE GLYCOL 
IN  THE G ASTR O IN TESTIN AL TRACT OF STARVED 
IM IP R A M IM E  PRETREATED RATS
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FIGURE 15
DISTRIBUTION WITH TIME OF ^‘♦C-POLYETHYLENE GLYCOL 
IN THE GASTROINTESTINAL TRACT 
OF FED CONTROL RATS
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FIGURE 16
D ISTRIBUTION WITH TIME OF  ^'^C-POLYETHYLENE GLYCOL 
IN THE G ASTROINTESTINAL TRACT OF FED 
IMIPRAMINE PRETREATED RATS
CHAPTER 4
THE EFFECT OF IM IPR AM IN E INDUCED DELAYED GASTRIC EMPTYING 
ON THE ABSORPTION OF TRIMETHOPRIM AND S A L IC Y L IC  ACID
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INTRODUCTION
From the discussion in Chapter 1 it is clear that the effects 
of gastric emptying on drug absorption do not appear to have been extensively 
investigated. Yet gastric emptying rate in certain circumstances could be a 
rate limiting factor in drug absorption. In which case alterations in gastric 
emptying rate might therefore be expected to have a profound effect on the plasma 
level profile and hence pharmacological activity of orally administered drugs.
It is apparent from the preceeding chapter that on oral dosing, imipramine 
(0.2 mmole/kg) produces a significant inhibition of gastric emptying and is 
effective for several hours. Thus imipramine provided a way of altering 
gastric emptying and allows the effects of alterations in gastric emptying 
on drug absorption to be investigated.
It is reasonable to assume that the plasma level profile of a 
drug which is rapidly and extensively absorbed from the stomach would be 
affected less by alterations in gastric emptying rate than the plasma 
level profile of a drug which is principally absorbed from the small intestine.
It may be predicted that acidic drugs which are largely unionized in the 
stomach might be gastrically absorbed, whilst basic drugs would be less likely 
to be gastrically absorbed.
In order to investigate the effects of alterations in gastric 
emptying rate on drug absorption two drugs were chosen as model compounds.
The drugs chosen were salicylic acid (an acidic drug) and trimethoprim (a 
basic drug). Both of these compounds were available labelled and thus
allowed easy measurements of total radioactivity in plasma, which in turn 
allowed an assessment of their rates of absorption. It is important to note 
that in the experiments described here the plasma levels of total radioactivity 
were determined; it was not possible to separate free drug and metabolites.
Two general approaches to the assessment of absorption rates 
from plasma level curves were used. The first of these is qualitative;
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absorption rate was assessed from an examination of the shape of the plasma 
level time curve, in particular the time of occurrence of maximum plasma 
levels and the levels observed at the maximum gave an indication of the rate 
of absorption. This method does not necessitate the presupposition of a 
pharmacokinetic model. However, in order to make quantitative comparisons 
between the absorption rates observed in different experimental groups and 
between absorption rates and gastric emptying rate, it is necessary to 
obtain a numerical estimate of absorption rate. In the in vivo situation 
this numerical estimate arises from a pharmacokinetic analysis of the plasma 
level data which requires that the body be conceived of as a compartmental 
model.
Once a suitable compartmental model has been conceived, analysis 
of plasma level curves allows assessment of the relevant rate constants for
passage into and out of the various compartments. Pharmacokinetic models 
have been described and discussed by a number of workers, notably Wagner 
(1971); Notari (1971) and Goldstein et al. (1974). In the work described 
here the single compartment open model has been used. This model is 
represented by the expression:
(1 ) Y = . (e"^2^ -
ki-k2
and diagramatically as:
kl k2
--- >y
where x = dose of drug at t=0
y = concentration of drug in 
compartment at time t
V = volume of compartment
kl = absorption rate constant
k2 = loss rate constant
A = the concentration of drug 
in the compartment extra­
polated back to t = 0 .
k2 is termed the loss rate constant to imply that it is a composite
constant for all processes involving loss from the compartment.
to note that this model has been applied to plasma radioactivity and not parent drug.
%
n e
In the case where k% = k£ the expression for a single 
compartment open model is:
(2) y = kl Ate
The equations for a single compartment model are derived and
discussed by Wagner (1971) and Goldstein et al. (1974).
The time of occurrence of maximum plasma levels is given by:
(3) = 1" kz/ki
k2 - kl
The value of y at t^^^ may be determined by substituting the 
value of t^^^ in the original expression.
The area under the curve is given by:
(4) Area = A/k2
(5) The apparent volume of distribution Vd = FD where FD =
A
fraction of the dose absorbed.
All the parameters shown above were calculated from the 
experimental data with a computer programme using non-linear least squares 
fitting procedures.
Riegelman et al. (1968) have highlighted the shortcomings 
of the single compartment model, and certainly in many situations a single 
compartment model will not adequately fit the data. The data presented here 
did not allow analysis of a more complex model. Riegelman et al. (1968) 
state that 'a model is only conceived to serve the purposes of the scientist; 
it need not be any more complex (nor should it be any less simplified) than 
required to serve this function'. Thus the one compartment model has been 
used, whilst this was not intended to imply that it was the only possible 
model, or that it has any particular physiological significance.
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PLASMA LEVEL OF RADIOACTIVITY FOLLOWING ORAL 
ADMINISTRATION OF RADIOLABELLED DRUGS
Assignment of Rate Constants
It is a feature of the one compartment model, when used to 
describe plasma levels resulting from the oral administration of a drug, that 
it does not allow an unambiguous determination of which of the two rate 
constants applies to absorption and which is the loss constant. The 
assignments were made in the following manner. The relationship between the 
Vd and the constant A is given by equation (5). However, the value of A is 
dependent on the value of k2 . Thus, two values of A may be calculated from 
the computer programme, where k2 is the smaller and k2 is the larger rate 
constant. The two possible values of A are also related to each other.
A (k2 large) = A(k2 small) x k2
kl
From these two values of A two possible values of the apparent 
volume of distribution were obtained; these are shown in Table 15. In both 
the fed and starved animals dosed with trimethoprim, one animal exhibited 
rate constants k% and k2 which were equal in value and therefore allowed only 
one possible assignment of Vd. The other animals in these groups exhibited 
two values of Vd one very much smaller and one similar to the value obtained 
when kl = k2 - Furthermore, the rate of absorption of trimethoprim was shown, 
by analysis of *^^ C remaining in the gastrointestinal tract, to be a rapid 
process ; this is discussed in detail later. It was thought on this evidence 
reasonable to assign the rate constant as k% (large) representing absorption 
and k2 (small) representing loss. This is in agreement with the "elimination 
constant" following i.v. administration of trimethoprim in rats reported by 
Schulz (1972) . It should however, be mentioned that Schulz did not describe 
how the elimination rate constant was derived, or give any indications of the 
errors associated with this parameter.
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Table 15
Apparent volume of distribution of radioactivity in 
rats dosed with trimethoprim and ^^C-salicylate
Rat Treatment
Group
Vd (k2 large) 
ml
Vd (k2 small) 
ml
51 Starved IM *226.4
52 Pretreated 86.2
53 Trimethoprim 107.5
*226.4
284.3
321.5
54 Starved
55 Control
56 Trimethoprim
96.4
47.4 
72.0
266.6
272.8
225.3
FI Fed IM *429.0
F2 Pretreated 141.1
F3 Trimethoprim 159.2
*429.0
359.3
496.6
F4 , Fed
F5 Control
F6 Trimethoprim
60.7 
56.9 
68.6
725.5
522.2
507.1
A1
A2
A3
Starved IM 
Pretreated 
Salicylate
3.1
2.1 
1.5
28.1
29.5
35.2
A4
A5
A6
Starved
Control
Salicylate
0.6
0.6
0.5
28.1
32.3
27.7
* kl = k2 kl and k2 rate constants fro the single 
compartment model as described in the text. Vd = Apparent 
value of distribution.
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In the case of salicylic acid, the assignment was more
positive. If the Vd was calculated with k2 as the larger constant, the
value of Vd was less than the plasma volume. This implies that the
assignment of the rate constants must be such that kj is the larger value.
The value of k2 when assigned as the smaller number is in close agreement
for total salicylate 
with the "elimination rate constant"^reported by Nelson et al. (1966) and
Andrews (1958).
Plasma Levels of Radioactivity Obtained by Analysis of Plasma from Pats 
Killed at Various Time Intervals after Dosing with ^^C-Trimethoprim
The plasma levels of radioactivity in control and imipramine 
pretreated rats killed at various time intervals after administration of 
l^C-trimethoprim are shown in Fig 17. It is apparent that large inter­
animal variations in the plasma levels were observed. Despite these
variations the parameters derived for best fit lines to the data reveal 
significant differences between control and imipramine pretreated animals 
(Table 16). The value of the rate constants k% and k2 and the plasma levels 
at t^^^ are lower in the imipramine pretreated animals and the time of 
occurrence of maximum plasma levels is greater in the imipramine
pretreated animals. These differences indicate that imipramine causes a 
decrease in the absorption rate constant and also a decrease in the loss 
rate constant.
The gastric emptying of radioactivity following oral 
administration of ^^C-trimethoprim to starved rats is shown in Fig. 18 and 
the values of the gastric emptying rate constants are shown in Table 17.
Figure 18 shows that the gastric emptying rate of radioactivity from ^^C- 
trimethoprim appears to be exponential. The large variation in gastric 
emptying rate which was observed with ^^C-PEG, is also seen with  ^^ C-trimethoprim, 
As with l^C-imipramine a relationship appears to exist between the percentage 
of the dose remaining in the stomach and the plasma levels. When the plasma 
levels and amount remaining in the stomach were compared using the t test
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FIGURE 17
PLASMA IN RATS KILLED AT VARIOUS TIME INTERVALS
AFTER ORAL ADMINISTRATION OF ^''C-TRIMETHOPRIM
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Table 17
Gastric emptying of from ^^C-trimethoprim parameter
derived from least squares fit
Number of data point A ± S.E. ot x 10""^  ± S.E. min ^
Control 19 63.63 ± 16.32 50.23 ± 2.08
IM Pretreated 33 66.51 ± 3.61 6.57 ± 0.81
A = Intercept at t = O 
a = Emptying rate constant
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Each point is from a single animal.
#  Imipramine pretreated 0.2 mmole/kg imipramine 1 hr before ^^C-TMP 
■  Controls 1 ml water 1 hr before ^^C-TMP
FIGURE 18
GASTRIC EMPTYING OF RADIOACTIVITY FROM ORALLY 
ADMINISTERED ^‘'C-TRIMETHOPRIM (5 mg/kg)
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for correlated data a significant level of correlation (t = 11.6 P<.OOl) 
was found for imipramine pretreated animals over the whole time scale. In 
controls a significant correlation (t = 46 P<.001) was found with the data 
up to 60 min, after which there was no measurable quantities of in the 
stomach. This indicates that plasma levels of radioactivity from ^^C- 
trimethoprim are related to the gastric emptying rate.
When these experiments were performed the whole of the 
small intestine of the rats was also removed and solubilized to assay for 
The results are shown in Table 18. In the imipramine pretreated 
animals, there was never more than 1 0% of the dose in the intestine up to 
60 min. In control animals at 5 minutes 50% of the dose had left the
stomach but no more than 8% was found in the intestine. These data may be
taken as evidence that the intestinal absorption of trimethoprim is rapid.
The larger percentage of the dose found in the intestine of controls at 
later times probably reflects biliary excretion, since the biliary excretion 
of trimethoprim in the rat is known to be very rapid, (26% of the radio­
activity from an intraperitoneal dose of ^ ^C-trimethoprim (3.9 mg/kg) was
excreted in the bile in one hour and 18% of the radioactivity from an oral
dose of trimethoprim (3.6 mg/kg) was excreted in the bile in Sh hours. 
(Personal communication, P. Johnson)).
If the gastric emptying rate constant for from
trimethoprim in control animals is compared with the value of kj, the latter 
is significantly larger. There is no obvious explanation for this difference, 
since the rate of absorption of radioactivity could not be greater than the 
rate of disappearance of radioactivity from the gastrointestinal tract.
This discrepancy combined with the large interanimal variation as seen in 
Figures 17 and 18, indicated the desirability of measuring plasma levels in 
individual animals. Furthermore, the fitting of plasma level data obtained 
from many animals at different time intervals to a composite curve (as has been 
described here) is unlikely to result in an accurate assessment of the relevant
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rate constants involved. The plasma levels in any given animal at a given 
time will be a function of the relevant rate constants for that animal.
The best fit curve using all the data points will be some complex function 
of all the exponentials from the different animals involved. When the data 
in Table 16 is compared with the pooled parameters in Table 19 (obtained from 
individual animals as described in the next section), it is immediately 
apparent that there is a significant difference in the results obtained by the 
different methods. In Table 16 a significant difference is observed between 
the value of A in the pretreated animals as compared with that estimated in 
controls. However, this difference is not reflected in the area under the 
curve and is accounted for by the difference in the value of k2 . This 
difference between controls and pretreated animals in loss rate constant was 
not observed in the pooled parameters from individual animals (Table 19). 
Furthermore, significant differences exist between the value of the parameters 
as obtained by the two different experimental methods (Table 20). The only 
parameter which is not significantly different regardless of the experimental 
method used to assess it is the loss rate constant. The absorption rate 
constant is significantly smaller as estimated from individual animals. All 
the other parameters were significantly larger.
Assessment of rate constants by fitting data from many different 
animals to a pharmacokinetic model is not mathematically justifiable. It 
is reasonable to assume that the measurement of the relevant rate constants 
in individual animals provides a more accurate method.
Plasma Levels of Radioactivity in Individual Animals Following 
Oral Administration of  ^^ C-Trimethopr'im to Starved and Fed Rats
The plasma level profiles of^^C following oral administration 
of l^C-trimethoprim to starved rats and fed rats are shown in Figures 19 to 
24 at the end of this chapter. It is immediately apparent that in both fed 
and starved rats imipramine has an affect on the plasma level profile.
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Furthermore, there are obvious differences in the plasma level profile of 
radioactivity in starved as compared with fed rats. The parameters obtained 
from the non-linear squares fitting procedure are given in Table 25 at the 
end of the Chapter. The value of the pooled parameters for each group of 
animals are given in Table 19.
In control rats the plasma levels of radioactivity 
show a fairly consistent profile, namely, a rapid rise to a maximum at 96 min 
or less in most instances, the exception being rat S4, Fig. 19. By 
contrast in imipramine pretreated animals the plasma level curves generally 
tend to be flatter and the maximum levels obtained tend to be lower than 
those in the controls. There are exceptions; Rat S2, Fig. 20 and rat F5, 
Fig. 23, show patterns similar to controls. Generally there is a reasonable 
degree of consistency between the animals in each group; this consistency 
is partly a reflection of the fact that experimental animals, in this case 
rats, are drawn from a population which is relatively genetically 
homogeneous and has been maintained in a controlled environment and on a 
controlled diet. This is particularly important especially in the light 
of the human studies discussed in a subsequent chapter (Chapter 6 ).
It may be concluded from the results presented in 
Figures 19-24 that imipramine pretreatment increases the time taken for 
maximum plasma levels of radioactivity to be obtained, decreases the level 
of the maximum and causes a general flattening of the plasma level profile 
of radioactivity resulting from an oral dose of ^^C-trimethoprim. It may be 
argued that these effects are the result of a delay in the rate of gastric 
emptying of trimethoprim which results in a slower rate of absorption of the 
trimethoprim.
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In order to make a quantitative assessment of the effects of 
imipramine on the plasma levels of radioactivity resulting from ^^C- 
trimethoprim,it is necessary to compare the Values of the parameters resulting 
from the pharmacokinetic analysis of the data.
The pooled values of k£ were not significantly affected by 
imipramine pretreatment in either starved or fed animals. This indicates 
that imipramine pretreatment did not appear to be affecting the rate at 
which the plasma levels decline. On the other hand the rate of absorption 
ki is significantly reduced by pretreatment with imipramine. This reduction 
in absorption rate is also manifested in an increase in the time taken for 
the maximum plasma levels to be attained and à reduction in the plasma 
concentration at the maximum. In starved animals the area under the curve 
was unaffected by imipramine pretreatment, whilst in fed animals the area 
under the curve was significantly larger in the pretreated animals This 
difference is discussed subsequently. From these data it may be concluded 
that imipramine pretreatment decreases the rate of absorption of trimethoprim 
as estimated by plasma concentrations.
If imipramine is affecting drug absorption as a result of an 
alteration in gastric emptying pattern, it should be possible to observe a 
correlation between gastric emptying rate and absorption rate. A comparison 
may be made between the emptying rate of trimethoprim (Table 17) the 
emptying rate of ^^C-PEG (Table 11, Chapter III) and the absorption rate 
constants. Such a comparison is shown in Table 21.
In starved control animals the rate of gastric emptying of 
l^C-TMP or l^c-PEG is significantly faster than the absorption rate of ^^C-TMP. 
However, in starved imipramine pretreated animals, the rate of gastric 
emptying is not significantly different from the absorption rate. This may 
indicate that gastric emptying has become the rate limiting step in the 
absorption of trimethoprim. In fed animals gastric emptying rate is not 
significantly different from the absorption rate constant in either the
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controls or the pretreated animals, and this may be taken to indicate that 
the emptying rate in fed control as well as pretreated fed animals is the rate 
limiting step. Thus the pharmacokinetic analysis of the data supports 
conclusions drawn from the subjective assessment of the plasma level curves, 
that a slowing of gastric emptying reduces the rate of absorption 
of trimethoprim.
It is also apparent from examination of the plasma level 
curves that there is a difference in the plasma profile of radioactivity in 
starved animals as compared with fed animals. This is manifested mainly as a 
difference in the level of the maximum seen in Figs. 19-21 as compared with 
Figs. 22-2 4. Generally, the shape of the profiles are similar in both groups. 
When the absorption rate constant in control fed animals was compared with 
that for control starved animals the former was found to be significantly faster 
(P<0.001). It was shown in the previous Chapter that the rate of gastric 
emptying is significantly slower in fed controls than in starved controls.
The more rapid absorption seen in fed animals may result from a more 
efficient presentation of the drug to the absorptive surfaces of the 
intestine. The surface area of the small intestine per unit length decreases 
with increasing distance from the stomach (Fisher and Parsons, 1950). A 
more even release of drug into the upper intestine may result in a more 
even and rapid absorption in the upper intestine.
It can be seen that the apparent volume of distribution 
of radioactivity resulting from ^^C-trimethoprim is greater in fed than in 
starved animals (Table 15). This is reflected as a smaller area under the 
curve (Table 2 3). Furthermore, the apparent volume of distribution in fed 
imipramine pretreated rats was significantly greater than that in fed 
control rats. In the initial calculation of the apparent volume of 
distribution it was assumed that the whole of the dose administered was 
absorbed. These differences in volume of distribution suggested that the 
fraction of the dose absorbed in fed animals was less than 100%. This
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possibility was investigated by collection of urine and faeces from starved 
and fed animals dosed with -trimethoprim.
The starved animals were denied access to food for 24 hours 
prior to dosing and for eight hours after dosing; rats in the fed group 
were allowed access to food ad lib. The excretion of radioactivity in 
urine and faeces is shown in Table 22. Fed rats excrete significantly
less radioactivity in the urine and significantly more in the faeces than
Although this may be partly attributable to differences in
controls./ A possible explanation for these results is that a portion of the 
trimethoprim was binding to the food in the gastrointestinal tract and was 
thus not available for absorption. A simple experiment to assess the 
extent of any binding was undertaken. The stomach contents from three
starved and three fed rats were washed into test-tubes with 1 ml of normal
saline. Then 1 mg of ^^C-trimethoprim lactate was added to each tube in
0.1 ml of water. The tubes were shaken on a mechanical shaker for 1 hr,
5 ml of saline were added to each tube and they were shaken for a further 
10 min and then centrifuged. All the supernatant was removed from the tubes 
containing food and 5 ml of supernatant was removed from the tubes with the 
washings from the starved animals. This procedure was repeated twice more.
The total recoveries were 98.8 ± 5.0% S.D. from the starved animals' stomach 
contents and 70.2 ± 2.4% S.D. from the stomach contents of the fed animals.
Two subsequent extractions, with 5 ml O.IN HCl, of the contents from fed 
animals' stomachs, recovered a further 6.1% of the added activity. Thus the 
total recovery was 76.3 ± 2.1% S.D. which is significantly less than the 
amount extracted from the contents of the starved animals (P<.001).
If it is assumed that the percentage dose absorbed was only 
70%, then the mean apparent volume of distribution in the fed imipramine 
pretreated animals is 300 ± 48 ml which is not significantly different to that 
in imipramine pretreated starved animals. However, the mean apparent volume 
of distribution in control fed animals using this correction factor is
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409 ± 85 ml which is significantly larger than in controls starved animals.
A possible explanation for these differences is that in imipramine pre­
treated animals more time is allowed for the compound which is bound to the 
food to be released as a result of the processes of digestion. It may be 
concluded that in the control animals the fraction of the dose absorbed 
may be less than 70% i.e. more than 30% of this dose is bound to the food.
A point which has not so far been discussed and which requires 
consideration is whether the one compartment model provides a "good fit" 
to the experimental data for plasma radioactivity resulting from ^^C- 
trimethoprim.
Examination of the non-linear least squares fit to the plasma 
level data indicates that in certain animals the single compartment model 
may not be providing a good fit to the experimental data. It is particularly 
noticeable that in rats S5, S6 and F5 (Figs. 20, 21 and 23) the line does 
not fit well to the points in the region of the maximum and there is a 
suggestion of a"hump"in the region of 252-522 mins. This hump could be the 
result of enterohepatic circulation or alteration in the volume of 
distribution of radioactivity as a result of metabolism of the trimethoprim. 
The biliary excretion of trimethoprim has been shown to be rapid and 
resorption of biliary metabolites may account for this hump. It is not 
possible to distinguish a hump in the pretreated- animals; this may be a 
reflection more of the shape of the plasma level curve than of the absence 
of the hump. These divergences from a "good fit" may indicate the 
unsuitability of the single compartment model for these data. However, 
the data presented here do not allow a more sophisticated analysis.
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Plasma Levels of Radioactivity in Individual Animals 
Following Oral Administration of ^^C^Salicylic Acid~~ 
to Imipramine Pretreated and Control Starved Rats
The plasma level profile of radioactivity following oral 
administration of ^^C-salicylic acid to starved control and imipramine pre­
treated rats is shown in Figs. 25 to 27. The parameters derived from the 
fitting procedure are given in Table 26. The pooled parameters are shown in 
Table 23. Imipramine pretreatment did not affect the loss rate constant, nor 
was the value of A or the area under the curve affected, indicating that the 
fraction of drug absorbed was the same in both groups of animals. However, 
the absorption rate constant is significantly reduced by imipramine pre­
treatment. The time taken for the maximum plasma levels to occur is extended 
and the levels at the maximum are reduced. It may be concluded from these 
data that imipramine reduces the rate of absorption of salicylic acid.
It can be seen in Table 24 that there is no significant 
difference between the absorption rate constant for salicylic acid and 
the rate constant for gastric emptying of ^^C-PEG in control animals. This 
may indicate that in starved controls gastric emptying rate is the rate 
limiting step in absorption and certainly indicates that salicylic acid is 
very rapidly absorbed from the intestine. However, the rate of gastric 
emptying of ^^C-PEG was significantly slower than the absorption rate constant 
in imipramine pretreated animals.
In imipramine pretreated animals the absorption rate of salicylic 
acid is reduced; however it is not reduced to the same degree that gastric '*
emptying rate is decreased. It may be concluded that if the rate of gastric 
emptying of salicylic acid in imipramine pretreated rats is accurately 
reflected by the rate of gastric emptying of ^*^C-PEG, then the rate of 
absorption of salicylic acid is more rapid than the rate at which it leaves 
the stomach and enters the intestine. This implies that the absorption of 
salicylic acid must occur at least in part from the stomach, and suggests 
that in animals where gastric emptying is severely inhibited, gastric
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absorption of salicylic acid may contribute significantly to the overall 
intestinal absorption rate. The fact that gastric emptying is so rapid in 
control animals suggests that the major site of absorption in this instance 
is the small intestine. Although the pH partition hypothesis would predict 
that the absorption of salicylate in the small intestine of the rat would be 
a very slow process, this is obviously not the case.
The fitting of data to a single exponential model for 
salicylic acid appears to give consistent results. There are no indications
from the plots that a one compartment model is unsuitable for salicylic acid.
However, the plasma levels were only measured up to 612 min after dosing by 
which time the plasma levels had only dropped to approximately one third of 
the maximum value. A more prolonged sampling scheme may have revealed 
inaccuracies in the tail end of the fit. It may be tentatively concluded 
that the single compartment model fits the plasma level data for radioactivity 
resulting from an oral dose of ^^C-salicylic acid.
A subjective examination of Figures 25-27 leads to the same
conclusions as the pharmacokinetic analysis. The plasma radioactivity levels 
in controls rise more rapidly to a higher maximum. In the imipramine 
pretreated animals the rise in plasma levels is less rapid, the levels 
attained are lower and the shape of the plasma level curves are flatter.
This may be taken to indicate that imipramine pretreatment reduces the rate 
of absorption of salicylate. It can also be seen in Figs. 25-27 that there 
is a high degree of consistency between animals within treatment groups.
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GENERAL DISCUSSION
It is apparent from the preceding results that inhibition of 
gastric emptying with imipramine provides a method for studying the effects 
of gastric emptying on intestinal drug absorption and also investigating the 
contribution of gastric absorption in vivo.
Inhibition of gastric emptying by imipramine resulted in a 
reduction in the rate of absorption of trimethoprim and salicylic acid.
The rate of absorption of salicylic acid was more rapid than the rate at which 
l^C-PEG empties from the stomach in animals pretreated with imipramine. This 
suggests the possibility that gastric absorption of salicylic acid makes a 
significant contribution to the overall absorption rate in the situation 
where gastric emptying is inhibited. In order to elucidate more fully the 
contribution of gastric absorption to the overall absorption rate constant 
a carefully designed series of experiments need to be performed. The rate 
of gastric emptying of salicylic acid needs to be determined, eliminating 
the contribution of gastric absoiqjtion to the rate of disappearance of 
salicylate from the stomach. This could be achieved by measuring the rate 
of emptying of ^^C-PEG co-administered with salicylate to imipramine pre­
treated animals. The rapid absorption of salicylic acid seen in control 
animals, indicates that when gastric emptying is delayed it is probably 
the rate limiting process in the intestinal absorption of salicylic acid.
Thus the gastric emptying rate would approximate to the rate of intestinal 
absorption. The overall absorption rate as calculated from plasma level 
data represents a combination of gastric and intestinal absorption rate and 
from this the contribution of gastric absorption may then be calculated.
If the assumption that gastric absorption makes a significant 
contribution to the overall rate constant is tenable, it is also necessary 
to postulate a more complex pharmacokinetic model where the plasma compartment 
has two input functions, gastric absorption and intestinal absorption rate
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constants, and in which the intestinal absorption rate constant can be 
limited by the gastric emptying rate constant. Unfortunately, the data 
presented here are not comprehensive enough to undertake such an analysis.
It is an unfortunate tendency in Pharmacology that because 
a phenomenon can be demonstrated under artificial circumstances it is 
assumed to happen under physiological conditions. Thus it has been demon­
strated that drugs can be absorbed from the stomach of rats (Schanker et al. 
1957) and humans (Hogben et al., 1957) but its practical importance has not 
been established. It was shown by Schanker et al. (1957) that when a solution 
of 4 ml of O.IM HCl containing 800 yg of salicylic acid was placed in a 
rat's stomach 60% of the drug was absorbed in 1 hr. In a subsequent paper 
(Schanker et al. 1958), the small intestine of rats was perfused with 30 ml 
of a solution containing 138 mg/1 of salicylic acid, 60% of which was 
absorbed in 30 min. This would support our view that salicylate is most
rapidly absorbed from the small intestine.
Pretreatment of animals with imipramine causes gastric
emptying rate to be drastically reduced and allows the effect of gross
changes in gastric emptying rate on drug absorption to be studied.
Imipramine was originally chosen as a compound to inhibit gastric emptying, 
mainly because it was found to be particularly potent in this respect.
However, the use of imipramine for this purpose does have some disadvantages; 
the two main ones are, the relatively high dose needed and the affects of 
imipramine on drug metabolism. Imipramine has been reported to be an 
inducer of drug metabolism (Breyer, 1972) and has also been found to be an 
inhibitor of the metabolism of barbiturates (loannides, 1973). Furthermore, 
imipramine was found to be an inhibitor of the metabolism of trimethoprim 
as is described in the next chapter. These metabolic effects of imipramine 
are particularly undesirable in connection with the work described here 
where a pharmacokinetic model has been used to assess absorption rate. An 
alteration in the metabolism of the agent whose absorption is being studied may 
affect the validity of the pharmacokinetic model.
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It was fortuitous that imipramine did not appear to have a 
significant effect on the loss rate constants, and that the effects of 
imipramine on drug metabolism, described in the next chapter, do not appear 
to have significantly affected the outcome of the absorption experiments.
In further investigations of the effect of altered gastric emptying pattern 
on drug absorption, it would probably be advantageous to use an alternative 
compound for the inhibition of gastric emptying. The ideal compound would be 
one which acts locally, which preferably is not absorbed and which has a long 
duration of action. Such a compound is not, to the author's knowledge, 
presently available. However, propanthaline bromide has been shown to 
inhibit gastric emptying in humans at a dose level of 30 mg injected 
intravenously. It has also been shown to decrease the oral absorption rate 
of paracetamol when given intravenously at this dose level (Nimmo et al.,
1973). Furthermore, propanthaline has been shown to increase the 
absorption of digoxin (Manninen et al., 1973) phenolsulphonphthalein (Ashley 
and Levy, 1973) and riboflavin (Levy et al., 1972). It is suggested that 
slower gastric emptying and a decrease in intestinal motility caused by 
propanthaline is responsible for the increase in the absorption of these 
poorly absorbed compounds. The me^bolic actions of propanthaline do not 
appear to be documented but as this compound is active at a relatively low 
dose it may be a more suitable compound for inhibiting gastric emptying in 
order to study drug absorption. These possibilities need further investigation.
Several conclusions can be drawn from the results described 
here. In summary, these conclusions are: the absorption of both salicylic
acid and trimethoprim are rapid processes; inhibition of gastric emptying by 
imipramine slows the absorption rate of both of these drugs; gastric 
absorption of salicylic acid may make a significant contribution to the 
overall absorption rate of salicylate, especially when gastric emptying is 
inhibited. Furthermore, gastric emptying rate can be a rate limiting step
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in the absorption of trimethoprim; the rate of absorption of trimethoprim 
is faster in fed control animals than in starved controls despite the fact 
that there appears to be less drug available for absorption in fed animals; 
this is possibly a reflection of a more even rate of presentation of the 
drug to the absorptive surfaces of the upper intestine. Finally, in fed 
cuiimals the fraction of a dose of trimethoprim which is absorbed appears to 
be reduced in fed animals possibly as a result of the drug binding tightly 
to a component in the diet.
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Table 20
Comparisons of parameters derived from non-linear least squares fit to 
the plasma levels of radioactivity resulting from orally dosed ^^C- 
trimethoprim in animals killed at different time intervals with the pooled 
parameters from individual animals.
Comparison Controls Imipramine Pretreated
Parameters from animals killed
at time intervals with pooled z P z P
parameters from individual animals
A -3.94 <.001 -4.41 < .oo i
kl 2.56 <.05 2.01 <.05
k2 0 . 8 8 >.05 -1.71 >.05
t -7.93 <.001 -3.28 <. 0 1max
V at t -4.24 <.001 -12.04 <.001max
Area -4.05 <. 0 01 -7.29 <.001
z = Statistic for a standard normal distribution 
P = Probability
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Table 22
The mean accumulative percentage dose of radioactivity excreted by 
fed and starved rats orally dosed with 5 mg/kg -trimethoprim
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Treatment Time 
hrs
Percentage Dose Excreted ± S.D. 
Urine Faeces Total
Starved 24
48
73.2 ± 7.1 
76.7 ± 11.7
9.5 ± 2.9 
15.3 ± 3.3
83.1 ± 9.3
92.2 ± 14.8
Fed 24 45.3 ± 12.7**
48 45.8 ± 12.8**
25.9 ± 8.9**
26.3 ± 8.9*
71.4 ± 5.4t 
72.2 ± 5.6t
Three rats in each group 
* P <.05 ** P <.01 t N.S.
Table 23
142
Pooled parameter from the computer fit to plasma levels of 
radioactivity in control and imipramine pretreated rats 
following oral administration of ^^C-salicylic acid.
Parameters from the single compartment model as defined in the text
Parameter A
VI g eq/ml X 10 3 min"l
^max
min
y at t^^x 
yg eq/ml
Area
yg eq/1 min
Imipramine 96-7t 23.77* 1.77t 113* 80.0*
Pretreated ±3.9 ±2.11 +0.16 ±5 ±1.6
56734t
±3114
Controls 100.4 85.21 1.66 46 89.7
± 0 . 8 ±3.98 ±0.05 ±2 ±0 .8
60278
±1560
Control rats received 1 ml water 1 hr before ^'^C-salicylic acid (15 mg/kg)
Imipramine pretreated rats received 0.2 mmole/kg imipramine 1 hr before 
l^C-salicylic acid (15 mg/kg)
Parameters were pooled according to the method 
in Appendix I and are shown ± S.E.
yg eq = plasma radioactivity expressed as yg 
equivalents of salicylic acid.
* P<.001 t N.S.
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Table 24
Comparison of absorption rate constants for salicylic acid 
with gastric emptying rate constant for ^^C-PEG
min“  ^ X 10~^ ± S.E. min  ^ x 10  ^ ± S.E.
85.20 92.3 -0.74 >0.1
Controls ±3.98 ±8. 7
Imipramine 23.77 8.52
Pretreated ±2.11 ± 0.99 6.54 0.001
z = statistic for standard normal distribution
P = probability
ki = absorption rate constant
= gastric emptying rate constant for ^^C-PEG
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FIGURE 19
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL STARVED RATS
FOLLOWING ORAL ADMINISTRATION OF 1‘+C-TRIMETHOPRIM (5 mg/kg)
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FIGURE 20
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL STARVED RATS
FOLLOWING ORAL ADMINISTRATION OF ^'^C-TRIMETHOPRIM (5 mg/kg)
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FIGURE 21
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL STARVED RATS
FOLLOWING ORAL ADMINISTRATION OF  ^^ C-TRIMETHOPRIM (5 mg/kg)
148
2.0
1.8
CONTROL RAT F4.6
Received 1 ml water 1 hr before C-TMP
.4
.0
2 0.8
0.6
0.4
0.2
24 48 72 96 132 192 252 342 432 522 612
Time (min)
2.0
1.8
1.6
I'"
0,1.2
1.0
0.8
A
a 0.6
0.4
0.2
IMIPRAMINE PRETREATED RAT FI 
Received 0.2 mmole/kg imipramine 1 hr before ^**C-TMP
24 48 72 252 342
Time (min)
FIGURE 22
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL FED RATS
FOLLOWING ORAL ADMINISTRATION OF ^'^C-TRIMETHGPRIM (5 mg/kg)
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LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL FED RATS
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FIGURE 24
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL FED RATS
FOLLOWING ORAL ADMINISTRATION OF ^‘^ C-TRIMETHOPRIM (5 mg/kg)
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FIGURE 25
LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL RATS
FOLLOWING ORAL ADMINISTRATION OF 1‘"C-SALICYLIC ACID (15 mg/kg)
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LEVELS OF RADIOACTIVITY IN THE PLASMA OF INDIVIDUAL RATS 
FOLLOWING ORAL ADMINISTRATION OF  ^'+C-SALICYLIC ACID (15 mg/kg)
CHAPTER 5
THE EFFECT OF IM IPR AM IN E ON THE LYMPHATIC ABSORPTION 
OF TRIMETHOPRIM AND S A L IC Y L IC  AC ID  AND ON THE 
METABOLISM OF TRIMETHOPRIM
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INTRODUCTION
Imipramine has several pharmacological effects other than its 
antidepressant activity and its influence on gastric emptying rate. Side- 
effects of imipramine are manifested in both the central and autonomic 
nervous system, on the cardiovascular system and on the respiratory system 
(Jarvik, 1965) . In respect of the work reported in this thesis perhaps the 
most important and least well documented effect of imipramine is action on 
drug metabolizing systems. Breyer (1972) has reported that pretreatment of 
rats with imipramine (12.5 mg/kg twice a day increasing to 25 rag/kg twice a 
day in 7 days) causes the induction of the drug metabolizing capacity of the 
animals as measured by hepatic P-450 levels, ethylmorphine déméthylation and 
aniline hydroxylation. It has also been shown that imipramine is capable of 
inhibiting drug metabolism in rats; Orr^nuis et al. (1972) reported that 
imipramine binds tightly to P-450.
loannides (1973) demonstrated that the concurrent administration 
by i.p. injection of 20 mg/kg of imipramine with 75 mg/kg pentobarbital 
completely abolished the metabolism of pentobarbital. He also showed 
that the metabolism of pentobarbital was reduced when given to rats 24 hours 
after the last of 3 daily doses of imipramine 20 mg/kg per day. Thus there 
is evidence that imipramine may act as an inducer and an inhibitor of drug 
metabolism.
Two aspects of the effects of imipramine are described in this 
chapter. Firstly, the effect of imipramine on lymphatic absorption is 
considered and secondly the effects of imipramine on the in vivo metabolism 
of trimethoprim.
THE EFFECT OF IMIPRAMINE ON LYMPHATIC ABSORPTION
It has already been mentioned that the lymphatics do not 
appear to be a major route for drug absorption. The slow rate of lymph flow 
relative to the intestinal blood flow rate is said to account for the general
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ineffectiveness of the lymphatic system as a drug absorption route. The lymphatic
absorption of trimethoprim has not been studied; however, lymphatic 
absorption of salicylic acid has been investigated (Sieber, 1970; Sieber 
et al. 1974). Sieber did not study directly the lymphatic absorption of 
compounds but rather the lymph was collected from the thoracic duct
therefore in these studies the appearance of radioactivity from radiolabelled 
drug in thoracic lymph could result partially from the distribution of the com­
pounds in total body water. In our studies lymph was collected directly from the 
mesentery, in this situation the appearance of radioactivity from radiolabelled 
drugs should be a better direct indication of the contribution of the lymphatics 
to absorption.
The Effect of Imipramine on the Lymphatic Absorption 
of Trimethoprim and Salicylic Acid
The accumulative appearance of radioactivity in mesenteric 
lymph following oral administration of ^^C-trimethoprim to control and 
imipramine pretreated rats, is shown in Fig. 2 8 . In control animals there 
was initially a rapid appearance of radioactivity in the lymph. The rate of 
appearance decreases with time, however radioactivity was still appearing 
in the lymph at 24 hr. The total amount of radioactivity which appeared in 
the lymph was less than 0.12% of the total dose. The pattern of appearance 
of activity in the lymph of imipramine pretreated animals was slightly 
different. Initially there was a slow rate of appearance which increased 
with time after about 1 hour, then eventually slowed down. Radioactivity 
was still appearing at 24 hr but at a much slower rate than during the 
first few hours. The total amount of radioactivity which appeared in the 
lymph was greater than in control animals but was less than 0.5% of the dose.
The appearance of radioactivity in the mesenteric lymph of 
animals dosed with ^^C-salicylic acid is shown in Fig. 2 9. The pattern in 
control animals is similar to that observed with trimethoprim, although the 
total amount of activity which appeared in the lymph was greater, about 
1,0% of the dose. In imipramine pretreated animals a greater proportion of the
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dose appeared in the lymph, about 3% (t = 15,3 P <001). Also the rate of 
absorption into the lymph appeared to be more rapid in imipramine pretreated 
animals. From these results it may be concluded that the amount of 
radioactivity which appears in the mesenteric lymph is increased by 
pretreatment of animals with imipramine. It may be postulated that this 
occurs because of slowed gastric emptying and a slower presentation of the 
drug to the surface of the intestine allowing a greater portion of the drug 
to pass into the lymph. It is likely that the lymph flow rate is the limiting
factor in drug absorption into the lymph. The blood flow rate in the
intestinal villi is 500 times faster than lymph flow rate (Hendrix and Sweet
1917). Thus a slower presentation of the drug to the villi would allow a 
greater proportion of the drug to pass into the lymph.
In the work reported by Sieber (1970) and Sieber et al. (1974)
it was found that in 24 hr 4% of the radioactivity from the dose of ^^C- 
salicylic acid appeared in the thoracic duct lymph. These workers suggest 
that this is mainly due to distribution of the drug in total body water. Since 
in control animals 1% of the radioactivity from a dose of ^^C-salicylic 
acid appears in the mesenteric lymph in 24 hr in our studies, it seems 
likely that a fairly large proportion of this is a direct result of lymphatic 
absorption, especially as 75% of the total radioactivity which appears in 
the lymph appears within 6 hour of dosing. It may be that the continued
appearance of radioactivity in lymph up to 24 hr after dosing is the result 
of distribution in total body water. The larger portion of radioactivity 
appearing in the lymph of imipramine pretreated rats following administration 
of l^C-trimethoprim and ^^C-salicylic acid, also suggests a significant 
contribution is being made by absorption into the lymphatics. However, 
the total amount of radioactivity absorbed via the intestinal lymphatics is 
small for both drugs described and doubt must be expressed with regard to 
the possible clinical significance of the lymphatics as a route of absorption, 
with these drugs. The work of Sieber showed that there was significant
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lymphatic absorption of certain compounds, notably octadecanoic acid, 
octadecanol and DDT. The possibility that drugs could be "tailor-made" for 
absorption via the lymphatics exists. The results presented here indicate 
that lymphatic absorption of drugs can be enhanced by pretreatment with an 
anticholinergic agent. It is possible that this could be of clinical 
importance with drugs which are absorbed by the lymphatics to a greater 
extent than salicylate and trimethoprim.
THE EFFECT OF IMIPRAMINE ON THE METABOLISM OF ^^C-TRIMETHOPRIM
Thé Metabolism of Trimethoprim
There have been two main studies on the metabolism of 
trimethoprim in the rat (Schwartz et al., 1970 and Meshi and Sato, 1972).
The known metabolites of trimethoprim produced in the rat are shown in
Table 27. The numbering of the metabolites is that used by Schwartz et al.
(1970). A further metabolite, the trimethoprim 3-oxide, has been found to be 
produced in man (Sigel and Brent, 1973). There is no evidence that this 
metabolite occurs in the rat.
The Rf's of authentic samples of the metabolites of trimethoprim 
in the solvent system used are shown in Table 27. In this study it was 
hoped to observe gross changes in metabolic pattern and therefore the areas 
eluted from the TLC plates contained more than one metabolite, as shown in 
Table 28. The areas for elution were selected after examination of the 
autoradiogram and the Rf values given in Table 28 are only a rough guide.
The Effect of Imipramine on the Metabolism of Trimethoprim
The majority of the trimethoprim metabolites in control rats 
given 5 mg/kg trimethoprim orally are unidentified polar compounds which 
remain at the origin. A portion of these polar metabolites are hydrolysable
glucuronides. It can be seen in Table 28 that p re treatment of rats with
imipramine 0.2 mmole/kg 1 hr before oral administration of trimethoprim causes
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-OCHH2N
OCH3
TRIMETHOPRIM
H2N
NH2
H
C
O
H
OCH
METABOLITE 2 (M2)
OH
METABOLITE 1 (Ml)
OCH2
H2
METABOLITE 3 (M3) 
Essentially Free
OH
H2N
METABOLITE 4 (M4)
Essentially conjugated 
to glucuronic acid
Rfs of free trimethoprim and metabolites in chloroform: 
n-propanol: ammonia 80:20:1 on silica gel plates.
Rf
TMP 0.64
Ml 0.50
M2 0.39
M3 0.17
M4 0.43
The numbering of the metabolites is that used by Schwartz et al.(1970)
TABLE 27
Metabolites of trimethoprim in the rat
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a decrease in the amount of polar metabolites formed from approximately 
70% to 20% of the recovered radioactivity whilst not appearing to have a 
very noticeable effect on the formation of the identifiable metabolites 
occurring in fractions 2 and 3. It was conlcuded that imipramine was 
inhibiting the formation of the polar metabolites. However, when 
trimethoprim was administered by the intraperitoneal route, imipramine 
pretreatment did not have such a pronounced effect on the pattern of 
metabolites, reducing the polar metabolites formed from 70% to about 40%.
It may be argued that the less pronounced effects of 
imipramine on trimethoprim metabolisnv when the latter is administered 
intraperitoneally, may be a reflection of the higher plasma levels of 
trimethoprim which would be expected to result from i.p. administration of 
trimethoprim. It has been shown that the oral absorption of trimethoprim 
in imipramine pretreated animals is slow. When trimethoprim was administered 
intraperitoneally to imipramine pretreated animals the absorption of 
trimethoprim would not have been limited by the gastric emptying rate. If 
imipramine was inhibiting the metabolism of trimethoprim by binding to the 
metabolizing enzymes, the higher trimethoprim plasma levels which would result 
from intraperitoneal administration could displace some of the imipramine and allow
more of the trimethoprim to be metabolized.
In order to determine whether imipramine inhibited 
preferentially the formation of any specific trimethoprim metabolite, urine 
from imipramine pretreated and control animals which had received ^^C- 
trimethoprim was subjected to enzymic hydrolysis using glusulase, a mixture 
of 3-glucuronidase and arylsulphatase. The results obtained are shown in 
Table 29. In control animals there is an increase of from 3 to 25%,in the 
amount of activity following enzymic hydrolysis, found in fraction three 
corresponding to the hydroxymetabolites. Schwartz et al. (1970) have shown 
that the ring hydroxymetabolites are the principle conjugates and are 
essentially in the form of glucuronides. Glusulase treatment of urine from
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Fraction
Table 29
Metabolites of trimethoprim in rat urine 
before and after glusulase treatment
Approx. Rf's Control Imipramine Pretreated
of each fraction Untreated Glusulase Untreated Glusulase
0 O - .05 69.3 ± 2.9 45.2 ± 10.0 19.5 ± 2.6 12.0 ± 3.5
1 0.05-0.1 0.0 2.1 ± 1.0 0.0 0.9 ± 0.1
2 0.1 -0.25 4.0 ± 0.6 5.5 ± 0 . 8 2.5 ± 0.3 2.1 ± 1.2
3 0.25-0.55 3.0 ± 0.4 24.6 ± 10.0 4.3 ± 0.4 6.2 ± 3.1
4 0.55-0.75 22.9 ± 2.1 22.4 ± 2.0 72.9 ± 2. 9  78.4 ±6.5
Controls received 1 ml water 1 hr before ^^C-TMP orally. Imipramine 
pretreated animals received 0.2 mmole/kg imipramine 1 hr before ^^C- 
TMP. l^C-TMP administered at 5 mg/kg. Metabolites in each fraction 
are shown in Table 27.
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imipramine pretreated rats has little or no effect on the distribution of 
radioactivity in the different fractions. This is possibly more a 
reflection of the extent of the inhibition of metabolism which makes 
it difficult to determine which, if any, specific metabolites are 
being inhibited. The metabolic pathway for trimethoprim suggested by 
Meshi and Sato (1972) involves the formation of the ring hydroxy­
metabolites directly from trimethoprim and then subsequent glucuronidation. 
It is not possible from these results to say at which step or steps 
imipramine is inhibiting these processes.
The results presented here show that imipramine at the 
dose level used to inhibit gastric emptying also inhibited the metabolism 
of trimethoprim. This inhibition of drug metabolism must be regarded as 
an undesirable effect of imipramine in relation to the studies on the 
effect of gastric emptying on drug absorption. In the work reported in 
Chapter 4 on drug absorption, it was not possible to measure the plasma 
levels of free trimethoprim. The effects of inhibition of metabolism 
were not distinguished in the plasma levels of radioactivity measured, 
although analysis of plasma radioactivity levels using the single 
compartment open model failed to distinguish any effects of inhibited 
metabolism on the apparent volume of distribution, or loss rate constant 
for radioactivity in imipramine pretreated rats as compared with controls. 
It must be concluded that the gross inhibition of metabolism described 
here would be likely to alter one or both of these parameters. However, 
a more extensive pharmacokinetic model and more rigorous plasma level 
sampling schedule would be required to identify these differences.
The results presented here indicate that the metabolic 
effects of imipramine are, at least in the case of trimethoprim, extensive. 
These effects must be considered when imipramine is used, as it has been 
in this work, to inhibit gastric emptying. The metabolic effects of
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imipramine indicate the desirability of finding a compound with a less 
diverse range of side-effects which may be used to inhibit gastric 
emptying in studies of drug absorption.
CHAPTER 6
THE EFFECT OF SOME ANTICHO LINERG IC AGENTS ON THE 
ORAL ABSORPTION OF S A L IC Y L IC  ACID IN  HUMAN VOLUNTEERS
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INTRODUCTION
The original concept of the experiments described in this 
Chapter was to examine the plasma level profiles of an acidic and basic drug 
administered simultaneously to human volunteers who had been pretreated with 
anticholinergic compounds. The rationale behind this approach was that if the 
acid drug was gastrically absorbed and the basic drug absorbed only from 
the intestine,a separation in the time of occurrence of the maximum plasma 
levels of the drugs was expected in volunteers where gastric emptying was 
inhibited. Thus it was hoped that if the anticholinergic agents used as 
pretreatments caused an inhibition of gastric emptying, and if salicylic acid 
(the acid drug) were gastrically absorbed, a separation between the time of 
maximum plasma levels of salicylate and trimethoprim (the basic drug) should 
have been observed in the subject when receiving the pretreatments as compared 
with placebo pretreatment. Unfortunately time did not allow the analysis of 
plasma trimethoprim levels, hence the work reported in this Chapter is incomplete.
PLASMA LEVELS OF SALICYLATE
Salicylic acid (sodium salt) and trimethoprim (free base) was 
administered to four volunteers who had previously received pretreatments with 
one of the anticholinergic compounds or a placebo as described in the Methods 
section. Plasma was prepared from blood samples collected at various time 
intervals and this was analysed for salicylate. This experiment was performed 
double blind and the code was not broken until all the plasmas had been 
analysed for salicylate. The plasma levels of salicylate obtained were fitted 
to a single compartment open model as described in Chapter 4. The fits 
obtained are shown in Figures 30-33 and the parameters derived by the computer 
fit are shown in Table 31.
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Examination of the experimental data shown in Figs. 30-33 
reveals considerable variation in the shape of the salicylate plasma level 
profiles. A comparison of the plasma level profiles of salicylate following 
lactose placebo pretreatment with those obtained following drug pretreatment 
in individual subjects, fails to reveal any consistent trend. For example, 
with Subject H, Fig. 30, plasma salicylate levels can be seen to rise rapidly 
when the subject was pretreated with the placebo, to a level of about 8 yg/ml 
in 10 minutes, and then fluctuated between 7 and 8 yg/ml until 80 minutes 
after which time a fall in levels was noted. Pretreatment with imipramine 
or atropine resulted in lower maximum plasma salicylate levels and a generally 
flatter plasma level profile; levels do not rise above 6 yg/ml. The levels 
of salicylate are seen to rise almost as rapidly after pretreatment with 
compound II as after placebo pretreatment but the maximum attained is 
considerably lower. In Subject U, Fig. 31, the maximum plasma levels of 
salicylate are similar following placebo, imipramine and atropine pretreatment, 
although the profile is slightly flatter following the drug pretreatments as 
compared with the placebo. The maximum plasma salicylate levels in Subject U 
after pretreatment with compound II are considerably lower than the placebo; 
less than 6 as compared with 9 yg/ml and the profile is generally flatter.
In Subject C, Fig. 32, the maximum plasma salicylate levels 
were similar after placebo pretreatment (approx. 6 yg/ml) to those seen after 
imipramine (approx. 7 yg/ml) and atropine pretreatment (approx. 6.5 yg/ml).
The time of occurrence of the maximum was similar in all three instances; 
somewhere between about 40 and 80 minutes. The plasma level profile of 
salicylate after pretreatment with compound II was very similar to that seen 
after placebo pretreatment. The maximum salicylate levels after placebo 
and imipramine pretreatment were similar in Subject F , Fig. 33, about 8 yg/ml, 
but the maximum occurred later when the subject had been pretreated with 
imipramine. A much flatter plasma level profile was seen when the pretreatment 
was with atropine and the maximum level attained was less than when the
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pretreatment was with a placebo. The plasma level profile after pre­
treatment with compound II shows a similar or earlier time of occurrence of 
the maximum levels but the level at the maximum is much less than that seen 
after placebo pretreatment.
It is evident that a subjective examination of the plasma 
levels indicates a variable effect of drug pretreatment compared with placebo 
pretreatment. The most consistent trend is the lower maximum salicylate 
levels following pretreatment with compound II. There is perhaps a general 
tendency for plasma salicylate levels to be lower at the maximum and the maximum, 
tends to occur later after atropine and imipramine pretreatment but the results 
vary from subject to subject. This variation could be as much a reflection 
of intra-individual variation as a drug effect.
The high degree of inter-individual variation is exemplified 
in the levels of salicylate which are seen following placebo pretreatment.
They vary from a maximum of about 9.0 yg/ml (Subject U, Fig. 31) to approx­
imately 6 yg/ml (Subject C, Fig. 32). An equally large degree of variation 
is seen in the time of occurrence of the maximum and the general shape of 
the plasma level profile. A similar degree of variation is seen between 
subjects within the other pretreatment groups. It must be concluded that 
although the pretreatments may be affecting the plasma levels of salicylate 
the inter-individual variation is such that it is difficult to conclusively 
identify the effects.
In order to perform any statistical analysis of the effect of 
the pretreatment it is necessary to fit the plasma level data to a pharma­
cokinetic model. The model used was the single compartment open model as 
described in Chapter 4. The fits obtained are shown in Figures 30-33 and 
the parameters derived are shown in Table 30. Considering the 
absorption rate constant kj, the value of k% is slightly smaller than that 
obtained with placebo pretreatment after pretreatment with imipramine and
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atropine and larger after pretreatment with compound II. These differences 
are not statistically significant mainly because of the large errors 
associated with estimation of the parameters in the case of placebo pre­
treatment. With Subject C the value of is smaller after pretreatment with 
all three drugs but the reduction is significant (P <01) only after pre- 
treatment with compound II. With Subject U, atropine is the only pre­
treatment which results in a significant reduction (P <01) in the value of k%.
With Subject H, atropine is also the only pretreatment which results in a 
significant lowering of k% (P <01).
As these experiments were performed on a balanced latin square 
design it is possible to perform an analysis of variance. An unweighted 
analysis of variance performed by D.A. Field indicated no statistically 
significant differences between days between individuals, or between treatments 
for any of the parameters shown in Table 30, with the exception of k2 , the loss 
rate constant. The value of k2 showed significant differences (P <05) 
between days and between individuals but was not affected by treatments.
However the analysis of variances was an unweighted one. As the parameters 
are all estimated with different degrees of accuracy, as is evident from the 
range of standard errors seen, a weighted analysis of variances would be 
more appropriate. At the present time a suitable method for making a 
weighted analysis does not appear to be available. Any differences in the 
parameter associated with drug pretreatments appear to be masked by the 
errors associated with their estimation and the inter-individual and possible 
intra-individual variation. A further possible source of error in the statistical 
analysis may be the unsuitability or otherwise of the pharmacokinetic model 
chosen.
An examination of the fits obtained indicates that in most 
cases the single compartment model appears to give a reasonably good fit.
There are exceptions, notably in Fig. 30, Day 2 and Fig. 33, Day 1, where
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the incorporation of an absorption delay in the model might have given a 
better fit. In these instances the early data points fall below the fitted 
line. Also Day, 4, Fig. 30, the points after 160 min fall below the line.
There are also instances where the fitted curve does not match the 
experimental data in the region of the maximum. The worst examples are Fig.
30, Days 2 and 4, Fig. 31, Day 1, and Fig. 33, Days 2 and 3. It may be that 
a more sophisticated model is required to describe salicylate plasma levels. 
Unfortunately, the data presented here does not allow the use of a more 
complex model. Furthermore, the model used does provide a reasonable fit to 
the experimental data.
GENERAL DISCUSSION
It is not possible to draw any firm conclusion with regard to 
the effects of the drug pretreatments on the absorption of salicylic acid in 
man. A subjective examination of the results suggests that the drug pre­
treatments may tend to result in a reduction of the maximum plasma levels 
of salicylate and an incre,ase in the time taken for the maximum to occur.
There is also an indication that the plasma level profiles tend to be less 
sharp following pretreatment with the anticholinergic drugs. However, the 
variations observed make it difficult to attribute this effect solely to the 
drug pretreatments. An analysis of variance with the parameters derived 
from the pharmacokinetic model failed to demonstrate any consistent effect, 
probably as a result of the extensive inter-individual variation.
Thus, it would appear that any effects of the pretreatments 
have masked the considerable variations observed in this study. This 
variation may in part arise from a misunderstanding which occurred during 
the experiment. The protocol stipulated that the volunteers should receive 
a standard light breakfast. In fact it transpired that they were able to consume 
as much fruit juice, cereals, milk, sugar, toast, butter and marmalade or
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jam as they wished. Interviews with the volunteers after the experiment 
revealed that they all consumed varying amounts of food. Food and in 
particular fat, is known to slow gastric emptying (Hunt and Knox, 1968); 
the volunteers admitted to having quite considerable amounts of butter and 
as many as six slices of toast. It is impossible to say how significantly 
this uncontrolled diet may have affected the experiment.
Marked effects of food on the absorption of trimethoprim were 
observed in the animal studies described in Chapter 4. Gastric emptying rate 
was found to be a factor of two slower in starved animals than in fed 
animals and although trimethoprim absorption is more rapid in fed rats it 
is likely that with other drugs, reduced gastric emptying rate may reduce the 
rate of intestinal absorption. It is of interest that Subject C was a 
pharmacologist who had read the experimental protocol and although he did not 
eat a standard light breakfast he recalled that he had attempted to eat the 
same amount of food each day. In fact he was the subject that showed the 
most consistent pattern of plasma level (Fig. 32). This could of course 
be pure coincidence. It must be concluded that the variable amount of 
food consumed by the subjects may have had a bearing on the results obtained.
The results of the animal studies (Chapter 4) indicate that 
when gastric emptying was inhibited by imipramine, gastric absorption made 
a significant contribution to the overall absorption rate of salicylate.
The failure of the anticholinergic pretreatments to consistently decrease 
the absorption of salicylic acid in humans may be a reflection of the extent 
of gastric absorption in humans. It is unlikely that trimethoprim is 
gastrically absorbed, and it is likely that the analysis of trimethoprim in 
the plasmas will give a clearer indication of the effects of the pretreatments 
on gastric emptying.
The results presented here indicate that within the different 
pretreatment groups the absorption of salicylate is variable but generally
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rapid. In most instances maximum plasma levels of salicylate are attained 
by 60 to 80 minutes. So even if the anticholinergic pretreatments are 
affecting salicylate absorption they are not causing a large decrease in 
the time of occurrence of the maximum plasma levels.
The large inter-individual differences in salicylate plasma 
level profiles are typical of the problems associated with this type of 
experiment in human volunteers. Whereas with rats it is possible to use 
a sample of animals which are relatively genetically homogeneous and have 
been bred and maintained in a control environment, on a standard diet, this 
is not possible with humans. The absorption studies in rats (Chapter 4) 
produced consistent results, the absorption rate constant for|salicylic 
acid ranged from 17 to 28 x 10“  ^min“  ^ in imipramine pretreated animals and from 
77 to 94 X  10"3 min  ^ in controls. With human volunteers the variation was 
much greater, following placebo pretreatment the absorption rate constant 
varied from 14 to 100 x 10“  ^min“ .^ This may be partly a result of the 
experimental procedure i.e. uncontrolled access to food, it must also be 
regarded as a reflection of the heterogeneous nature of the sample in respect 
of dietary status, genetic constitution, and other environmental factors.
These variations highlight the need for sophisticated statistical methods 
for analysing results from humans and also the necessity for imposing a rigid 
control of experimental conditions.
If the analysis of trimethoprim plasma levels fails to assist 
in interpretation of these results and the experiments were to be repeated, 
special care should be exercised in the control of the pre-experimental diet.
It might also be advisable to restrict more rigidly the volunteer's movements 
during the experimental period. Although this was originally proposed in the 
experimental protocol, it was not possible to implement in practice.
The final interpretation of the results presented here waits 
on the analysis of the trimethoprim plasma levels. However, even when this
176
analysis has been performed the interpretation of results will still have 
to be made with caution bearing in mind the uncontrolled food intake.
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CHAPTER 7
THE EFFECT OF IM IPR AM IN E AND FOOD 
ON IN T E S T IN A L M O T IL IT Y  IN  THE RAT
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The work described in this Chapter was undertaken in close 
collaboration with Dr, B.C. Weatherley of The Department of Drug Metabolism, 
The Wellcome Research Laboratories.
INTRODUCTION
Most of the previously described methods for assessing 
gastrointestinal transit are unsatisfactory, either because they are not 
acceptable on physiological grounds or because they fail to measure directly 
intestinal transit. The available methods have been reviewed briefly 
by Nylander and Wikstrom (1968). It is generally agreed that intestinal 
transit is rapid in the upper intestine and decreases with increasing 
distance from the pyloric sphincter. Reynell and Spray (1956) attempted 
a semi-quantitative investigation of gastric motility. The method they 
used involved the assessment of the amount of an orally administered 
marker in segments of the small intestine. They defined transit rate 
as, "the amount of marker entering a segment, during the time since the 
marker was administered, which had moved on to the next segment during 
the same period of time". If, for example, the intestine is divided into 
two equal segments, transit through the first half of the intestine is 
given by the ratio
X 100
Pb + Fd
where Pd is the amount of marker recovered from all parts distal to the 
mid point of the intestine and Pb is the amount of marker recovered from 
the first half of the small intestine. Using this method Reynell and 
Spray demonstrated that transit was more rapid in the proximal small 
intestine than in the distal part of the intestine.
It would however be difficult to apply Reynell and Spray's 
method to the distribution patterns of marker obtained from intestines
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divided into more than three or four segments. Furthermore, their method 
does not give a quantitative measure of intestinal motility and it is 
difficult to conceive how their model could be related to the physiology 
of the small intestine.
A  SUGGESTED MATHEMATICAL MODEL TO DESCRIBE INTESTINAL TRANSIT
The distribution patterns of marker in intestine of rats 
(Fig. 13-16, Chapter 3) suggested to us that intestinal motility might be 
better described as initially rapid and continually decreasing as the 
length of intestine traversed increased.
It seemed likely that a standard equation for diffusion 
in one dimension of the form:
9 n 9 D 9 n
9 X
where D is the diffusion rate constant 
n is amount. t is time. x is distance
might be applicable to this problem.
The above equation may be written as : 
,-bx9 n = 9
9 t 9 X
ae 9 n 
9 X
ae-bx represents the diffusion rate constant which decreases 
exponentially as distance increases and where a and b are constants to be 
determined by the computer fitting procedure. The solution of this 
equation using the Laplace transformation is:
n = - exp(bx),exp-a t-(e^-l
ab
t- (e^— 1)
ab
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where n = amount of marker
a = rate constant for gastric emptying
b and a are the constants from the diffusion equation 
X = distance along the intestine
t = time in min
H t-(e^-1 )
ab
= Heavyside step function; this ensures that the 
expression is used only up to and including the 
last segment with marker in.
The experimental data was fitted to the expression above by 
integrating over the length of each segment. It was thus possible to obtain 
several solutions with each batch of experimental data. Taking as an 
illustrative example the case where the intestine was divided into 10 equal 
segments, values of a and b were obtained with 10 segments, 5 segments comprising 
each pair of adjacent segments, i.e. 1 + 2 ,  3 + 4 ,  etc., and two segments, 
comprising the first 5 and the last 5 segments combined. Furthermore, the 
parameters a and b as calculated by this method are directly comparable regardless 
of the number of segments into which the intestine was divided. When fitting 
the data, the stomach emptying rate constant a was first fitted independently 
and was then fixed at the value determined by the fit. This reduced the 
number of variables fitted in the final procedure. The values of a and b 
were then computed from the experimentally determined marker distribution 
pattern by a non-linear least squares method. The errors associated with these 
parameters were estimated by examination of the least squares function in the 
region of the minima.
It was found that the shape of the least squares function 
was such that in several cases it exhibited multiple minimas, and thus 
gave rise to several possible values of the parameters when fitted to the 
same data with different starting values for the fitting procedure. Where
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several possible answers arose the fit which gave the smallest residual sum 
of squares (r.s.s.) was chosen. In an effort to determine the value of 
the parameter which gave the smallest r.s.s., the parameters obtained from 
fits to data from the least number of segments possible in a given group, were 
used as starting values for the programme fitting to a greater number of 
segments. In all instances this gave rise to fits which produced similar
values for the parameters and the smallest r.s.s. Ideally parameters obtained
from a given number of segments should be identical with those obtained from 
combinations of the segments. Within limits, this was found to be the case 
(Table 31).
For some as yet unexplained reason the computer programme 
sometimes failed to converge on a minima when the intestinal data had 
been combined into only two segments. Theoretically, the case where only 
two segments were fitted should give the most reliable results as combination 
of the data should effectively reduce the variation in the intestinal 
distribution pattern.
The values of the parameters derived from the fitting 
procedures are shown in Table 31. In each case the parameters derived
from the total number of segments and from combinations of segments are
shown. Some of the fits obtained are shown in Figs. 34-37. Only the fits 
to original data, i.e. ten or six segments are indicated. The fits obtained 
in these instances deviated most from the observed experimental data as
compared with the fits obtained when the same data was combined into less
segments as shown by the r.s.s. in Table 31.
It is not possible to test in a quantitative way the accuracy
of a model such as the one proposed here. But it can be seen from the figures 
that the model fits the experimental data well. Assessment of the model 
relies on a subjective examination of the computer fitted data in comparison 
with the experimentally determined results. The computer fitted data closely 
resembles the experimental data obtained from fed control rats (Figure 34).
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A close similarity between fitted and experimental is also seen with 
imipramine pretreated fed rats (Figure 35). However in this latter case 
although the general trend in the fitted data is the same as the experimental 
data, there are discrepancies at 20 minutes and 60 minutes. These discrepancies 
arise as a result of the fact that at 20 minutes more marker had passed into 
the intestine than at 30 minutes, and at 60 minutes the marker had not 
travelled as far down the intestine as it had in the other animals at all time 
points after 20 minutes. These discrepancies in the fitted data arise in this 
instance from inconsistencies in the experimental data which are a reflection 
of interanimal variation in gastric emptying rate and intestinal transit, and 
are accentuated by the necessary averaging of results from pairs of animals.
The computer fitted results for starved control rats (Figure 36) tend to 
give a sharper peak of distribution in the intestine than that observed with 
the experimental data. The fitted data for starved imipramine pretreated 
animals (Figure 37) is generally a good fit. The most obvious anomaly is at 
30 minutes where the marker was found in segments 8 and 9 whilst the bulk 
of the marker in the intestine had not reached further than segment 4.
Generally the fits produced closely simulate the distribution of marker 
which was observed. This is particularly encouraging in the light of the 
high degree of interanimal variation in gastric emptying rate and 
intestinal distribution patterns and also the fact that only two animals 
were used for each time point. It would appear from the fits obtained that 
the model proposed does fit the experimental data.
Because of the uncertainty associated with the statistical 
part of the computer programme, it was not possible to make statistical 
comparisons between the results obtained in the different treatment groups.
It was however possible to make qualitative comparisons of the results.
Firstly, it can be seen in Table 31 that the values of the 
parameters a and b are of the same order of magnitude when the distribution 
of marker is analysed in the individual segments originally measured, or
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is combined in adjacent segments or combined in the two halves of the 
intestine.
To consider firstly the effects of food on intestinal motility. 
The value of the parameter ’a', which represents the initial rate of transit 
of marker immediately it has left the stomach, is smaller in fed than in 
starved animals; it is reduced by a factor of approximately a half. Also 
the value of 'b', which represents the exponential factor by which 'a ' decreases 
with distance, is reduced by approximately a half in fed animals. Essentially, 
intestinal motility in starved control animals may be described as initially 
rapid and decreasing exponentially with increasing distance from the stomach.
In fed controls the initial transit rate is less rapid and this initial rate 
does not decrease as rapidly with distance as in starved control animals.
The effect of imipramine on intestinal motility is most 
dramatic in starved animals where the value of 'a' is decreased by a factor 
of between 5 and 10 and the value of 'b' is approximately halved.
Imipramine may be said to cause a large decrease in the initial transit 
rate and also a reduction in the rate at which transit rate decreases with 
increasing distance along the intestine. In fed animals there is also a 
reduction in the value of both 'a' and 'b' following imipramine pretreatment. 
However, it is not such a large reduction as that seen in starved animals.
It is interesting to note that in starved imipramine pretreated animals the 
initial rate of transit 'a' is slower than that in imipramine pretreated 
fed animals. A possible explanation for this is that the presence of food 
in the intestine stimulates, in some way, intestinal motility so that the 
inhibition by imipramine is less pronounced.
These results indicate that imipramine affects not only gastric 
emptying but also causes a reduction in intestinal transit rate. The effects 
of imipramine are manifested as a decrease in the initial rate of intestinal 
transit and also a reduction in the rate at which transit decreases with 
increasing distance along the small intestine from the stomach.
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GENERAL DISCUSSION
Within the limits of this method, i.e. the uncertainty about 
the accuracy of the assessment of errors and the possibility of the selection 
of the wrong minima, the results indicate that imipramine decreases the rate 
of intestinal transit. Intestinal transit is also seen to be slower in fed 
animals than in starved animals. In fed animals the effect of imipramine 
on intestinal transit is not as pronounced as in starved animals.
One group of workers have described a method for assessing 
intestinal transit in the rat using sodium chromate (Na2 ^^CrOi^) as a marker 
(Derblom et al. 1966). These workers also describe a mathematical analysis 
of their data (Grevsten et al. 1967). The distribution of marker was measured 
by passing the intact small intestines, from rats killed at various time 
intervals after administration of the marker, under a scintillation detector.
The detector output was recorded on a chart recorder synchronized with the 
rate at which the intestine was passed under the detector. Using this method 
these workers were able to obtain a continuous pattern of distribution of 
marker in each intestine examined. Although Derblom et al. claim that 
sodium chromate is non-absorbable and does not bind to the mucous membrane 
in the intestine, Mackenzie et al. (1959) reported that at least 6 % of an oral 
dose of sodium chromate was absorbed in rats. In a review by Mertz (1969) 
there is evidence that chromium does bind quite readily to various proteins.
It is perhaps surprising that Derblom et al. (1966) used sodium chromate
as there is good evidence that chromium oxide is much less absorbable, only
0.5% of an oral dose is absorbed in the rat (Mertz, 1969). In principle 
the method described by Derblom et al. is superior to the method used in 
the work reported here, essentially because the continuous distribution of 
marker in the intestine can be recorded. Unfortunately the necessary equipment,
1.e. a scintillation detector, was not available and the method could not be used 
here.
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The mathematical analysis of the distribution of marker 
described by Grevsten et al. (1967) assumes that a relationship existed 
between the rate of gastric emptying and the rate of intestinal motility. 
The equation derived to express this relationship was:
w.
i-1 
V + 13 X 
j=l ]
where = quotient for segment
x^ = percentage of marker in segment i
V = percentage of marker remaining in the stomach
i-1
YJ X . = percentage of the marker in all segments proximal
 ^ to segment i
This relationship is based on the observation that gastric 
emptying is exponential and the assumption that propagation in the small 
intestine is principally the same. In order to calculate the quotients the 
traces recording distribution of the marker in the intestine were divided 
into 10 equal segments, the area under the trace in each segment was found 
to be proportional to the percentage marker in the segment. It is 
unfortunate that this procedure was necessary, presumably due to a lack of 
computer facilities, as it reduces the potential value of obtaining 
continuous distribution patterns. It was shown that the quotient y^ was 
"essentially" constant up to about the fifth or sixth of 10 intestinal 
segments. This was taken to indicate that motility in the upper intestine 
is exponential and limited by gastric emptying rate. However the conclusions 
drawn from these results are open to question.
In order to calculate the quotients the data from many animals, 
(54 at each time interval) was averaged. It can be seen from the continuous 
distribution patterns shown in the paper by Derblom et al. (1966) that this 
procedure would tend to "flatten" out the distribution of marker, such that
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it would appear to be fairly evenly distributed throughout the small 
intestine; this would tend to result in a constant value for the quotients. 
Also if intestinal transit in the upper intestine were very rapid and 
declined proportionally but by a small amount as the distance from the 
stomach increased, as our model indicates it does, this relationship would 
still hold in as much as the quotients would be expected to be "essentially" 
the same in the upper intestine where transit is rapid. Furthermore, the 
calculation of this quotient does not take into account the possibility that 
in given distal segments the marker may have only just reached that segment,
i.e. the recording of a low percentage of marker in the most distal segment 
may indicate that marker has just entered the segment but not traversed the 
whole length of the segment. Such a situation would give rise to an 
artificially low value for the quotient. This appears to have been observed 
by these authors but has not been commented on. The inclusion of the "heavy- 
side function" in the expression we have used does not allow this situation 
to occur in our model.
It is also of interest that the expression used by Grevsten 
et al. (1967) may be equated exactly with the expression we have used when 
the value of 'b' tends to O. It is apparent from Table 31 that the value of 
'b' does not in any of the examples we have analysed tend to O. Also if the 
value of 'b' were O the quotient would be constant over the whole range of 
the intestine. The statement by Grevsten et al. (1967) that the quotient 
is "essentially" constant is itself open to question. In the region where 
they claim constancy the value of the quotient varies from 0 . 1 to 0.16; it 
is difficult to assess to what degree this indicates constancy. Had these 
authors analysed the data from individual animals and meaned the quotients, 
rather than averaging distribution and then calculating the quotients, they 
would have been able to assess the constancy of the quotient statistically.
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The model we have outlined here provides a method for assessing 
gastrointestinal transit which does not require the presupposition that the 
pattern of transit be regarded as governed by the pattern of gastric emptying. 
The results of the analysis of distribution patterns of marker using the 
model indicate that intestinal motility is initially rapid and declines 
exponentially as the distance from the stomach increases. Our results indicate 
that the analysis of intestinal motility described by Grevsten does not fully 
account for the distribution pattern of marker in the intestine. Their 
analysis overlooks the exponential decline in transit rate associated with 
an increase in the distance travelled from the stomach.
Using the model we have described it would be possible to 
analyse the effects on intestinal motility of compounds shown to inhibit 
gastric emptying. It was suggested in Chapter 3 that, for example,
the distribution of marker in the intestines of rats pretreated with 
amitriptyline and nortriptyline suggests that these compounds have a more 
pronounced effect on intestinal motility than does imipramine or desmethyl- 
imipramine. Measuring marker distribution at one time point does not allow 
the effects of alterations in intestinal motility to be distinguished from 
alterations in the pattern and timing of gastric emptying. If the 
distribution of marker in animals pretreated with amitriptyline and 
nortriptyline was measured at different time intervals, and the results 
subjected to analysis in the model described here, it should be possible 
to determine whether these drugs affect intestinal motility differently 
from the imipramines.
Intestinal motility has been shown to be slower in fed rats 
than starved rats. This difference in intestinal transit rate may account 
for the more rapid absorption of trimethoprim in fed rats described in 
Chapter 4. A slower rate of transit in the upper intestine would allow the 
trimethoprim a longer contact time in the upper intestine where it would 
be presented with a larger surface area of absorption sites. The
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possibility exists that the model described here in conjunction with drugs 
which alter intestinal transit rate, could be used to advantage in the 
investigation of the sites and kinetics of drug absorption in vivo. Further 
work using drugs which speed intestinal transit as well as those which delay 
it offers the prospect of investigating much more fully than has previously 
been possible the importance of the different areas of the intestine in drug 
absorption and the importance of intestinal motility in drug absorption.
It must be concluded that the model described above requires 
further investigation and can only be regarded as a preliminary study. In 
particular the statistical part of the computer programme needs further 
investigation and consideration should be given to the possibility of using 
a method similar to that of Derblom et al. (1966) when continuous marker
distribution patterns can be measured. It remains to be seen whether the 
derived constants 'a' and ’b' can be related to the physiology of 
intestinal motility.
194
: Table 31
Parameters derived from non-linear least squares fit to the 
model proposed to describe intestinal motility
Parameters fitted
Treatment No. Segments r.s.s. a ± S.E. X: 10  ^ min  ^ b ± S.E. x 10  ^ min
Starved . lO* 0.6487 10.358 ± 1.328 5.507 ± 0.302
Control 5 0.3664 12.564 ± 3.218 5.883 ± 0.580
Rats 2 0.3600 11.376 ± 0.843 5.896 ± 0.218
Starved lO* 0.0252 1.591 ± 0.062 1.834 ± 0.154
Imipramine 5 0.0261 2.130 ± 0.476 3.526 ± 0.929
Pretreated 2 0.0143 1.916 ± 0.339 2.013 ± 0.613
Rats
Fed 6 * 0.0507 6. 8 6 8 ± 0.826 2.621 ± 0.228
Control 3 0.0340 7.362 ± 2.111 2.919 - 0.654
Rats 2 0.0204 8.399 ± -t 2.830 ± -t
Fed 6 0.0944 5.553 ± 0.449 2.354 ± 0.148
Imipramine 3 0.1004 3.543 ± 0.774 0.906 ± 0.406
Pretreated 2 0.0941 4.483 ± 1.927 1.189 ± 0.766
Rats
No. Segment = Number of segments in which the marker distribution was described
* shows the number of segments analysed in the original experiment. The others 
are a combination of these as described in the text.
r.s.s. is residual sum of squares from the fitting procedure.
a and b are described in the text.
t = Statistical part of the computer programme failed to converge on a mininum.
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CHAPTER 8
F IN A L  DISCUSSION
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The work described in this thesis was designed to determine 
the effects of a range of compounds on gastric emptying rate in the rat, to 
investigate the influence of gastric emptying rate on drug absorption in 
the rat, and also to investigate the effects of compounds, found to reduce 
gastric emptying rate in the rat, on drug absorption in humans.
A range of compounds were found to delay gastric emptying 
in the rat. With the exception of quinidine, all the compounds which 
were found to delay gastric emptying were anticholinergic, and their anti­
cholinergic potency fell in the same order as their potency in inhibiting 
gastric emptying. These data support the hypothesis that gastric emptying 
may be inhibited by an anticholinergic mechanism, especially as several 
other possible means by which the compounds could delay gastric emptying 
were found to be inoperative. The fact that non-anticholinergic compounds 
other than quinidine have been reported to delay gastric emptying, for example 
phthalapramine (Stadaas and Aune, 1971) and some phenylpyrazole derivatives 
(Takanaka et al. 1973) , suggests that there are other possible mechanisms 
by which gastric emptying can be delayed. It should however be noted that 
the dose levels of the compounds used in the study reported here were high 
relative to the therapeutic dose levels at which the compounds would be 
used in humans. There is obviously a need to investigate the effects of 
these agents on gastric emptying at lower dose levels especially if an 
attempt is to be made to extrapolate from the animal studies to the human 
situation. The one compound, desmethylimipramine, which was studied at 
levels comparable to the human dose range did not specifically demonstrate 
an inhibiting effect on gastric emptying under the experimental conditions 
used. However the distribution of marker in the small intestine of animals 
treated at these lower dose levels did suggest that gastric emptying may 
have been delayed. There is also an obvious need to investigate the 
effects of these compounds on gastric emptying in man to determine whether
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normal therapy with these agents is likely to result in alteration in 
gastric emptying.
Pretreatment of rats with imipramine, a compound found to be 
a potent inhibitor of gastric emptying, reduced gastric emptying rate by a 
factor of ten-fold in both fed and starved animals. Pretreatment of 
animals with imipramine also resulted in a decrease in the absorption rate 
of salicylic acid and trimethoprim. In starved control animals gastric 
emptying rate was found to be more rapid than the absorption rate for trimethoprim 
as determined in a single compartment open model. Following pretreatment 
with imipramine the absorption rate fell to a level where it was not signi­
ficantly different from the gastric emptying rate. In fed animals, where 
gastric emptying was found to be slower, the rate of trimethoprim absorption 
was not significantly different from the gastric emptying rate in controls 
or pretreated animals.
These data indicate that the absorption of trimethoprim is 
rapid and the rate at which trimethoprim is transferred into the lumen of 
the intestine can be rate limiting. This is not an unexpected finding; 
trimethoprim is a base and would be expected to be highly ionized in the 
stomach. The absorption of trimethoprim in the ionized form from the much 
smaller surface area of the stomach would be expected to be less rapid than 
absorption of the unionized trimethoprim from the larger surface area of the 
small intestine.
Imipramine was also found to have an effect on the 
absorption of the acidic compound salicylic acid. With this agent there 
was no statistically significant difference between gastric emptying rate 
and absorption rate in control animals. However, the rate of absorption 
was reduced by a delay in gastric emptying. It is likely that a large 
fraction of the salicylic acid in the duodenum is ionized. However, 
absorption was found to be very rapid and a large proportion of the compound
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must have been absorbed from the intestine. Gastric absorption of salicylic 
acid was shown to contribute to the intestinal absorption of this compound. 
When the rate of gastric emptying was reduced by imipramine pretreatment, 
the rate of absorption of salicylic acid was significantly faster than the 
rate of gastric emptying of the marker substance used to measure gastric 
emptying rate. If the emptying rate of the marker was representative of 
the rate of transfer of salicylic acid from the stomach to the intestine, 
a point which requires further investigation, then it may be concluded that 
the gastric absorption of salicylic acid makes a contribution to its overall 
rate of absorption.
It may be concluded from these results that gastric emptying 
rate is an important factor influencing drug absorption in experimental 
animals. Furthermore, the inhibition of gastric emptying rate with a 
compound such as imipramine allows the relative importance of gastric 
absorption to be investigated in the intact animal. It must be noted 
however that imipramine may not be the ideal compound with which to delay 
gastric emptying rate in order to study drug absorption. It was found 
(Chapter 5) that imipramine was a potent inhibitor of the metabolism of 
trimethoprim. Ideally the compound used to delay gastric emptying should 
have no pharmacological action other than that of delaying gastric emptying, 
preferably should not be absorbed and should have a long and consistent 
duration of action. Whether a compound fulfilling these requirements exists 
is unknown. The anticholinergic agent propanthaline bromide has been shown 
to delay gastric emptying in humans at the relatively low dose level of 30 mg 
intravenously. There do not appear to be any reports in the literature as to 
the metabolic effects of this compound, however it would seem to be a likely 
candidate for further studies.
An investigation with a range of drugs with differing pKa's 
and lipophilicity in animals with altered gastric emptying would enable the
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importance of gastric absorption to be determined. Up until the present 
time most of the studies of gastric absorption have been made in surgically 
prepared animals i.e. where the stomach has been tied off from the intestine. 
These experiments have usually involved the measurement of the amount of 
drug which has disappeared from the stomach over a relatively long time 
interval. It is difficult to determine the importance of gastric absorption 
in such a system especially when considering that the absorption from a 
similar preparation of the intestine may be very much more rapid.
It would appear from the results presented here that gastric 
absorption may be less important than had previously been thought.
It is generally postulated that acids will be absorbed in the stomach. 
Salicylic acid is very rapidly absorbed from the intestine and its 
absorption from the stomach and intestine when gastric emptying is delayed 
is four-fold slower than absorption in controls. If the factors other than 
surface area which control the rate of absorption are similar in the stomach 
and the small intestine it may be predicted that other acidic drugs which 
are less well absorbed in the intestine will be absorbed to a much 
smaller extent in the stomach.
Gastric emptying rate was found to be slower in fed control 
animals than in starved controls. It was expected that the absorption of 
trimethoprim would also be slower in the former group. In fact it 
transpired that the absorption of trimethoprim was very much more rapid in 
fed animals than it was in starved animals. An analysis of the rate of 
intestinal transit in fed and starved rats revealed that the rate of 
transit was slower in fed animals than starved. This may account 
for the more rapid absorption seen in fed animals, when the drug would be 
allowed a longer contact time with the larger surface area in the upper 
intestine. This interpretation, if correct, does indicate that with a well 
and rapidly absorbed drug such as trimethoprim, the surface area available
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for absorption and the contact time a confound is allowed with this area 
may be prime controlling factors.
The model used to describe intestinal motility has only been 
investigated and used to a limited extent. It does however appear to hold 
considerable promise and has several applications: in describing intestinal
motility in a quantitative way it allows the effects of drugs on this motility 
to be investigated, also in providing a better understanding of the factors 
which are involved in the control of intestinal motility. This latter 
possibility depends on whether the model can be related to the physiology 
of intestinal motility, an area which is incompletely understood. It is 
encouraging that the model distinguished the effect of imipramine on 
intestinal transit, especially in view of the potent inhibition of gastric 
emptying caused by this compound and consequently the small quantity of 
marker which had passed into the intestine during the experimental period 
involved. Whether the other compounds found to inhibit gastric emptying 
also alter intestinal motility and whether the effects of the other 
compounds are the same or different from those seen with imipramine awaits 
further investigation.
The results presented here indicate the importance of food, 
gastric emptying rate and intestinal motility on drug absorption in 
experimental animals. These results have a bearing on studies of drug 
metabolism, pharmacokinetics and toxicology. The fact that gastric 
emptying rate can have such a pronounced effect on drug absorption indicates 
that in the experimental situation factors affecting gastric emptying must 
be carefully considered in the design and execution of animal experiments.
It is not known, for example, if stress in the experimental situation, or 
methods of dosing affect gastric emptying rate. It seems likely that these 
and other factors may have pronounced effects. Certainly the volume of a 
dose solution and the dose vehicle used can be predicted to be factors
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influencing gastric emptying. It is important that these factors be at 
least controlled and consistent between toxicity studies and metabolic 
studies. It is obviously important that the dietary status of the animals 
is the same. The pharmacokinetic profile of a drug is likely to be 
different in the starved animals, often used for metabolic work, from the 
profile observed in a toxicity study in fed animals. In studies of biliary 
excretion it is necessary to perform surgery in order to cannulate the bile 
duct. It must be remembered that this operation will almost certainly alter 
gastric emptying rate and intestinal motility patterns. Therefore a method 
should be used which allows the animal sufficient time to recover fully 
from the surgical procedures; such a method would also require that the 
bile be returned to the intestine during the recovery period. The results 
presented here indicate the potential importance of the factors involved 
with the control and maintenance of normal gastrointestinal motility patterns 
and point to the importance of these factors in the design and control of 
animal experiments.
The effects of agents found to delay gastric emptying in 
these animal studies need to be investigated in the clinical situation: 
firstly, to determine whether therapeutic doses of the compounds studied 
affect gastric emptying and secondly, to investigate their effect on 
drug absorption. Although it was not possible to investigate the first 
of these possibilities, an attempt was made to study the second. Unfortunately 
the results of the human studies reported here (Chapter 6 ) were inconclusive 
for two reasons: firstly, the failure to complete the experiment due to a 
shortage of time and secondly, problems which arose in the execution of the 
experiment, namely a failure to control properly the volunteers' diet. The 
results do indicate that salicylic acid is rapidly absorbed in humans and 
that a large inter-individual variation in the plasma level profile of 
salicylate occurs, possibly as a result of variations in diet. The
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variations observed demonstrate the large inter-subject variation which 
may arise in human studies as compared with animal studies. These variations 
reflect the environmental, genetic and dietary differences between individuals 
and indicate the need for careful experimental design in human experiments 
and the requirement for sophisticated statistical methods with which to 
analyse human results.
Although the volunteer studies reported here could not be 
completed and do not as yet allow a positive indication that the anti­
cholinergic agents affect absorption of salicylic acid and trimethoprim, 
reports in the literature indicate that alterations in gastric emptying 
rate have been observed following drug treatment of humans. Sacchetti et al. 
(196 4) showed that levomepate delayed gastric emptying in humans and Nimmo 
et al. (1973) showed that propanthaline bromide delayed gastric emptying; 
it is of note that both of these compounds are anticholinergic agents.
These data combined with the results of the animal studies presented here 
and the reported clinical side-effects of the agents studied here, indicate 
that a delay in gastric emptying is a likely consequence of therapeutic 
administration of these agents to humans. For example, the tricylic 
antidepressants are reported to cause gastric stasis, paralytic ileus 
and constipation as side-effects (Jarvik, 1965). These side-effects may 
result at least partly from alterations in gastrointestinal motility.
Also of importance are the reports that the side-effects of the tricylic 
antidepressants occur shortly after initiation of treatment and may persist 
for from 6 weeks to three months. Thus it would appear that alterations 
in gastric emptying may be expected to result from clinical use of drugs 
with anticholinergic properties. This possibility indicates potential 
toxicity hazards.
With regard to multiple drug therapy it can be predicted 
that alterations in gastric emptying rate caused by one therapeutic agent.
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may well result in an alteration in the normal plasma level profile of 
another orally administered therapeutic agent. Two possible extremes can 
be envisaged and have in fact been shown to occur in volunteers. The first 
of these possibilities is that the absorption of a rapidly absorbed agent 
may be slowed by a decrease in gastric emptying rate, in a similar fashion 
to the effects of imipramine and trimethoprim absorption in the rat. This 
situation has been observed experimentally in humans. Nimmo et al. (1973) 
demonstrated that pretreatment, intravenously, of human volunteers with 
30 mg of propanthaline delayed gastric emptying, reduced the maximum 
plasma levels of paracetamol and delayed the occurrence of the maximum 
obtained following oral administration of the paracetamol. If therapy 
with antidepressants does inhibit gastric emptying, the plasma levels of 
other rapidly absorbed orally administered drugs may be lower than would 
otherwise be expected. This could result in failure to attain thera­
peutically active levels of the drug. Also the situation can be envisaged 
that where the drug other than the antidepressant is being titrated, dose 
levels are given which result in therapeutic plasma levels. Then on 
cessation of antidepressant therapy or as the patients become conditioned 
to the antidepressant therapy the gastric emptying rate increases and toxic 
plasma levels of the other agent result.
The effect of reduced gastric emptying rate and decreased 
intestinal motility on the absorption of slowly or poorly absorbed compounds 
is the opposite to that on rapidly absorbed agents. Levy et al. (1972) 
showed that pretreatment of volunteers with propanthaline bromide resulted 
in an increased absorption of the poorly absorbed vitamin riboflavine. 
Manninen et al. (1973) demonstrated that propanthaline treatment of 
patients on maintenance therapy of digoxin caused an increase in the plasma 
levels of digoxin. Antidepressant therapy may therefore be expected to 
increase the absorption of poorly absorbed compounds and high and possibly
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toxic, plasma levels of poorly absorbed compounds may be associated with 
antidepressant therapy. On cessation of therapy with antidepressants or 
as the patient becomes conditioned to side-effects the plasma levels may
fall below the therapeutically active level.
Obviously, the possibility exists for putting these 
undesirable side-effects to therapeutic advantage. If a compound could 
be found which affected intestinal motility and gastric emptying without 
exhibiting other undesirable side-effects, or a compound found which had 
such potent effects on the gastrointestinal tract that very low doses 
could be used, then the possibility of altering absorption could be used
to therapeutic advantage. A lower, flatter plasma level profile of
rapidly absorbed agents could be obtained thus avoiding side-effects and 
allowing a prolongation of the period where therapeutically active plasma 
levels occur. Conversely, the absorption of poorly absorbed agents could 
be enhanced. A further therapeutic potential suggested by the results 
arose from the studies of lymphatic absorption. Although trimethoprim 
and salicylic acid are absorbed only poorly into the lymphatic system, 
pretreatment with imipramine increases the amount passing into the lymph by 
a factor of about three. If this occurs in humans it presents a potentially 
useful possibility. The lymphatic system does not pass through the liver 
and absorption into the lymph therefore offers the possibility of by­
passing the so-called 'first pass effect" on metabolism. Absorption directly 
into the lymphatics could be of considerable importance in certain infective 
diseases and in patients suffering from lymphom^a. It may be that with a 
drug absorbed lymphatically to the extent of 3% the possibility of increasing 
that absorption to 10% becomes an attractive proposition. Whether these 
propositions are feasible awaits further investigation.
The dramatic effects of alterations in gastric emptying on 
plasma levels of orally absorbed compounds in rats also points to
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another unconsidered possibility. Patients who have undergone surgery, 
especially gastrointestinal surgery, who are suffering from shock, are 
emotionally disturbed, disabled or suffering from disease may well be 
expected to exhibit different patterns of gastric emptying from the 
"normal volunteer". One may therefore predict that the patterns of drug 
absorption may be significantly different in such patients from those 
observed in volunteer studies. A potential toxic reaction or a failure 
to reach therapeutically active plasma levels must be considered in such 
cases.
Another possible hazard may be predicted to result from delays 
in gastric emptying. This relates to the potential for the formation of 
nitrosamines from nitrate and amines in the environment of the mammalian 
stomach. Nitrosamines are known to be potent carcinogens (Wolff and 
Wasserman, 1972; Sebranek and Cassens, 1973). Druckery et al. (1963) 
proposed that amines and nitrite may react in the mammalian stomach to 
produce nitrosamines. The formation of nitrosamines in vitro from 
secondary amines and nitrite in human gastric juice has been demonstrated 
(Saunders, 1967) and the formation of lung adenomas in mice has been shown 
to occur following administration of nitrite in drinking water and amines 
in the food (Greenblatt et al. 1971). The reaction between nitrite and amines 
which will occur readily in the acid environment of the stomach will proceed 
only very slowly, if at all, in the more alkaline environment of the small 
intestine.
A delay in gastric emptying essentially prolongs the 
time available for the nitrite-amine reaction. If the nitrosamines formed 
are carcinogenic the increased reaction time must be related to an increased 
hazard. This potential hazard may be of particular in^ortance in the 
hospital environment where patients on antidepressant therapy may also be 
receiving other amine drugs, and where the diet is likely to be quite high
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in both nitrite, from preserved meats and vegetables, and amines. The 
hazards outlined need further investigation. Firstly, it must be 
established whether compounds with anticholinergic activity inhibit gastric 
emptying in humans. Secondly, the potential enhancement of nitrosamine 
formation by delayed gastric emptying need to be investigated in animal 
studies. If this hazard then appears to be a real one, effective 
preventative measures must be developed. It is possibly unrealistic to 
suggest not using all drugs which delay gastric emptying or all amine drugs.
A more practical approach may be to attempt to prevent nitrosamine formation. 
Amine drugs could be administered enterically coated, however the possibility 
of nitrosamine formation with naturally occurring amines would still be 
present. Dashman et al. (1973) have reported that ascorbate is an 
effective inhibitor of the reaction between nitrite and amines. It remains 
to be determined whether the incorporation of a substance such as ascorbate 
could prove an effective protective measure, and the presence of yet another 
agent, such as ascorbate, would need to be investigated for possible 
interaction with the drugs being used.
As the search for new drugs becomes increasingly difficult 
and expensive, the need for a greater understanding of the processess 
of drug absorption, action, metabolism, toxicity and excretion increases.
The primary barrier between an orally administered drug and efficacy is 
the intestinal wall. The need to predict the rate and extent to which new 
drugs will be absorbed, and to develop means of controlling absorption becomes 
ever more desirable. The work described in this thesis shows that the 
effect of alteration in gastric emptying rate and intestinal motility can 
be investigated in vivo and that these functions have a profound effect on 
drug absorption. Further work with these methods may lead to a better 
understanding of the sites of drug absorption in the intestinal tract, 
mechanisms of absorption, and may provide ways in which the intestinal
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absorption of drugs can be modified and controlled. Animal studies provide 
a way of investigating fundamental principles, predicting toxicity, assessing 
efficacy, and providing indications of drug interactions but ultimately 
drugs are administered to humans. In the final analysis it is the human 
that has to absorb the drug. Ultimately the side-effects and efficacy of 
drugs must be established in the patients to whom they are administered, 
whilst every effort is made to reduce the risks associated with drug therapy.
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Pooling of Parameters Obtained by Non-Linear Least Squares 
Fitting Procedure to Plasma Level Data from Individual Animals
It is frequently the case that considerable time and effort
is expended in obtaining plasma level data from individual animals or subjects
following drug administration. These data need to be combined in order to
make comparisons between treatments. The two most often used methods are:
(1) To apply the relevant fitting procedures to the meaned
data obtained from a particular treatment group.
(2) The fitting procedure may be applied to the data from
each individual animal, the parameters so derived are
then meaned and the standard errors of the means
calculated.
The first possibility is unacceptable as it involves meaning 
at each time point the data from several animals. The plasma level at a 
given time in a given animal is a function of the time and as many 
exponential terms as the model used to describe the plasma levels requires. 
Meaning the data from several animals at a given time, is attempting to 
combine numbers, which are the products of one or more exponential term, 
in a linear fashion. When this procedure is repeated over several time 
points the resulting answer may bear no relationship to the exponential 
teirms for each animal. In the second case, meaning the parameters obtained 
from all the individuals is also inaccurate. Each parameter derived from 
the fitting procedure has an error associated with it. This error is a 
measure of the reliability with which the parameter has been estimated. Taking 
the arithmetic mean of the parameters implies that all the parameters are
equally accurately measured; this is obviously not the case.
If it is accepted that combination of data in the fashion 
described above is undesirable the problem of how to express data derived from
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several animals remains. There is apparently no statistical method
published for combining and comparing constants derived from non-linear
least squares fitting procedures.
A method was suggested by D.A. Field whereby parameters
derived from the fitting procedures could be combined. The method is in
some aspects approximate, nevertheless, it is the only one presently available
It is desired to combine several parameters derived from
non-linear least squares fitting procedures. For the i^^ curve the variance 
2
s^ may be estimated as:
2
s. = rss Where rss = residual sum of squares of
(df).
(df) . = number of data points minus 
number of parameters fitted
The variances obtained for the fits to different data may 
then be tested for homogeneity using the F test. , With the data presented 
here it was never desired to combine data from more than three animals so 
F tests were performed by analysis of all combinations.
Pooling Data with Homogeneous Variances
The variance is estimated as
s2 = S(df)^.s2
E(df)^
This is the best estimate of the residual variance 
The variance of is some function (f^ ) of i.e.
variance = G^f^
= (SEa^)2
therefore f^ = (SEa^)^
226
The pooled value of the a's (A) will be a function of 
weighted according to the variance of each individual a.
therefore Variance A =
l‘«J
Pooling Data with Heterogeneous Variances
be assumed that:
Where the variances s^ are found to be heterogeneous it must
2 2 2
Variance a. = a.f. where a. is estimated by s.
I l l  1 1
Z “i/[SE(a^)]
1 / 2 
Z /[SE(a.)]
Therefore Variance A =
2
Z a.f. 
1 1 %
7 '
y  V
/ Z ' [SE(a^) ]
To derive this result the number of degrees of freedom for
is assumed large,
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Statistic for Testing Differences Between Parameters
To make comparisons between different A's the statistic:
i/var Aj + Var Ag
is assumed to follow a normal standard distribution.
This test was also used to test for significance between 
parameters derived from the fits. It is important to appreciate that this 
test assumes a normal distribution of errors involved with the fitting 
procedures.
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lu b ilis e r
Volum e of 
so lu b ilise r S cin tilla to r E x tra  steps
T im e fo r  
satis facto ry  
solubilisation  
(h)
:s 1 m l 10 m l toluene butyl PBD (7 .5  g / l i t r e ) Add 30 [ilitre s  g lacia l acetic acid  
afte r addition of sc in tilla to r
2
luene 2 m l 10 m l toluene, Me^ POPOP 100 m g /lit re  
PPG 6 .0  g / l i t r e
7
BS 1 m l 2M NaOH 12 m l toluene/BBS3 (5:1) 
butyl PBD 6 .25  g / l i t r e
Add 2 .5  m l BBS2 to NaOH digest 
p rio r  to addition of s c in tilla to r
0 .5
rotosol 1 m l 10 m l toluene Me^ POPOP 100 m g /lit re  
PPG  6 g / l i t r e
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srch loric
:id
0 .4  m l H C IO  4 
0. 8 m l 60% H .O ,
16 m l tT21 0 .5
iT 1 m l 10 m l tT21 N eutra lise w ith 0. 5 m l 4M  HNO^ 0 .5
Î T 1 m l 10 m l S .20 0 .5
ib le .6 . Mean counting e ffic iency (%) o f Carbon-14 fo r solubilised ra t tissues.
Lubilised
tissue
NCS Soluene 100 BBS IIC IO , Protosol SHT S H T /S . 20
rain 8 6 .9 -  0 .6 7 0 .7 2 1 8 .7 67 .42  1 .3 7 8 .3 2  1 .0 8 7 .42  1 .5 79 . 72  4 .3 8 2 .4 2  2 .3
in 8 4 .1± 1 .7 87 .72  2 .4 72 .42  6 .4 80.1-2 6.1 77 .32  2 .1 , 7 6 .1 2  1 , 6 8 2 .3 2  2 .2
mg 6 1 .9 i  5 .6 4 5 . 9214.0 6 3 .12  2 .4 8 2 .5 2  3 .7 5 1 .6 2 1 3 .2 57 .32  4 .1 7 6 .1 2  3 .3
îa r t 8 1 .s i  3 .9 66. 7:  9 .7 66.22 4 , 0 77 .72 1.4 66 .121 2 .8 7 0 .5 2  1 .7 7 9 . 92  2 .8
v e r 7 0 .1± 3 .7 4 7 .0 :1 4 .9 60 .62  1 . 6 74 . 92  0 ,7 4 1 .0 2 2 0 .5 65 .52  3 . 6 8 0 .3 2  3 .8
)leen 1 7 .7 1  1 .3 1 5 .8 2  5 ,0 4 6 .6 2  2 .2 7 5 .62  2 .2 15.72 6 .6 2 9 .7 2 1 1 .5 6 3 .9 2  2 .6
idney 7 2 .2 2  0 .9 4 6 .3 2 1 0 .6 5 3 .8 2 1 6 .3 73.92 1 .2 5 8 .9212 .1 60 .72  2 .9 7 7 .8 2  2 .0
te Stine 8 7 .0 2  1 .5 74 . 9211.3 6 7 .22  7 .4 7 8 .52  2 .0 80 .22  1 .5 79 .42 3 .6 8 1 .5 2  1 .3
uscle 8 7 .0 2  3 .0 6 7 . i 2 i 4 .6 65 .92  3 .9 7 8 .12  1.3 7 9 .12  4 .2 7 8 .8 2  2 .0 8 1 .5 2  0 .8
dipose 9 0 .3 2  1 .8 77 .2219. 6 78 .42  1 .3 8 1 .3 2  1 .5 68. 7222.2 8 2 .1 2  2 .9 8 3 .7 2  2 .8
lood 8 .0 2  0 .4 5 . i 2 4 .4 4 . 7 2  1 .6 77 .22  1 .1 4 . 7 2  2 .7 2 .52  0 .3  , 1 2 .6 2  1 ,0
2sults a re  the m eans of six determ inations - S .D .
able 7. Mean counting effic iency (%) of Hydrogen-3 fo r solubilised ra t tissues.
)lubilised
tissue
NCS Soluene 100 BBS HCIO, Protosol S H T /tT 2 1 S H T /S . 20
rain 32 .12  2 .9 6 .12 0.8 13.92 0 .8 11 .42  0 .6 23 .22  0 .8 15 .92  0 .9 1 8 .5 2  0 .9
ang 14 .62  3 .4 9 .6 2  6 .8 6 .32  2 .6 6 .42  0 .8 13.72 1 .6 7 .8 2  1 .2 9 . l 2  1 .7
Lver 13 .22  5 .7 4 .8 2  0 .4 10.32 0 .9 8 .1 2  0 .4 15.92 1 .4 6 .42  0 .3 1 1 . l 2  0 .2
)leen 2 .4 2  0 .5 2 .0 2  0 .3 2 .2 2  0 .9 7 .6 2  0 .9 4 .2 2  0.1 3 .1 2  1 , 9 4 . 5 2  1 .4
lood 0 .42  0 .1 1 .6 2  0 .1 0 . l 2  0 .1 9 .1 2  0 .4 0.52 0.1 0 . l 2  0 .1 0 .2 2  0 .1
omach and contents l . l 2  0 .1 2 .6 2  0 .5 6 .1 2  0 .9 8 .8 2  0 .9 8 .72 1.4 2 .32  0 .1 7 .32  0 .9
aecum and contents 1 ,2 2  0 .1 2 .42  0.1 4 .6 2  0 . 6 9 .6 2  0 .5 8.42 0.1 2 .8 2  0 .4 8 . 3 2  1 .2
esulis a re  the means of six determ inations -  S .D .
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